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 Abstract 	  
Genome-wide association studies have identified TCF4 (transcription factor 4) as a 
susceptibility gene for schizophrenia. In addition, rare TCF4 mutations cause Pitt 
Hopkins syndrome (PTHS), a severe form of intellectual disability associated with 
characteristic facial features, developmental delay and autonomic dysfunction. TCF4 
belongs to the basic helix-loop-helix family (bHLH) of transcription factors that play 
a central role in development, however the precise function of this gene in the brain is 
unknown. In this study, I use molecular and cellular techniques to improve our 
understanding of TCF4 function in the brain. 
 
Modeling of PTHS-associated missense mutations in transfected cells showed that 
TCF4 mutations affecting the DNA-binding domain cause mislocalisation of the 
mutant protein. DNA-binding domain mutations also impaired dimerisation and 
attenuated transcriptional activity at the NRXN1 and CNTNAP2 promoters. TCF4 
mutations affecting other domains of the protein had context-specific deficits in 
dimerisation and transactivation under the same conditions. 
 
Microarray analysis of SH-SY5Y cells where all TCF4 isoforms had been knocked 
down identified gene expression changes affecting cellular processes including 
epithelial-to-mesenchymal transition, apoptosis and neurodevelopment. However, 
isoform-specific knockdown experiments showed that TCF4-A and TCF4-B isoforms 
affect distinct biological processes such as the cell cycle, chromatin modification 
(TCF4-B), cell adhesion and cytoskeletal remodeling (TCF4-A). 
 
Finally, mass spectrometry was used to identify TCF4-associated proteins in SH-
SY5Y cells. These experiments showed that TCF4-B and TCF4-A co-purified with 
proteins involved in chromatin organization, cell cycle control and RNA splicing. In 
addition to the bHLH factors HAND2 and TWIST2, TCF4 co-purified with 
components of the nuclear co-repressor complex. TCF4 also has multiple 
phosphorylation sites in both activation domains suggesting that TCF4 function may 
be regulated by kinase signaling. 
 
In conclusion, these data provide a mechanistic insight into the function of TCF4 that 
may advance our understanding of disease processes in PTHS and schizophrenia. 
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Chapter 1 
 
Introduction 
 
 
Human genetic studies have been instrumental in uncovering part of the genetic 
etiology of complex psychiatric disorders (Sullivan et al., 2012). However, 
understanding the function of genes that contribute to disease processes in these 
disorders presents a major challenge in biology and medicine. Transcription factor 4 
(TCF4) is a gene that has been implicated in the genetics of intellectual disability and 
schizophrenia.  Rare mutations affecting the coding regions of TCF4 cause Pitt-
Hopkins syndrome (PTHS), a severe form of intellectual disability associated with a 
range of other developmental abnormalities (Amiel et al., 2007). Furthermore, 
common variation in TCF4 is associated with a small but robust increase in risk for 
schizophrenia (Stefansson et al., 2009).  The genetic association of common and rare 
variants in TCF4 to neurodevelopmental disorders underscores its importance for 
brain development and function. These discoveries therefore offer a unique 
opportunity to understand the function of this gene in the context of the nervous 
system. Advancing our knowledge of the fundamental biology of TCF4 will be an 
essential part of deciphering disease mechanisms related to schizophrenia and 
intellectual disability. 
 
TCF4 is a member of the basic helix-loop-helix (bHLH) family of transcription 
factors that have an important role in a number of developmental processes (Massari 
and Murre, 2000). Many members of the bHLH family are involved in regulating 
neurodevelopment although the function of TCF4 in the nervous system remains 
largely unknown. The following chapter is divided into two sections: The first 
summarises the current knowledge on the molecular and cellular functions of TCF4 
whilst the second provides an overview of PTHS and schizophrenia and their genetic 
association to TCF4. 
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1.1. TCF4 Nomenclature 
Although TCF4 (GeneID: 6925) is the gene’s official Human Genome Organisation 
(HUGO) symbol, in the literature it is often referred to as E2-2, immunoglobulin 
transcription factor 2 (ITF2) or SL3-3 enhancer factor (SEF2). Importantly, 
transcription factor 4 should not be confused with transcription factor 7-like 2 
(TCF7L2), a gene on chromosome 10q25.3 that is also referred to T-cell factor 4, and 
therefore shares the TCF4 acronym. The T-cell factor 4 (TCF7L2, TCF4) gene 
encodes a high mobility group (HMG) box-containing transcription factor of the Wnt 
signaling pathway, and is not related to the work in this thesis. 
 
1.2 TCF4: gene discovery and alternative splicing 
In humans, TCF4 is located on chromosome 18q21.1 that spans approximately 450kb 
and has at least 20 coding exons. The TCF4 cDNA was initially discovered as its 
cognate protein was able to bind the µE5 heavy chain and κE2 light chain 
immunoglobulin enhancers (Henthorn et al., 1990). In this study, the TCF4 cDNA 
was found to encode a 623 amino acid isoform that was designated ITF2 for 
‘immunoglobulin transcription factor 2’. The µE5 and κE2 enhancer sequences both 
shared an E-box (Ephrussi-box) DNA element (CACCTG) that was recognised as an 
important binding site (Murre et al., 1989a; Henthorn et al., 1990). Independently, the 
canonical TCF4 sequence, encoding a 667 amino acid protein (SEF2-1B), was 
isolated from human thymocytes along with truncated TCF4 isoforms TCF4-A 
(SEF2-1A) (Corneliussen et al., 1991). These isoforms were identified by their ability 
to bind an enhancer of the murine leukemia virus SL3-3 and were termed SEF2 for 
'SL3-3 enhancer factors 2’. Orthologues (mouse and rat) of TCF4 were found to 
regulate other E-box-containing regulatory regions such as the rat tyrosine hydroxlase 
(TH) enhancer and the	  human somatostatin receptor-2 (SSTR2) promoter (Yoon and 
Chikaraishi, 1994; Pscherer et al., 1996). Together, these studies established TCF4 as 
a conserved bHLH transcription factor that binds E-box sequences in the promoters 
and enhancers of certain genes.  
 
Since these initial discoveries, an extensive list of alternatively spliced TCF4 
transcripts has been identified (Figure 1.1). Many of these transcripts have different  
5’ exons and may be transcribed from alternative intragenic promoters. The most 
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detailed study of TCF4 alternative splicing in humans identified 18 transcripts with 
distinct N-terminal sequences that result from the use of alternative start sites within 
the gene (Sepp et al., 2011). TCF4 transcripts can contain an alternatively spliced 
exon of 12 bp that code for the amino acids “RSRS”. Transcripts that contain the 
insertion are denoted with a “+” whilst transcripts that do not contain the insertion are 
denoted with a “-” (Corneliussen et al., 1991; Sepp et al., 2011). For the purpose of 
this thesis,“TCF4” will refer to the canonical TCF4-B+ isoform that contains 671 
amino acids (including RSRS) unless otherwise specified. 
 
	  
 
Figure 1.1 Transcriptional architecture of TCF4.  
TCF4 transcripts from the NCBI Reference Sequences Database (RefSeq) are shown. 
Some of the mRNA transcripts described by Sepp et al. 2011 are not in the RefSeq 
database (see Table 5.1) (Sepp et al., 2011). The level of transcription in 9 different 
cell lines measured by RNA-seq is indicated in the track below the TCF4 mRNA 
schematic. The image was modified from data in the UCSC genome browser. 
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1.3 E-protein Isoforms 
The E-proteins are a class of bHLH transcription factors that are orthologous to the 
Drosophila protein daughterless (da) (Murre et al., 1989a; Bain and Murre, 1998). In 
humans, these proteins include TCF4, Transcription factor 3 (TCF3, E2A) and 
Transcription factor 12 (TCF12, HEB). E-protein genes encode at least two distinct 
alternatively spliced protein isoforms (Figure 1.2). The TCF3 (E2A) gene is capable 
of producing two highly similar protein isoforms called E12 and E47 that differ 
uniquely in the bHLH region of their sequence, giving them different DNA binding 
properties (Sun and Baltimore, 1991). In contrast, the TCF12 (HEB) gene produces 
two protein isoforms that differ in their N-terminal domain (Wang et al., 2006b). The 
alternative HEB isoform (HEBAlt) is 170 amino acids shorter than the canonical 
HEB isoform (sometimes called HEBCan). TCF4 is able to produce a wide variety of 
transcripts with different N-termini, however only two protein isoforms have been 
consistently described, TCF4-A (SEF2-1A, E2-2A, ITF2A) and TCF4-B (TCF4, 
SEF2-1B, E2-2B, ITF2B) (Sepp et al., 2011). Similarly to the HEB isoforms, TCF4-
A is a truncated form of TCF4-B, missing the first 183 amino acids. Multiple 
sequence alignment of the four most studied E-protein isoforms (TCF4-B, HEBcan, 
E47, E12) reveals their high degree of sequence similarity, especially in regions of 
the bHLH domain and the adjacent domain C that is unique to E-proteins (amino 
acids 566-644). 
 
 
 
Figure 1.2  Structure of E-protein isoforms. The illustration depicts the 
structure of the two alternatively spliced protein isoforms for TCF4, TCF3 (E2A) and 
TCF12 (HEB). The TCF3 isoforms (E47, E12) contain two activation domains (AD1 
and AD2) and only differ slightly in their basic helix-loop-helix domain (bHLH). 
TCF4 and TCF12 (HEB) encode full length isoforms (TCF4-B and HEBCan) and 
one shorter protein isoform that lack the N-terminal AD1 (TCF4-A and HEBAlt). 
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1.4 The bHLH family 
The bHLH family is organised into seven functional classes according to tissue 
expression, dimerisation capability and DNA binding specificity (Appendix I) 
(Massari and Murre, 2000). bHLH family members are characterised by their core 
bHLH structural domain and their ability to bind E-boxes (consensus sequence 
“CANNTG”). TCF4 and the other E-proteins form the Class I bHLH proteins. E-
proteins are widely expressed in different tissues and are able to form stable 
homodimers that interact with E-boxes on DNA (Ellenberger et al., 1994). Class I 
proteins also form heterodimers with class II (e.g. ASCL1, MYOD), class V (ID 
proteins) and class VI (HES1) members of the bHLH family that regulate its DNA 
binding properties (Figure 1.3).  Class II transcription factors have tissue-restricted 
expression patterns and are potent inducers of cell-type specification such as MyoD 
for myogenesis or ASCL1 for neurogenesis (Tapscott et al., 1988; Turner and 
Weintraub, 1994; Farah et al., 2000). E-proteins allow other bHLH to bind to DNA 
and activate transcription, making E-proteins key regulators biological activity 
(Murre et al., 1989b; Longo et al., 2008).  
 
Conversely, class V proteins and class VI transcription factors are characterised by 
their inhibitory or repressive activities. The ID proteins (ID1-4, Class V) are 
orthologous to the Drosophila protein extramacrochaetae (emc) and lack the basic 
region of the bHLH sequence rendering them unable to bind DNA (Benezra et al., 
1990). ID proteins heterodimerise with E-proteins and sequester them into inactive 
complexes that limit their availability for class II transcription factors (Sun et al., 
1991). The expression of ID proteins affects the balance between cell growth and 
differentiation (Lyden et al., 1999; Zebedee and Hara, 2001). The hairy and enhancer 
of split (HES) proteins (Class VI) are unique as they contain a proline residue in their 
basic region. This unique structure enables them to bind N-boxes (consensus 
sequence “CACNAG”) rather than E-boxes (Akazawa et al., 1992; Ohsako et al., 
1994). HES proteins also heterodimerise with class I factors and inhibit their DNA 
binding properties in a dominant negative manner (Akazawa et al., 1992; Sasai et al., 
1992). HES proteins play a central role in maintaining progenitor cells in an 
undifferentiated state (Kageyama et al., 2007). The balance of bHLH factors during 
development is therefore essential in regulating E-protein activity as well as the 
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lineage specification of different cells types (Massari and Murre, 2000; Jogi et al., 
2002). 
 
 
 
Figure 1.3  Model of transcriptional regulation by bHLH proteins. The 
schematic depicts the general mechanisms by which bHLH proteins regulate E-box 
containing promoters or enhancers. (A) E-proteins (class I), such as TCF4 can self-
associate as homodimers to bind DNA and activate or repress transcription. (B) E-
proteins associate with class II transcription factors such as MYOD or ASCL1 to 
form DNA binding heterodimers. E-protein/Class II heterodimers activate lineage 
specific gene expression programs such as myogenesis or neurogenesis. (C) E-
proteins can heterodimerise with ID proteins (class V) which prevents them from 
binding DNA. ID proteins lack the crucial basic domain required for DNA binding. 
(D) E-proteins can heterodimerise with class VI proteins such as HES1. HES1 can 
interact with E-proteins and inhibit their DNA binding activity. 
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1.5 Structure and function of the TCF4 protein 
The canonical human TCF4 (TCF4-B+, NP_001077431) protein sequence is 671 
amino acids and is encoded by at least 18 exons and includes the RSRS insertion 
sequence (Figure 1.4). Critical to its function, the TCF4 protein contains an 
assortment of structural and function domains that regulate multiple aspects of its 
biochemistry including transcriptional activity, DNA binding, protein dimerisation 
and cellular localisation. The N-terminal region of the protein contains regions that 
modulate transcriptional activity and a nuclear localisation signal (NLS) that controls 
subcellular location of TCF4. The C-terminal region of the protein contains the 
bHLH domain and domain C that us essential for the DNA binding and dimerisation 
properties of the protein. TCF4 isoforms all share the same C-terminus but vary in 
composition at their N-termini, multiplying the properties of their transcriptional and 
biological activity. 
 
 
Figure 1.4. TCF4 protein structure. The illustration shows the conceptual 
organisation of the TCF4 protein domains and their summarised functions. AD1 and 
AD2 are proposed to interact with the p300 co-activator whilst AD1 also participates 
in ETO co-repressor recruitment. The basic region of the bHLH domain mediates 
DNA binding to E-boxes whilst the helix-hoop-helix forms an interaction surface for 
dimerisation. Domain C is required for in vivo homodimerisation. Numbers represent 
the approximate amino acid positions of each domain in full length TCF4 (TCF4-B+; 
671 amino acids including RSRS insertion). Abbreviations and amino acid positions: 
Activation domain 1 (AD1; 1-100), CE repressor domain (CE; 160-179), nuclear 
localisation signal (NLS; 157-176), activation domain 2 (AD2; 340-400), Rep 
repressor domain (Rep; 511-540), basic domain (b; 566-583), helix-loop-helix 
domain (583-622), domain C (C; 622-646). Illustration not to scale. 
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1.5.1 Activation domains and transcriptional co-factors 
The E-proteins all contain two activation domains (AD) that have been defined by 
deletion mapping and mutagenesis (Figure 1.4). These domains are highly conserved 
across the E-proteins and are required for activity in yeast and mammalian cells 
(Quong et al., 1993; Massari et al., 1996). AD1 is located within the first 100 amino 
acids of TCF4, a region sharing 45% similarity with the other E-proteins (Massari et 
al., 1996) (Figure 1.4). Within this region is a highly conserved alpha-helical 
structure (amino acids 11-38) containing the LDFS motif that is essential for 
transactivation properties (Massari et al., 1996). Interestingly, the transactivation 
properties of the AD1 domain vary across mammalian cell lines, with the highest 
activity found in neuroblastoma cells (Aronheim et al., 1993). The TCF4-A isoform 
is truncated at its N-terminus and is devoid of AD1 (Figure 1.2).  
 
AD2 is predicted to be a loop-helix (LH, amino acids 340-400) structure or leucine 
zipper (LZ, amino acids 379-400) that is highly conserved and present in all 
described TCF4 isoforms (Quong et al., 1993; Sepp et al., 2011) (Figure 1.4). In 
general, AD2 has relatively less activation potential than AD1 in many cell lines, 
although it is highly active in cells derived from the pancreas (Aronheim et al., 1993). 
Further in vivo experiments in Zebrafish have identified cell-type specificity for AD1 
and AD2. AD1 activates expression in all major cell types of the embryo (skin, 
sclerotome, myotome, notochord, and nervous system) whilst AD2 is principally 
active in the myotome (muscle precusors) (Argenton et al., 1996). 
 
In yeast, AD1-mediated transactivation is dependent on the SAGA (Spt-Ada-Gcn5 
acetyltransferase) complex, a multifunctional co-activator that regulates transcription 
(Massari et al., 1999; Wu et al., 2004). AD1 can directly interact with the SAGA 
complex in a manner that is dependent on the integrity of its alpha helical structure 
and LDFS motif (Massari et al., 1999). In mammalian cells, AD1 and AD2 cooperate 
to recruit p300 (EP300) or its close paralogue CBP (collectively referred to as 
p300/CBP) that are	  transcriptional co-activators with histone acetyltransferase 
activity (Bradney et al., 2003; Bayly et al., 2004). The KIX domain of p300/CBP and 
the two alpha-helical surfaces of AD1 and AD2 mediate the interaction between these 
proteins (Bayly et al., 2004; Denis et al., 2012). A PCET motif (LXXLL) is critical 
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for the interaction with AD1 and overlaps with the LDFS sequence important for 
SAGA recruitment (Denis et al., 2012). Interestingly the PCET motif in AD1 is also 
able to interact with the transcriptional co-repressor ETO (RUNX1T1) (Zhang et al., 
2004). ETO represses TCF4 by competing with p300 for the AD1 binding site, 
abrograting its association the with histone deacetylase complexes, and thereby 
repressing transcription (Hug and Lazar, 2004; Zhang et al., 2004). Although these 
interactions have not yet been studied in the context of the nervous system, E-protein 
activation domains remain essential interfaces for the recruitment of transcriptional 
co-regulator complexes that have import roles in physiological processes (Bayly et 
al., 2004; Bhalla et al., 2008).  
  
1.5.2 Repressor domains and the nuclear localisation signal 
In addition to AD1 and 2, two repressor domains have also been identified by 
deletion mapping of the TCF4 protein sequence (Figure 1.4). The CE repressor is 
located between the AD1 and AD2 activation domains (amino acids 160-197, Figure 
1.4). Deletion of the CE repressor from TCF4 leads to an augmentation of 
transcriptional activity in mammalian cells, beyond that of the full length TCF4 
protein (Herbst and Kolligs, 2008). The CE repressor is also sufficient to abolish the 
transcriptional activity mediated by AD1 when the two domains are directly fused 
together without intervening sequences (Herbst and Kolligs, 2008). The CE repressor 
is therefore a modulator of transcriptional activity that can interact with AD1 to 
govern transcriptional output. 
 
Imbedded in the CE repressor domain are the residues encoding an NLS (Figure 1.4). 
This motif is characterised by two clusters of basic amino acids that are important to 
direct TCF4 to the nucleus (RRR, amino acids 157-159; KVKK, amino acids 171-
174; Figure 1.4) (Sepp et al., 2011). TCF4 isoforms that contain these residues have 
an exclusively nuclear localisation whereas isoforms that lack this motif, such as 
TCF4-A, are present in both the nucleus and the cytoplasm of cells. Isoforms lacking 
an NLS are able to translocate to the nucleus by dimerising with other bHLH family 
members that do contain an NLS in a so called ‘piggy-back’ mechanism (Sepp et al., 
2011). 
 
Chapter 1: Introduction 
 
	   10 
The second repressor region, termed the Rep domain, is located between AD2 and 
the bHLH domain (amino acids 511-540, Figure 1.4).  The Rep domain can repress 
both AD1 and AD2 independently in a selection of mammalian cell lines (Markus et 
al., 2002b). The Rep domain plays a role in maintaining E-protein homodimers in an 
inactive state on certain enhancers (Markus et al., 2002b). The intramolecular 
repression mediated by the Rep domain may be necessary for AD2 to function in 
particular heterodimeric complexes (Markus et al., 2002b). Intramolecular repressor 
domains are therefore able to regulate the E-protein activation domains in a context 
dependent manner (Markus et al., 2002b; Wong et al., 2008). 
 
1.5.3 Structure and function of C-terminal domains 
TCF4 and other members of the bHLH family possess as their defining feature a 
structural motif consisting of two alpha-helices connected by an intervening loop 
termed the bHLH domain (Phillips, 1994). The N-terminal part of this domain 
contains a highly conserved set of positively charged amino acids that make up the 
basic region and participates in DNA interactions (Voronova and Baltimore, 1990; 
Ellenberger et al., 1994). The remainder of the bHLH motif is a surface that favours 
homo- and hetero- dimerisation through the assembly of a stable four-helix bundle 
with a defined hydrophobic core (Ellenberger et al., 1994; Longo et al., 2008). The 
structure of E-protein dimers exploits the central two-fold symmetry of the E-box 
(“CACCTG”) with each monomer contacting an E-box half site (“CAC” or “CTG”) 
(Ellenberger et al., 1994). Directly C-terminal to the bHLH domain is a highly 
conserved set of amino acids termed domain C. This domain is exclusively present in 
E-proteins and is critical for dimerisation in physiological contexts (Goldfarb et al., 
1998). 
 
1.6 Ca2+-dependent regulation of TCF4 
The DNA binding properties of E-proteins are regulated by Ca2+ binding proteins 
such as Ca2+-dependent calmodulin (CaM), S100α and S100β (Corneliussen et al., 
1994; Onions et al., 1997; Larsson et al., 2001, 2005). These proteins are all Ca2+-
sensing molecules that have important roles in intracellular signaling (Hermann et al., 
1998). CaM is ubiquitously expressed whereas S100α and S100β are predominantly 
expressed in muscle and glial cells respectively but are also found in neurons 
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(Corneliussen et al., 1994; Donato et al., 2013). In the presence of Ca2+, CaM can 
selectively inhibit the DNA binding of E-protein homodimers whereas E-protein 
heterodimers are much less sensitive (Corneliussen et al., 1994). Ca2+-dependent 
proteins interact directly with the basic region of the bHLH domain, involved in 
DNA binding (Onions et al., 1997). Consistent with these interactions, altering levels 
of CaM or Ca2+ in cells has a direct effect on E-protein-mediated transcription 
(Hauser et al., 2008a; Hauser et al., 2008b). 	  
1.7 TCF4 expression  
TCF4 is widely expressed during development and in adult tissues (Soosaar et al., 
1994; Shain et al., 1997; Brockschmidt et al., 2007; de Pontual et al., 2009). In mice, 
Tcf4 (ME2) is expressed in the developing nervous system including the cortex, 
cerebellum, pons, medulla and spinal chord (Soosaar et al., 1994; Pscherer et al., 
1996; Dorflinger et al., 1999). TCF4 also has high expression in non-neuronal tissues 
such as skeletal muscle, subepidermal connective tissue and in the developing limbs 
(Soosaar et al., 1994; Dorflinger et al., 1999). Later in development (e18) and during 
adulthood, Tcf4 mRNA is detected at high levels in the hippocampus, olfactory bulb, 
ventricular zones, rostal migratory stream (RMS), cerebellum and at a lower levels in 
the neocortex and amygdala (Soosaar et al., 1994; Dorflinger et al., 1999). The 
widespread expression during developmental and more specific expression pattern 
during adulthood has led to the proposal that Tcf4 could have different regulatory 
roles in these two developmental stages (Soosaar et al., 1994). Tcf4 expression is also 
distinct from the genes encoding the other E-proteins (Chiaramello et al., 1995). E-
protein gene expression is generally high during neurodevelopment however, Tcf4 
expression persists in proliferative regions of the adult brain where Tcf3 and Tcf12 
expression declines (Neuman et al., 1993; Uittenbogaard and Chiaramello, 1999; 
Ravanpay and Olson, 2008; Brzozka et al., 2010). This places TCF4 in a unique 
position to regulate bHLH transcription factor networks in the adult brain. 
 
Examination of human TCF4 mRNA revealed a similar expression pattern to that of 
the mouse, with high TCF4 expression identified in human foetal and adult brain 
(Sepp et al., 2011). During human development, TCF4 is expressed throughout the 
central nervous system (CNS), sclerotome, lateral plate mesoderm and pharyngeal 
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arch mesenchyme (de Pontual et al., 2009). TCF4 is also expressed in NCAM (neural 
cell adhesion molecule)-expressing sympathetic, parasympathetic and enteric ganglia 
and the ventricular zones of the CNS (de Pontual et al., 2009). In the adult brain, 
TCF4 expression is highest in the cerebellum but is also prominent in the cerebral 
cortex (Sepp et al., 2011). TCF4 mRNA is also present in non-neuronal tissues such 
as the spleen, uterus, lung, thymus and placenta (Sepp et al., 2011). In situ 
hybridization analysis of adult human brain demonstrated that TCF4 is expressed in 
the dentate gyrus and in the CA1-CA3 regions of the hippocampus, neurons of 
subiculum and parahippocampal gyrus of the cortex, and cerebellar granule neurons 
(Sepp et al., 2011). 
 
1.8 Non-neuronal functions of TCF4 
Consistent with its widespread expression throughout development, TCF4 has been 
implicated in a number of cellular and disease processes. In addition to neuronal 
functions, TCF4 has been studied for its role in the development of immune system 
and epithelial-to-mesenchymal transition (EMT) (Kee, 2009; Cano and Portillo, 
2010). TCF4 is also a highly significant risk factor for Fuchs’ endothelial corneal 
dystrophy (FECD) (Baratz et al., 2010). 
 
E-proteins are critical regulators of lineage specification in the immune system (Kee, 
2009). Analysis of Tcf4 knockout mice has revealed that Tcf4 expression can effect 
B- and T- cell development. Although Tcf4 is not absolutely required for B cell 
development, Tcf4 knockout mice display a reduced number of pro-B cells 
demonstrating a role for Tcf4 in early B-cell development (Zhuang et al., 1996). 
Expression of Tcf4 may be required in marginal versus follicular zone fate decisions 
during pro-B cell expansion (Wikstrom et al., 2006). Specific deletion of Tcf4 can 
also lead to a partial block in T-lymphocyte development when targeted postnatally 
(Bergqvist et al., 2000). In contrast, Tcf4 has crucial role in plasmocytoid dendritic 
cell development (pDC), a unique immune cell type specialised in type I interferon 
secretion in response to viral nucleic acids (Cisse et al., 2008). Tcf4 is highly 
expressed in pDCs and it is essential for the development and maintenance of the 
pDC phenotype (Ghosh et al., 2010). Signal transducer and activator of transcription 
5 (Stat5) controls the expression of Id2 and Tcf4 during pDC development(Li et al., 
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2012a). Heterozygous Tcf4 mutant mice have decreased expression of many pDC-
associated genes (Cisse et al., 2008). Interestingly, PTHS patients show similar 
defects in pDC development and function to mice that only have one functional Tcf4 
allele (Cisse et al., 2008).  
 
In epithelial cells, TCF4 is emerging as an important regulator of EMT (Cano and 
Portillo, 2010). EMT is a complex cellular process that is required for embryonic 
development, tissue repair and cancer metastasis. Epithelial cells undergoing EMT 
lose their apico-basal polarity and intercellular junctions to become migratory 
acquiring a mesenchymal cell phenotype  (Lim and Thiery, 2012). This process 
enables cells to penetrate the extracellular matrix and coordinate tissue remodeling. A 
hallmark of EMT is the loss of E-cadherin (epithelial-cadherin, CDH1) expression, 
although multiple epithelial and mesenchymal markers are differentially expressed 
during the EMT process (Kalluri and Weinberg, 2009). Over-expression of TCF4 in 
epithelial MDCK cells leads to a potent induction of EMT (Sobrado et al., 2009). 
Cells over-expressing TCF4 acquire a motile and highly invasive phenotype that is 
associated with change in a number of EMT markers (Sobrado et al., 2009). E-
cadherin expression is down-regulated with other epithelial markers whilst 
mesenchymal markers such as N-cadherin (neural cadherin, CDH2), vimentin and 
fibronectin are upregulated in these cells (Sobrado et al., 2009). The phenotype is 
similar to epithelial cells over-expressing the transcription factors SNAI1, SNAI2, 
and TCF3 (E47) that are also important regulators of EMT (Cano et al., 2000; Perez-
Moreno et al., 2001; Bolos et al., 2003). However, TCF4 appears to be acting 
downstream of these transcription factors and is not required to maintain the 
mesenchymal cell fate (Moreno-Bueno et al., 2006; Sobrado et al., 2009). In 
agreement with EMT functioning during cancer metastasis, TCF4 expression is also 
dysregulated in a number of human cancers (Kolligs et al., 2002; Zhai et al., 2002; 
Vicent et al., 2008; Herbst et al., 2009). However, by contrast to TCF4 mediated 
effects in epithelial cells, TCF4 expression is associated with inhibition of migration 
in vascular endothelial cells underscoring its context dependent activities (Tanaka et 
al., 2010). 
 
Common variation in TCF4 is associated with increased risk of FECD, a condition 
affecting 5% of the U.S. population over 40 years of age (Baratz et al., 2010). FECD 
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is caused by a progressive degeneration of the corneal endothelium that is 
accompanied by deposition of abnormal extracellular matrix in the cornea (Schmedt 
et al., 2012). These aberrations lead to corneal edema and reduced vision in patients. 
A genome-wide association study identified TCF4 as highly significant (rs613872, P 
= 2.3 × 10-26) risk factor in typical FECD (Baratz et al., 2010). This association 
increased the odds of having FECD by a factor of 30 and allowed cases to be 
predicted from controls with 76% accuracy, suggesting TCF4 is a major contributor 
to FECD. The risk allele rs613872 is also associated with FECD disease severity and 
central corneal thickness, enforcing its role in the endothelial organisation of the 
cornea (Igo et al., 2012). However, rs613872 was not associated to a change in 
corneal endothelial cell density or morphology in a study of 445 young adults 
(Mackey et al., 2012). In addition to the rs613872 allele, a separate study identified a 
trinucleotide expansion (TGC) in intron 3 of TCF4 that is present in a high proportion 
of FECD cases (Wieben et al., 2012).  A repeat length of 50 or more trinucleotides 
was identified in 79% patients (n = 66) and 3% of controls (n = 63) although the 
mechanism by which this expansion causes susceptibility to FECD is unknown. 
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1.9 TCF4 and neurodevelopment 
The association of TCF4 variants with neurological and neuropsychiatric disease has 
prompted attention to its role in brain development and function (Blake et al., 
2010).Our current understanding of TCF4 in this context is limited, although 
emerging evidence suggests that it contributes to neurodevelopmental events and has 
an impact on brain function.  
 
1.9.1 The proneural genes and neurogenesis 
In the vertebrate embryo, neurodevelopment begins with the creation of the 
neuroepithelium that contains neural stem cells (or neuroblasts) with self-renewing 
properties. Neuroepithelial cells can divide symmetrically to produce two neuroblasts 
with stem cell characteristics or divide asymmetrically to generate intermediate 
progenitors (Huttner and Brand, 1997; Farkas and Huttner, 2008). During asymmetric 
division, intermediate progenitors derived from neuroepithelial cells lose their 
epithelial characteristics and migrate away from the basal lamina. Intermediate 
progenitors have a limited proliferation potential and eventually differentiate into 
mature neurons and glia. The process of neurogenesis is dependent on the expression 
of the proneural bHLH transcription factors of the Drosophila atonal (ato) and 
achaete-scute (ac/sc) families (Bertrand et al., 2002). Proneural genes are first 
expressed in neuroepithelial cells that are committed to a neural fate but are also 
implicated in the delamination and migration of intermediate progenitors as well as 
the final steps of neuronal differentiation (Bertrand et al., 2002). The correct spatial 
and temporal distribution of proneural genes in the developing brain is crucial for the 
specification of different neuronal subtypes (Bertrand et al., 2002). 
 
In vertebates, the proneural proteins are members of the class II bHLH transcription 
factors and accordingly, their activity can be modulated by the expression of cell 
intrinsic transcription factor networks, E-proteins, ID proteins and HES proteins, to 
coordinate cortical development (Ross et al., 2003). In agreement with this model, 
TCF4 is known to heterodimerise with a variety of proneural proteins including 
neurogenic differentiation 1 (NEUROD1), neurogenic differentiation 2 (NEUROD2), 
achaete-scute complex homolog 1 (ASCL1), achaete-scute complex homolog 3 
(ASCL3) and atonal homolog 1 (ATOH1) (Persson et al., 2000; Yoshida et al., 2001; 
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Flora et al., 2007; Ravanpay and Olson, 2008; Brzozka et al., 2010). TCF4 is also 
able to heterodimerise with other bHLH family members with important roles in 
neurodevelopment such as the ID proteins (ID1-4), HES1 and heart and neural crest 
derivatives expressed transcript 1 (HAND1, dHAND) (Jogi et al., 2002; Liu et al., 
2004; Murakami et al., 2004). 
 
In mice, Ascl1 is expressed in the ventral telencephalon, a region of the brain that 
gives rise to GABAergic and cholinergic neurons (Guillemot and Joyner, 1993; 
Wilson and Rubenstein, 2000). In Ascl1 knockout mice, the loss of proneural activity 
leads to the loss of neural progenitor cells and a decrease in GABAergic interneurons 
in the cortex (Casarosa et al., 1999). Ngn2 expression is complimentary to that of 
Ascl1 and is distributed over the dorsal telencephalon. Absence of Ngn2 and Ascl1 
exacerbates the depletion of neuronal progenitors originating in the ventral and dorsal 
regions of the telencephalon demonstrating their combined importance in early neural 
fate commitment (Fode et al., 2000).  
 
Neurod1 is a downstream mediator of Ngn2 and is expressed in immature and 
differentiating neurons (Lee et al., 2000). Consistent with this expression pattern, 
Neurod1 and Neurod2 are required for the terminal differentiation of granule cells in 
the dentate gyrus and cerebellum (Miyata et al., 1999; Schwab et al., 2000). Neurod1 
expression persists in adulthood where it has a role in postnatal neurogenesis and 
survival of hippocampal and olfactory neurons (Gao et al., 2009; Boutin et al., 2010). 
Studies on adult mouse brain have established that Tcf4 and Neurod1 physically 
interact in the hippocampus and cerebellum (Brzozka et al., 2010).  
 
Thus, through interactions with proneural proteins, TCF4 may participate in the early 
stages of neuronal cell commitment or later in neuronal differentiation. TCF4 
transcripts are also found in regions undergoing adult neurogenesis such as the 
hippocampus and olfactory bulb. This expression pattern coupled to its role in 
regulating proneural function, suggests that TCF4 may play a part in prenatal 
neurodevelopment in addition to postnatal neuron generation. 
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1.9.2 Tcf4 Mouse models 
Mouse knockout studies have been instrumental in determining the function of bHLH 
transcription factors during development (Casarosa et al., 1999; Lyden et al., 1999; 
Miyata et al., 1999; Fode et al., 2000). Studies on the proneural genes have 
established the bHLH family as critical regulators of neurogenesis, however the role 
of Tcf4 and other E-proteins in this process is poorly understood (Ik Tsen Heng and 
Tan, 2003). This is presumably because E-proteins are to a certain extent, 
functionally redundant and individual E-protein knockout mice have no gross 
neurological phenotype (Flora et al., 2007; Ravanpay and Olson, 2008). In spite of 
this, it has become clear that E-proteins have non-redundant unique properties in 
particular contexts that will require further detailed characterisation (Zhuang et al., 
1998). 
 
Homozygous Tcf4 knockout (Tcf4-/-) mice die postnatally from undetermined causes, 
suggesting that Tcf4 has a crucial role in normal development (Zhuang et al., 1996). 
While the brains of Tcf4-/- mice have no overt morphological abnormalities, specific 
defects in Atoh1-dependent hindbrain structures have been identified (Flora et al., 
2007). As mentioned above, Atoh1 is a proneural protein that forms transcriptionally 
active complexes with Tcf4. Both Atoh1 and Tcf4 are expressed in the rhombic lip, a 
region of the developing hindbrain that matures to form the granule cells of the 
cerebellum and five distinct brainstem nuclei (Flora et al., 2007). To determine the 
function of Tcf4 in Atoh1-dependent neural progenitors, heterozygous Atoh1 
knockout (Atoh1+/-) mice were crossed with viable heterozygous Tcf4 mutant (Tcf4+/-
) mice. On the Atoh1+/- background, Tcf4-/- mice display disrupted development of the 
pontine nucleus (PN) – one of the five brainstem nuclei specified by precursor cells 
in the rhombic lip (Flora et al., 2007). Here, Tcf4 deletion causes a reduction in the 
number of neurons and an accumulation of ectopic neurons that fail to migrate to 
their correct location in the pontine nucleus. Heterozygous Tcf4 knockout mice 
display less severe migratory deficits than the double mutant, demonstrating a dose 
dependent response to Tcf4 levels. The defects in hindbrain development are 
remarkably specific, as the development of other Atoh1-dependent structures remains 
apparently intact. The Ascl1-dependent development of the locus coeruleus is also 
normal in Tcf4-/- mice, suggesting that Tcf4 can specify very distinct progenitor cells 
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by dimerising with partner bHLH proteins (Flora et al., 2007). Importantly, these 
deficits are highly specific to Tcf4, as pontine development in Tcf3 and Tcf12 
knockout backgrounds were normal (Flora et al., 2007). The requirement of Tcf4 
heterodimers to specify particular neuronal precursors reveals the unique functions of 
Tcf4 in the brain and suggests that delineation of context specific Tcf4 interactions 
will be essential to understand its function in neurogenesis.  
 
A mouse model over-expressing Tcf4 has also been generated to explore the function 
of Tcf4 in the adult brain (Brzozka et al., 2010). The transgenic Tcf4 mouse (Tcf4tg) 
has an approximately 1.5 fold increase in Tcf4 expression in the forebrain structures 
of the hippocampus, cortex and amygdala. In behavioural tests, Tcf4tg mice showed 
no defects in exploratory, motor, and motivational behavior however they had 
significantly reduced freezing in the contextual and cued fear memory tests (Brzozka 
et al., 2010). Deficits in higher order cortical processing measured by trace fear 
conditioning were also observed in Tcf4tg mice (Brzozka and Rossner, 2013). 
Furthermore, the mice displayed impaired sensorimotor gating measured by pre-pulse 
inhibition (PPI); a common behavioural endophenotype found in animal models of 
schizophrenia and patients (Braff and Geyer, 1990; Brzozka et al., 2010). 
Examination of gene expression changes in the hippocampus identified increased 
expression of the circadian clock gene Per2 and Id2 that is known to regulate Tcf4 
function (Brzozka et al., 2010). This mouse model demonstrates that the precise 
control of Tcf4 dosage is critical for certain aspects of cognitive processing. 
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1.10 Pitt-Hopkins Syndrome 
1.10.1 Genetics of PTHS 
Pitt-Hopkins syndrome (PTHS) was first described in 2 unrelated children with 
severe intellectual disability (ID), similar facial features and episodes of 
hyperventilation followed by apnea and cyanosis (Pitt and Hopkins, 1978). Very few 
cases of PTHS were reported until two groups independently discovered that 
haploinsufficiency of TCF4 was the cause of the disorder (Amiel et al., 2007; Zweier 
et al., 2007). Determining the genetic cause of the PTHS has greatly increased the 
recognition of the disorder. 112 diagnosed patients are currently reported in the 
literature that have a wide spectrum of de novo heterozygous mutations including 
partial and whole gene deletions and a variety of point mutations (Table 1.1) (Amiel 
et al., 2007; Brockschmidt et al., 2007; Zweier et al., 2007; Giurgea et al., 2008; de 
Pontual et al., 2009; Takano et al., 2010; Lehalle et al., 2011; Marangi et al., 2011; 
Whalen et al., 2012b). The patients range from 20 months to 32 years of age, with a 
mean age of 11 years (Whalen et al., 2012b). Inherited cases of PTHS are rare but 
have been described in individuals where one of the parents was a somatic mosaic for 
a TCF4 mutation (de Pontual et al., 2009; Kousoulidou et al., 2013; Steinbusch et al., 
2013). Mosaic status can impact on disease severity for certain mutation types (Rossi 
et al., 2012; Kousoulidou et al., 2013; Steinbusch et al., 2013). PTHS is caused by 
loss-of-function of a singe TCF4 allele, leading to haploinsufficiency of the gene 
product. In agreement with this hypothesis, frameshift, missense and nonsense 
mutations found in patients induce similar defects in TCF4-mediated transactivation 
on luciferase reporter constructs (Zweier et al., 2007; de Pontual et al., 2009). 
However, missense mutations affecting the bHLH domain appear to be more 
damaging then those outside the bHLH domain in in vitro assays (Sepp et al., 2012b).  
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Table 1.1 Range of TCF4 mutations that cause PTHS. The number of patients 
with each mutation type and its corresponding percentage is presented in the table. 
This table was modified from data published by Whalen et al. 2012. 
 
Mutation type Number of patients % of patients 
Deletions 
Whole gene deletion 23 21 
Partial gene deletion 10 9 
Point mutations 
Frameshift 33 29 
Nonsense 18 16 
Splice site 6 5 
Missense 22 20 
Total 112 100 
 
1.10.2 Clinical symptoms 
A constellation of symptoms has been described in PTHS patients but few genotype-
phenotype correlations have been documented (Table 1.2) (Whalen et al., 2012b). 
The most prominent features are severe intellectual disability associated with 
distinctive facial features, developmental delay, stereotypic movements, absent 
speech and breathing abnormalities. Epilepsy is reported in nearly 40% of cases 
(Table 1.2). Initially, a single report documented a higher incidence of epilepsy in 
patients with missense mutations (7/8, 88%) compared to other mutations types 
(6/36, 17%) (Rosenfeld et al., 2009). However, this relationship remains to be 
confirmed since more patents are being identified that have epilepsy without 
missense mutations (Marangi et al., 2011). A study of 10 cases found that many of 
the behavioural abnormalities exhibited by PTHS patients could be associated to 
autism spectrum disorders, such as severe impairments in communication and 
language, difficulties in social engagement, fascinations with specific objects, and 
intense motor stereotypies (Van Balkom et al., 2012). The facial gestalt in PTHS is 
recognisable clinically by a wide mouth with prominent Cupid’s bow upper lip, a 
broad and beaked nasal bridge and flaring nostrils, deep-set eyes and mildly cup-
shaped, fleshy ears (Zweier et al., 2007). Non-neurological symptoms are also very 
common; PTHS patients often present with constipation and/or ocular anomalies such 
strabismus, myopia, and astigmatism. Particularities of the hands and feet are 
noticeable and have been suggested as a useful diagnostic criterion (Lehalle et al., 
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2011). Patients are mostly within the normal ranges of height and weight (± 2 SD) 
although of these patients, 81% fall at the lower end of normal growth parameters (0 
to –2 SD) (Whalen et al., 2012b). Finally, a number of brain abnormalities have been 
detected in PTHS patients using magnetic resonance imaging (MRI) (Table 1.3). The 
most common irregularity is agenesis or hypoplasia of the corpus callosum (40%) 
however decreased hippocampal volume or enlarged ventricles are recorded in over 
30% of patients. The structural abnormalities observed by MRI strongly support a 
role for TCF4 in regulating normal brain morphology and development. 
 
Table 1.2 Neurological and behavioural abnormalities in PTHS patients. A 
number of characteristic symptoms have been described in PTHS; the most common 
(>30%) symptoms are presented in the table. This table was modified from data 
published by Whalen et al. 2012. 
 
Clinical Feature Observed Total % 
Psychomotor development 
Severe ID or DD 31 31 100 
Hypotonia 19 26 81 
Delayed walking 24 24 100 
Walking achieved 21 30 47 
Ataxic gait 18 23 60 
Absent language or <10 words 32 32 100 
Stereotypic movements 
Positive history 29 31 77 
Arm flapping 20 25 62 
Hand nibbling/biting 13 24 45 
Movement of fingers 11 23 48 
Movement of wrists 10 21 48 
Hand washing 9 20 57 
Head stereotypies 9 22 42 
Median line 11 21 62 
Behavior 
Smiling appearance 25 28 91 
Harm to self 15 25 52 
Anxiety 17 21 57 
Agitation 23 26 68 
Agitation outbursts 15 21 71 
Unmotivated laughing 17 27 55 
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Breathing anomalies 
Hyperventilation 19 31 56 
Apnoea 13 28 54 
Cyanosis 6 28 32 
Seizures 
History of seizures 6 30 39 
 
Table 1.3  MRI brain abnormalities exhibited by PTHS patients. Patients 
with PTHS have been scanned by magnetic resonance imaging (MRI) to detect 
specific abnormalities in brain structure. The number of patients affected by each 
abnormality is presented. This table was modified from data published by Whalen et 
al. 2012. 
 
Cerebral MRI Observed Total % 
Normal 30 85 35 
Corpus callosum: hypoplasia or agenesis 34 85 40 
Temporal lobe hyperintensity 13 35 37 
Small hippocampi 15 44 34 
Ventricular dilatation 20 64 31 
Minor posterior fossa abnormalities 
(other than dentate nuclei) 7 25 28 
Cortical atrophy 4 21 19 
Dentate nuclei hyperintensity 4 24 17 
Abnormal myelinisation / reduced white 
matter volume 4 32 13 
Frontal lobe hypoplasia 4 42 10 
Large caudate nuclei 4 46 9 
 
Despite PTHS symptomatology having strongly associated features, confirmation of 
the diagnosis is impeded by the phenotypic similarities with Rett (RTT; MIM# 
312750), Angelman (AS; MIM# 105830) and Mowat-Wilson syndromes (MWS; 
MIM# 235730) that share the traits of severe intellectual disability, absent speech, 
delayed walking, epilepsy, microcephaly and a happy disposition (Marangi et al., 
2011; Armani et al., 2012; Whalen et al., 2012b). In a group of 86 patients suspected 
to have AS but with normal UBE3A (ubiquitin protein ligase E3A) sequencing and 
methylation analysis, two percent were found to have TCF4 mutations (Takano et al., 
2010). PTHS has also been recommended as differential diagnosis for α-thalassemia 
X-linked intellectual disability syndrome (ATRX; MIM# 301040) (Takano et al., 
2011). Finally, TCF4 mutations have been identified in a few patients with milder, 
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non-syndromic neurodevelopmental disorders, indicating that TCF4 mutations may 
be associated with a broader clinical phenotype than is currently recognised 
(Kalscheuer et al., 2008; Rauch et al., 2012; Talkowski et al., 2012; Hamdan et al., 
2013). 
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1.11 Schizophrenia  
1.11.1 Schizophrenia and neurodevelopment 
Schizophrenia is a severe, life-long, psychiatric disorder that usually manifests in 
early adulthood, and is characterised by auditory hallucinations, delusions, cognitive 
deficits, and affective retraction. The disorder is estimated to affect up to 1% of the 
world population and is associated with substantial morbidity, mortality and societal 
costs (Knapp et al., 2004; Saha et al., 2007). Psychological, pharmacological and 
genetic studies have advanced our general understanding of the etiology of 
schizophrenia (Keshavan et al., 2008; Tandon et al., 2008). The prevailing hypothesis 
is that schizophrenia is a neurodevelopmental disorder induced by genetic and 
environmental risk factors (Lewis and Levitt, 2002). Twin studies estimate that 
genetics could account for up to 80% of the disease susceptibility (Sullivan et al., 
2003). Environmental risks come from a potentially diverse range of sources that 
include biological, psychological, social, and physical stresses compounding genetic 
susceptibility during development (Tsuang, 2000). The neurodevelopmental 
hypothesis is supported by lack of neurodegenerative processes during the course of 
the disease, and by the fact that affected individuals show cognitive and social 
impairment before the first episode of the disease (Lewis and Levitt, 2002). Early 
neurodevelopmental defects caused by genetic and/or environmental insults may be 
responsible for an altered developmental trajectory causing brain dysfunction (Insel, 
2010). In addition, later developmental maturation processes may be defective, 
causing brain dysconnectivity through aberrant synaptic pruning and axonal 
myelination (Insel, 2010). Together, the neurodevelopmental deficits are thought to 
alter brain circuitry, connectivity and synaptic plasticity resulting in symptoms of 
schizophrenia (Stephan et al., 2009). 
 
1.11.2 Schizophrenia genetics   
Schizophrenia is complex and heterogeneous genetic disorder (Rodriguez-Murillo et 
al., 2012). The high heritability of schizophrenia is well established although the 
search for robust genetic associations has, until recently, yielded few compelling 
results. Two major models for the genetic basis of the disorder have been proposed, 
which differ fundamentally in their conception of the genetic architecture and 
heritability of the disorder (Mitchell and Porteous, 2011). The most common 
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conceptualisation of the disorder is the common disease–common variant (CDCV) 
model of schizophrenia (Lohmueller et al., 2003). This model proposes that 
schizophrenia is caused by the inheritance of multiple genetic variants of small effect 
that are common in the population. The additive effect of each variant causes a 
genetic burden of susceptibility to the disease.  In contrast, the multiple rare variants 
model proposes that each case of schizophrenia is caused by a single rare variant of 
large effect (McClellan et al., 2007). In this model, rare variants can affect different 
genes in different families or individuals making the disorder genetically 
heterogeneous. Neither model excludes the contribution from environment factors.  
 
Human genetic studies of schizophrenia have so far provided evidence for both rare 
and common variants conferring risk to disease suggesting that each can contribute to 
the genetic etiology (Sullivan et al., 2012). Large case-control genome-wide 
association (GWA) studies of schizophrenia have begun to uncover common disease 
variants of small effect sizes (odds ratio (OR) < 1.3) (Stefansson et al., 2009; Ripke et 
al., 2011; Steinberg et al., 2011; Ripke et al., 2013). Focusing on results that achieve 
genome-wide significance in large case-control studies (P < 5x10-8), 14 
schizophrenia susceptibility loci have been discovered to date including variants 
associated to the MHC, MIR137, ZNF804A and TCF4 genes (Sullivan et al., 2012). 
Consistent with a CDCV model, up to 23% of variation in susceptibility to 
schizophrenia is estimated to be conferred by common single nucleotide 
polymorphisms (SNPs) (Lee et al., 2012). Schizophrenia is also predicted to have 
high degree of shared genetic etiology with bipolar disorder (68%) and major 
depressive disorder (48%) and a lower concordance with autism (16%), as measured 
by common SNPs (Cross-Disorder Group of the Psychiatric Genomics et al., 2013). 
 
In contrast, several studies have identified an important role for rare variants in the 
etiology of schizophrenia; in the form of single or multi- gene deletions and 
duplications (copy number variants, CNVs) (International Schizophrenia, 2008; 
Walsh et al., 2008; Levinson et al., 2011; Mitchell and Porteous, 2011). Currently, 
eight rare copy number variants of strong effect (odds ratio between 4–20) and with 
consistent replication have been described for schizophrenia, including the most 
highly associated regions of 22q11.21 (OR 20.3) and 16p11.2 (OR 9.5) (Sullivan et 
al., 2012). However, rare mutations that confer high risk of schizophrenia can also 
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cause other neurodevelopmental disorders such as bipolar disorder, major depression, 
autism, attention deficit hyperactivity disorder (ADHD), epilepsy and mental 
retardation (Sebat et al., 2009). The shared genetic risk factors between multiple 
neuropsychiatric disorders suggest that they have a common pathophysiology. 
Functional gene set analyses of common and rare variants have determined that 
susceptibility genes converge on diverse biological networks such as chromatin 
remodeling, cell adhesion, axon guidance, neuronal cell mobility and synaptic 
signaling, supporting a neurodevelopmental basis for the disorder (Walsh et al., 2008; 
O'Dushlaine et al., 2011; Gilman et al., 2012; Lips et al., 2012). The most recent 
advance in schizophrenia genetics has focused on trying to find single nucleotide 
variants (SNVs) in schizophrenia patients using exome-sequencing technologies 
(Need et al., 2012). This high-throughput methodology is expected to deliver a new 
source of genetic variability with moderate effect sizes, however large studies and 
careful interpretation of the genetic data will be required to identify causal variants 
with confidence (Piton et al., 2013). 
 
The widespread use of genomic microarray-based SNP genotyping and next-
generation sequencing technologies has also paved the way for the discovery de novo 
CNVs and SNVs in schizophrenia (Kirov et al., 2012; Xu et al., 2012). De novo 
mutations have the potential to be highly damaging, as they represent a sporadic 
source of rare genetic variation that has not been confronted with purifying, natural 
selection (Veltman and Brunner, 2012). It has already been proposed that patients 
with schizophrenia carry a higher burden of de novo mutations than unaffected 
relatives indicating that these rare mutations participate in the genetic etiology of the 
disorder (Girard et al., 2011; Xu et al., 2011; Xu et al., 2012).  
 
1.11.3 TCF4 and the genetic association to schizophrenia 
As mentioned above, TCF4 is one of the few genes robustly associated with 
schizophrenia through common genetic variation (Sullivan et al., 2012). Three 
independent genetic loci in and near TCF4 have been associated with schizophrenia 
(Figure 1.5). The initial discovery identified SNP rs9960767, located in intron 3 of 
TCF4, as genome wide significant (P = 4.1×10-9; OR 1.23) in a large meta-analysis 
of 12,945 schizophrenia cases 34,591 controls (Stefansson et al., 2009) (Figure 1.5). 
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A second variant, downstream of the TCF4 gene (rs4309482) reached genome-wide 
significance (P = 7.8×10-9; OR 1.09) in a follow-up study with 18,206 cases and 
42,536 controls (Figure 1.5) (Steinberg et al., 2011). Two more variants were 
identified in a GWAS mega-analysis from the Psychiatric Genetics Consortium 
(PGC). rs12966547 was genome-wide significant in the combined data set of 17,839 
schizophrenia cases and 33,859 controls (P = 2.6×10-10; OR 1.09) whereas 
rs17512836 (Figure 1.5) was significant in the initial stage with 9,394 cases and 
12,462 controls (P = 2.35 × 10-08; OR 1.40) (Ripke et al., 2011). A fifth SNP 
(rs1261117), in intron 8 of TCF4, was the most significant variant in a family based 
replication study of GWAS results (P = 2.53×10-10, OR 1.60) (5 green, Figure 1.5) 
(Aberg et al., 2013). Although five TCF4-associated SNPs have been identified as 
genome-wide significant in different studies, SNPs cluster into three independent 
genetic loci (r2<0.1) due to linkage disequilibrium (Figure 1.5). The SNP cluster 
downstream of TCF4 (Figure 1.5) is also located near CCDC68 (coiled-coil domain 
containing 68), a gene with unknown function. Interestingly, SNP rs17512836 
(Figure 1.5) nearly reached genome wide significance (1.05×10-⁶) in a large cross-
disorder GWAS investigating shared risk variants between autism spectrum disorder 
(ASD), ADHD, bipolar disorder, major depressive disorder, and schizophrenia. 
Modelling analysis revealed that the best-fit model for the rs17512836 SNP 
encompassed both schizophrenia and ASD, suggesting that TCF4 could also 
contribute to ASD. The functional effects of SNPs surrounding TCF4 are currently 
unknown however many SNPs associated with schizophrenia risk appear to affect 
gene expression (Bacanu et al., 2013).  
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Figure 1.5  Distribution of genome-wide significant SNPs in the TCF4 gene. 
The location of genome-wide significant SNPs from GWAS of schizophrenia is 
illustrated (1-5). The graphic displays data from the Psychiatric Genetics Consortium 
study (Ripke et al., 2011), however genome-wide significant SNPs from other studies 
have been annotated (Stefansson et al., 2009; Steinberg et al., 2011). SNPs labeled 
with different coloured numbers represent genetically independent loci (r2 < 0.1). The 
r2 values and the GWAS graphic were obtained from the Broad Institute website 
(Section 2.10.1). 	  
 
 
1.11.4 TCF4 risk alleles and cognitive endophenotypes 
The impact of schizophrenia-associated TCF4 risk variants on cognition and 
information processing has been analysed by neuropsychological testing. In a sample 
of 401 schizophrenia patients, the TCF4 variant rs9960767 was demonstrated to 
influence verbal memory in the Rey Auditory Verbal Learning Test (Lennertz et al., 
2011). Impaired verbal memory is among the most prominent cognitive deficits in 
schizophrenia patients (Toulopoulouand and Murray, 2004). Contrary to 
expectations, carriers of the schizophrenia risk allele (C-allele) showed better 
recognition in verbal memory, suggesting a role of this variant in the development of 
memory-related brain structures. TCF4 genotype did not impact on various other 
cognitive tests measuring the domains of attention and executive function. 
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The effect of the TCF4 variant rs9960767 on sensorimotor gating was also assessed 
in 107 healthy volunteers and a schizophrenia spectrum group with 113 patients 
(Quednow et al., 2011). Sensory gating is an essential psychological process that 
allows the filtering of sensory information during cognitive tasks (Cromwell et al., 
2008). This mechanism is disrupted in several psychiatric disorders and is considered 
a schizophrenia endophenotype (Braff and Geyer, 1990). PPI is a translational task 
that can be used to measure sensorimotor gating in humans and animals (Braff and 
Geyer, 1990). In PPI, subjects presented with a weak pre-stimulus (pre-pulse) are 
able to inhibit their reaction to a strong stimulus (Li et al., 2009). Carriers of the 
schizophrenia risk variant in both the healthy control and patient groups produced a 
statistically significant reduction in PPI, indicative of an impaired inhibitory response 
(Quednow et al., 2011). Remarkably, PPI is also reduced in transgenic mice that 
over-express TCF4 (Brzozka et al., 2010) (Section 1.9.2). A follow up study 
measured auditory sensory gating assessed by P50 suppression of the auditory 
evoked potential (Quednow et al., 2012). P50 suppression has been related to 
attentional performance, working memory, and behavioral inhibition and is another 
measure of gating function (Lijffijt et al., 2009). In this large multi-center study, 
1,821 healthy volunteers were genotyped for 21 different TCF4 polymorphisms. The 
schizophrenia risk alleles for four polymorphisms (rs9960767, rs10401120rs, 
rs17597926, and 17512836) were associated with a highly significant reduction in 
P50 suppression. This decrease in P50 suppression was more pronounced in smokers 
than in non-smokers, suggesting an interaction between TCF4 risk alleles and 
smoking behaviour on cognitive functioning (Quednow et al., 2012). These studies 
indicate that TCF4 may influence key mechanisms regulating information processing 
that could contribute to the cognitive deficits and other endophenotypes observed in 
schizophrenia.  
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1.12  Thesis aims and structure  
The importance of TCF4 in brain developmental and function is apparent from its 
genetic association to debilitating neurodevelopmental disorders. However, the 
function of TCF4 in the nervous system is largely unknown. Accordingly, our 
understanding of TCF4-mediated pathophysiology in PTHS and schizophrenia is 
scarce. Preliminary evidence from mouse models and psychological testing suggests 
that TCF4 has a role in neurodevelopment and cognitive function, but the molecular 
basis underlying these processes has not yet been addressed. Consequently, the 
objective of this study was to gain further insight into the molecular and cellular 
function of TCF4 in order to better understand TCF4-associated disease mechanisms 
in PTHS and schizophrenia. Experiments in this thesis were designed to address the 
following aims: 
 
1) To determine the effect of PTHS-associated missense mutations on the 
function of TCF4 (Chapter 3). 
 
2) To understand the effects of TCF4 on the cellular transcriptome in SH-SY5Y 
cells (Chapter 4). 
 
3) To characterise endogenous TCF4 isoforms and identify novel TCF4-
interacting proteins (Chapter 5), 
 
4) To understand the effects of different TCF4 isoforms on gene expression in 
SH-SY5Y cells (Chapter 6). 
 
The novel findings presented in this thesis are summarised and discussed in Chapter 
7. 	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Chapter 2 
 
Materials and Methods 
 
 
2.1 General 
All chemicals used for experiments were of analytical grade and were purchased 
from Fisher or Sigma-Aldrich unless otherwise stated. All molecular biology reagents 
were purchased from New England Biolabs (NEB) and Promega unless otherwise 
stated. All kits were used as per manufacturer’s instructions.  
	  
2.2 Cell strains and media 
2.2.1 Bacterial cell culture 
Plasmid propagation was performed using Escherichia coli (E.coli) XL1-Blue cells 
(Stratagene), genotype: recA1 endA1 gyrA496 thi-1 hsdR17 supE44 relA1 lac 
[F’proAB laclqZΔM15 Tn10 (Tetr)]. For expression of fusion proteins with the pET-
32 (Novagen) and pGEX-4T (Promega) vector constructs, the Escherichia coli BL21-
Gold (DE3) strain was used (Stratagene), genotype: E.coli B F- ompT hsdS(rB-mB-) 
dcm+ Tetr gal λ (DE3) endA The. Bacterial cells were grown in Luria-Bertani (LB) 
media (liquid culture) and on LB-agar media (plate culture) (Tryptone (pancreatic 
digest of casein) 10 g/l, yeast extract 5 g/l, NaCl 5 g/l and agar 15 g/l). Media was 
autoclaved for 30 min at 115oC and cooled to below 50oC prior to addition of the 
appropriate antibiotic. The final concentrations of antibiotics used were: ampicillin 
100 µg/ml (LB-amp), kanamycin 30 µg/ml (LB-kan), tetracycline 100 µg/ml (LB-
tet). In liquid culture, E. coli strains were grown for 16-20 h at 37°C in LB with 
shaking at 200 rpm for all recombinant DNA methods. In solid culture, E. coli strains 
were grown on LB plates for 16-20 h and stored at 4°C for up to one month. Before 
picking colonies, the LB plates were removed from storage one hour before use, 
inverted and allowed to dry. For long term storage of E. coli strains, fresh cultures in 
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mid-log phase (optical density measured at 600 nm (OD600) = 0.6-0.8) were frozen 
in 15% (v/v) glycerol and stored at -80°C. 
 
2.2.2 Mammalian cell culture 
COS-7 (African green monkey kidney), HEK293T (human embryonic kidney 293T) 
and SH-SY5Y (neuroblastoma) cell lines were purchased from the European 
Collection of Cell Cultures (ECACC) and the American Type Culture Collection 
(ATCC). The 9E10 (anti-myc) hybridoma and 12G10: a-tubulin (isotype IgG1) cell 
lines were obtained from the Developmental Studies Hybridoma Bank (DSHB) at the 
University of Iowa. All cell lines were cultured in Dulbecco’s modified Eagle 
medium (DMEM, Invitrogen) supplemented with 10% (v/v) foetal calf serum (FCS, 
PAA laboratories) and 1% (v/v) penicillin/streptomycin except for siRNA 
knockdown experiments were antibiotic-free medium was used. All cells were grown 
as adherent cultures in T175 cm2 tissue culture flasks containing 30ml of cell culture 
medium. Cultures were maintained at 37oC with 5% CO2 in a humidified incubator. 
Cells were passaged at 80% confluence to ensure the cultures remained healthy. Cells 
were washed twice with 10 ml Ca2+and Mg2+ free Hanks balanced salt solution 
(HBSS, Sigma) and detached with 3 ml 1× trypsin-EDTA (Sigma) at 37oC for 2-5 
min. Trypsin was inactivated with addition of 7ml growth media followed by 
collection of cells by centrifugation at 2000 rpm for 3 min at room temperature. The 
cell pellet was resuspended in 10 ml fresh media and reseeded at an appropriate 
density. For medium term storage of cell lines the cell pellet was resuspended in 
freezing media (90% (v/v) FCS, 10% (v/v) DMSO) and aliquoted in cryovials at 
3x106 cells/vial, followed by storage at -80oC.    
 
2.3 Molecular biology 
2.3.1 Plasmid Vectors 
Name Description Antibiotic Selection Supplier 
pCMV-Myc 
Myc fusion protein. Mammalian expression 
vector that expresses proteins containing an N-
terminal c-myc epitope tag. 
Ampicillin Clontech 
pCMV-HA 
HA fusion protein. Mammalian expression vector 
that expresses proteins containing an N-terminal 
hemagglutinin epitope tag. 
Ampicillin Clontech 
pEYFP-C1 GFP fusion protein. Mammalian expression vector that expresses proteins as an N-terminal Kanamycin Clontech 
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fusion of enhanced yellow fluorescent protein. 
pGL3-Basic 
Luciferase reporter construct. contains a 
modified coding region for the firefly (Photinus 
pyralis) luciferase enzyme. Regulatory DNA 
sequences can be cloned upstream to monitor 
transcriptional activity in eukaryotic cells. 
Ampicillin Promega 
pGEX-4T1 
GST fusion protein. E.coli expression vector that 
utilises the tac promoter to control expression of 
cloned insert. Expression is induced upon addition 
of IPTG in any E.coli host though preferably 
BL21. The cloned insert is expressed with a 
glutathione S-transferase (GST) tag. 
Ampicillin Promega 
pET-32 
Thioredoxin and His-tagged fusion protein. 
E.coli expression vector that utilises the T7 lac 
promoter to control the expression of cloned insert. 
Expression is induced upon addition of IPTG in 
the host strain BL21. The cloned insert is 
expressed with N-terminal thioredoxin (TRX) and 
6 x histidine (His) fusion tags. ( 
Ampicillin Novagen 
 
2.3.2 Plasmid construction 
cDNA sequences were amplified from the ProQuest™ Human Fetal Brain cDNA 
Library (Invitrogen) and mutagenised where necessary (Section 2.3.4). All constructs 
were created according to cloning methods described in Sections 2.4.2, 2.4.3, 2.4.7. 
The primers used for construct generation are provided in Appendix II. The same full 
length TCF4 sequence was used for the GFP-TCF4, myc-TCF4 and HA-TCF4 
constructs (ENST00000565018). The HA-NEUROD1 and HA-ID2 constructs were 
prepared by Mrs. M. Doyle (DJ Blake Lab, Cardiff University). The HA-ASCL1, 
GFP-G358V, GFP-D535G, GFP-R578W and GFP-A614V constructs were prepared 
by Mrs. R. Chapman (DJ Blake Lab, Cardiff University).  
 
Name Insert Vector Restriction sites 
GFP-TCF4 Full length human TCF4-B
+ (671 amino 
acids) pEYFP-C1 EcoRI/SalI 
GFP-G358V GFP-TCF4 with amino acid number 358/671 converted from glycine to valine pEYFP-C1 EcoRI/SalI 
GFP-D535G GFP-TCF4 with amino acid number 535/671 converted from serine to glycine pEYFP-C1 EcoRI/SalI 
GFP-R578P GFP-TCF4 with amino acid number 576/671 converted from arginine to proline pEYFP-C1 EcoRI/SalI 
GFP-R580W 
GFP-TCF4 with amino acid number 
580/671 converted from arginine to 
tryptophan 
pEYFP-C1 EcoRI/SalI 
GFP-A614V GFP-TCF4 with amino acid number 614/671 converted from alanine to valine pEYFP-C1 EcoRI/SalI 
myc-TCF4 Full length human TCF4-B
+ (671 amino 
acids) pCMV-Myc EcoRI/NotI 
myc-G358V myc-TCF4 with amino acid number pCMV-Myc EcoRI/SalI 
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358/671 converted from glycine to valine 
myc-D535G myc-TCF4 with amino acid number 535/671 converted from serine to glycine pCMV-Myc EcoRI/SalI 
myc-R578P myc-TCF4 with amino acid number 576/671 converted from arginine to proline pCMV-Myc EcoRI/SalI 
myc-R580W 
myc-TCF4 with amino acid number 
580/671 converted from arginine to 
tryptophan 
pCMV-Myc EcoRI/SalI 
myc-A614V myc-TCF4 with amino acid number 614/671 converted from alanine to valine pCMV-Myc EcoRI/SalI 
HA-TCF4 Full length human TCF4-B
+ (671 amino 
acids) pCMV-HA EcoRI/NotI 
HA-ASCL1 Full length human ASCL1 (ENST00000266744) pCMV-HA EcoRI/KpnI 
HA-ATOH1 Full length human ATOH1 (ENST00000306011) pCMV-HA EcoRI/SalI 
HA-NEUROD1 Full-length human NEUROD1 (ENST00000295108) pCMV-HA SalI/NotI 
HA-ID2 Full-length human ID2 ((ENST00000331129) pCMV-HA SalI/NotI 
GST-TCF4 Amino acids 361-554 of the full length TCF4-B+ sequence (exons 14-18) pGEX_4T2 EcoRI/SalI 
TRX-TCF4 Amino acids 361-554 of the full length TCF4-B+ sequence (exons 14-18) pET_32c EcoRI/SalI 
pcDNA-E47 
The pcDNA-E47 plasmid was a kind gift 
from Dr.Carme Gallego, Molecular 
Biology Institute of Barcelona, Barcelona. 
pcDNA3.1 EcoRI/EcoRI 
myc-E47 Full length E47 cDNA cloned from the pcDNA-E47 plasmid pCMV-Myc EcoRI/SalI 
pLuc-CNTNAP2_F 2434bp of the CNTNAP2 promoter (5’ to 3’) (chr7:145811615-145814049) pGL3-Basic HindIII/HindIII 
pLuc-CNTNAP2_R 2434bp of the CNTNAP2 promoter (3’ to 5’) (chr7:145811615-145814049) pGL3-Basic HindIII/ HindIII 
pLuc-NRXN1β _F 599bp of the NRXN1β promoter (5’ to 3’) (chr2:50574779-50575378) pGL3-Basic HindIII/ HindIII 
pLuc-NRXN1β _R 599bp of the NRXN1β promoter (3’ to 5’) (chr2:50574779-50575378) pGL3-Basic HindIII/ HindIII 
 
2.3.3 Polymerase chain reaction (PCR) 
For polymerase chain reaction (PCR), oligonucleotide primers were designed 
complementary to 18-24 base pairs of the target sequence with an estimated melting 
temperature of 60°C. PCR primers are listed in Appendix II. When required, 
restriction endonuclease sites were added to the 5’ end of the primer sequence. To 
increase the efficiency of restriction enzyme cleavage, three base pairs were included 
at the 5’ end of the restriction enzyme recognition sequence. PCR was routinely 
performed using Red Taq (Sigma). When high fidelity PCR was required, Easy A 
(Stratagene) was used. A typical PCR reaction with cycling parameters is provided 
below. As an optimisation step, DMSO was optionally added to a final concentration 
of 5% (v/v). PCRs were performed using a GeneAmp PCR system 9700 (Applied 
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Biosystems) or a PTC-220 DNA Engine Dyad Thermal Cycler (MJ Research Inc.). 
PCR products were separated by gel electrophoresis using 1-3% agarose gels as 
described in Section 2.3.6. 
 
A typical PCR reaction with cycling parameters consisted of the following: 
Reagent Volume (µl) Final concentration Program 
10× PCR buffer  5 1× 1. 95°C for 5 min 
Forward primer (10µM) 1 0.2µM 2. 95°C for 30 s 
Reverse primer (10µM) 1 0.2µM 3. 56-62°C for 30 s Deoxynucleotide	  mix	  (10mM)	   1 200µM 4. 72°C 1 kb / min 
Template (10ng/ul) 1-5 10-50ng 5. cycle steps 2-5 20-40 times 
DNA polymerase (5 U/µl) 1 5U 6. 72°C for 7 min 
Molecular grade water Up to 50 	   7. hold at 4°C 	  	  
2.3.4 Site-directed mutagenesis 
Site-directed mutagenesis was used to introduce mutations into cDNA plasmid 
constructs. The primer design and protocol was based on the Quick-change site-
directed mutagenesis system and utilised the Pfu-Ultra high-fidelity DNA polymerase 
(Stratagene). A typical mutagenesis reaction with cycling parameters is provided 
below. 10 µl of reaction product was run on a 1% (w/v) agarose gel to confirm 
amplification of the DNA. 1 µl of DpnI restriction enzyme was added to the 
remaining reaction mix and incubated for 2 h at 37oC to digest the methylated, double 
stranded non-mutated DNA template. 2-5 µl of the digest product was used to 
transform 50-100 µl of chemically competent XL1-Blue cells using the heat shock 
method (Section 2.4.6). Multiple colonies were picked for plasmid purification 
(Miniprep) and the DNA was subsequently sequenced to confirm successful 
mutagenesis (Section 2.4.7). 
 
A typical mutagenesis reaction with cycling parameters consisted of the following: 
Reagent Volume	  (μl)	   Final concentration Program 
10× Pfu-Ultra reaction buffer  5 1× 1. 95°C for 2 min 
Forward primer (100µM) 1.25 2.5µM 2. 95°C for 30 s 
Reverse primer (100µM) 1.25 2.5µM 3. 55°C for 1 min 
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Deoxynucleotide	  mix	  (10mM)	   1 200µM 4. 68°C 1 kb / min DMSO	   2.5 5% (v/v) 5. cycle steps 2-5 16-18 times 
DNA template 1-5 5-50ng 6. hold at 4°C 
Pfu-Ultra DNA polymerase 1 2.5U - 
molecular grade water Up to 50 	   -­‐	  
 
2.3.5 PCR screening of colonies 
Bacterial colonies were resuspended in 50 µl sterile LB medium using radiation 
sterilised inoculation needles (Fisher Scientific). 5 µl was used as a template for the 
PCR reaction. A scaled-down standard PCR reaction using Red-Taq DNA 
polymerase was used with the appropriate primers to check for the presence of insert, 
with a reaction volume of 25 µl. The PCR reaction was resolved on an agarose gel 
and positive clones identified by presence of a band of correct size. For positive 
clones, the remaining 45 µl of colony resuspension was used to inoculate 5ml liquid 
media plus appropriate antibiotic, and incubated for 12-16 h at 37oC, 200 rpm. 
Plasmid DNA was prepared from this culture as described in Section 2.4.1. 
 
2.3.6 Agarose gel electrophoresis 
Agarose gels were typically made as 1% (w/v) agarose (Invitrogen) in 1× TAE buffer 
(40mM tris-acetic acid, 10mM EDTA pH 8.0). However, 0.5-2.0% gels were used 
according to the final size of the expected DNA fragments. The agarose was 
dissolved in 1× TAE by heating in a microwave oven on full power for 1 min cycles 
and cooled to 50oC. Ethidium bromide solution was added to a final concentration of 
0.5 mg/ml, and the gel solution poured into a gel former with comb inserted. The set 
gel was transferred to an electrophoresis tank and submerged in 1× TAE buffer. 
Samples were mixed with 6x gel loading buffer (30% (v/v) glycerol, 20 mM EDTA 
pH 8.0, 0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol in water) before 
loading into wells. A 1Kb Plus DNA Ladder (Invitrogen) was used as a size standard. 
The gel was run at 100 V for approximately 30 min or until an appropriate resolution 
was achieved. Ethidium bromide stained nucleic acid was visualised using a UV 
transilluminator system (Bio-Rad Gel Doc 2000 or UVP Bioimaging Systems AC1 
Auto Darkroom). 
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2.3.7 Gel extraction of DNA 
For the extraction of DNA from agarose gels, the QIAquick Gel Extraction kit 
(QIAGEN) was used according to manufacturers’ instructions. Samples were eluted 
in 30-50 ml of elution buffer or molecular biology grade water. 
 
2.4 Cloning 
2.4.1 Preparation of plasmid DNA  
DNA was isolated from either small-scale cultures (10 ml) or large-scale cultures 
(250 ml) of E.coli. The QIAGEN Spin Miniprep or Plasmid Maxiprep kits were used 
for all plasmid preparations according to manufacturers’ instructions. DNA was 
quantified using a Nanodrop spectrophotometer (GE Healthcare). 
 
2.4.2 Restriction digestion of DNA  
All restriction enzymes were purchased from NEB. For preparation of vectors for 
cloning, 1 µg of purified vector was cut with 20 U of the appropriate enzymes in a 
final reaction volume of 50 µl for 2 h at 37°C. The reaction mix was additionally 
treated with 10 U of calf intestinal alkaline phosphatase (CIP) for a further 1 h at 
37°C to minimise re-circularisation of the vector DNA. Digest reactions were 
resolved on an agarose gel, and the appropriate DNA fragment purified by gel 
extraction (Section 2.3.7). For digestion of purified PCR products, the entire purified 
product was mixed with the appropriate 10× buffer and restriction enzyme 
(approximately 20 U) for 1-2 h at 37°C. The digest was purified using the Qiagen 
PCR purification kit. To confirm the presence of an insert in a new vector, 1 µl of 
DNA was digested with the appropriate restriction enzyme (approximately 10 U) and 
10× buffer in a total volume of 20 µl for 1 h at 37°C. The restriction digest products 
were separated by agarose gel electrophoresis. 
 
2.4.3 Ligation of DNA sequences into expression vectors 
Ligation reactions of digested DNA were performed using T4 DNA ligase 
(Promega). A typical reaction consisted of a 3:1 molar ratio of insert to vector. 10µl 
ligation reactions contained 1 µl 10× ligase buffer, 1 µl T4 DNA ligase. Reactions 
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were centrifuged briefly before incubation overnight at 4°C. Control reactions 
containing insert only or vector only were prepared to confirm complete digestion of 
the insert and vector. Typically, 5 µl of the ligation reaction was used to transform E. 
coli (Section 2.4.6).  
 
2.4.4 Large-scale preparation of chemically competent E.coli XL1-Blue cells  
An E. coli XL1-Blue glycerol stock was streaked onto LB- tetracycline plates and 
grown overnight at 37°C. A single colony was inoculated into 10 ml LB-tet media 
and grown overnight (37°C, 200 rpm). 5ml of the overnight culture was used to 
inoculate 500ml LB-tet, which was grown at 37°C with agitation (200 rpm) until the 
cells reached mid-log phase (OD600 approximately 0.5). The culture was cooled on 
ice for 2 h and the bacteria were pelleted by centrifugation at 4000 rpm for 20 min at 
4°C. The pellet was gently resuspended in 250 ml fresh, ice-cold, filter sterilised salt 
buffer (100 mM calcium chloride (CaCl2), 70 mM manganese chloride (MnCl2), 40 
mM sodium acetate	  (NaOAc) pH 5.5) and incubated on ice for 45 min. After 
incubation, the bacteria were pelleted by centrifugation at 4000rpm for 10 min at 
4°C. The pellet was resuspended in a total of 50 ml salt buffer and 11.5 ml ice-cold 
filter sterilised 80% (v/v) glycerol was added drop-wise with gentle agitation, to give 
a final concentration of 15% (v/v). Single aliquots of 500 µl were stored at -80°C. 
 
2.4.5 Small-scale preparation of chemically competent E.coli BL21  
A single colony was used to inoculate 10 ml LB media that was incubated overnight 
at 37oC, 200 rpm. 500 µl of the overnight culture was used to inoculate 10 ml LB 
media and was incubated at 37oC, 200 rpm until OD600 reached 0.2-0.3 
(approximately 90 min). Cells were harvested by centrifugation at 4000 rpm, 15 min, 
4oC, and the pellet resuspended in 5 ml of ice-cold 100 mM CaCl2. The cells were 
incubated on ice for 10 min, centrifuged again (as above) and the pellet resuspended 
in 400ml 100mM CaCl2. Cells were stored at 4oC for a maximum of 7 days. 
 
2.4.6 Transformation of bacteria using the heat-shock method   
An aliquot of chemically competent cells was thawed on ice before use and the 
contents mixed thoroughly. 5 µl of ligation mix or 1 µl diluted plasmid (10 ng) were 
mixed with 50 µl of competent cells in a pre-chilled 15 ml polypropylene tube 
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(Falcon 2059, BD Bioscience) and incubated on ice for 30 min. Cells were heat-
shocked for 45 s at 42oC and immediately cooled on ice for a further 2  min before 
addition of 1 ml LB media. Cells were incubated at 37oC for 30-60 min to allow 
recovery before transfer to a 1.5 ml microcentrifuge tube and centrifugation at 13,000 
rpm, 1 min, and the pellet resuspended in 200 ml LB media. The cell suspension was 
plated onto LB agar plates supplemented with appropriate antibiotic. The plates were 
incubated overnight at 37oC. 
 
2.4.7 DNA sequencing  
Sequencing reactions were carried out by the Geneservice Oxford DNA sequencing 
service at the Department of Biochemistry, University of Oxford. All sequencing was 
performed using ABI BigDye Terminators V3.1 (Applied Biosystems). The 
sequencing chromatogram traces were checked using Chromas Lite, version 2.01 
(Technelysium Pty Ltd). 
 
2.5  Protein analysis 
2.5.1 Sample preparation 
For the detection of recombinant proteins in mammalian cells, 7.5x105 SH-SY5Y or 
5x105 HEK293T cells were seeded into 6-well plates, transfected after 24h, and 
harvested after a further 24 h. To detect endogenous protein in SH-SY5Y, 7.5x105 
cells were seeded into 6-well plates and grown for 48 h. Cells were washed twice 
with PBS and lysed directly in 250 µl 2× SDS-sample buffer (0.125 M Tris pH 6.8, 
4% sodium dodecyl sulphate (SDS), 20% (v/v) glycerol, 5% (v/v) β-mercaptoethanol, 
0.001 (w/v) bromophenol blue). Lysed cells were scraped, transferred to a 1.5ml 
microcentrifuge tube and sonicated using a UP50H Ultrasonic Processor (Hielscher). 
10-20 µl was used for analysis by SDS-PAGE (Section 2.5.2). For quantitation of 
protein levels after siRNA treatment, transfected SH-SY5Y cells were washed twice 
with PBS and lysed in 100 µl of RIPA (150mM NaCl, 50mM Tris pH 8.0, 1% (v/v) 
Triton X-100, 0.5% (w/v) sodium deoxycholate, and 1mM EGTA) buffer. Lysed 
cells were scraped, transferred to a 1.5ml microcentrifuge tube and sonicated with a 
UP50H Ultrasonic Processor (Hielscher). The lysates were clarified by centrifugation 
at 13’000 rpm for 10 min and the protein content of the supernatant was quantified 
using a BCA assay (Pierce). The required amount of protein was diluted in 2× sample 
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buffer and analysed by SDS-PAGE (Section 2.5.2). For all other samples, a 1:1 ratio 
of 2× SDS-sample buffer was added to the sample prior to sonication using a UP50H 
Ultrasonic Processor (Hielscher). All samples were boiled for 5 min at 95oC and 
cooled on ice prior to separation by SDS-PAGE. All samples were stored at –20oC 
for long-term storage. 
 
2.5.2 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)  
Protein samples were separated on 10 or 12% (v/v) acrylamide gels by SDS-PAGE, 
under denaturing and reducing conditions using the Mini Protean III Gel System 
(Bio-Rad). The resolving gel contained 380mM Tris-HCl  pH 8.8, 6-15% (v/v) 
acrylamide (30% (w/v) acrylamide: 0.8% (w/v) Bis-acrylamide (37.5:1)) (National 
Diagnostics), 0.1% (w/v) SDS, 0.1% (w/v) ammonium persulphate (APS) and 0.08% 
N,N,N´,N´-Tetramethylethylenediamine (TEMED). The stacking gel consisted of 
125mM Tris-HCl pH 6.8, 5% (v/v) acrylamide (30% (w/v) acrylamide: 0.8% (w/v) 
Bis-acrylamide (37.5:1)), 0.1% (w/v) SDS, 0.1% (w/v) APS and 0.1% TEMED. The 
resolving gel was layered with isopropanol during the polymerisation process to 
ensure a level interface with the stacking gel. Following polymerisation, the IPA was 
discarded and the top of the gel was gently washed with water. The stacking gel was 
then layered onto the resolving gel and a lane-forming comb was inserted. When the 
stacking gel had polymerised, the gels were immobilised in the clamp system, 
submerged in SDS-PAGE running buffer (25 mM Tris-base, 192 mM glycine, 1% 
(w/v) SDS). Pre-stained Protein Marker, Broad Range (6-175 kDa) (New England 
Biolabs) or all blue prestained Precision Plus (10-250 kDa) (Bio-Rad) were used as 
protein standards. Gels were run at 150 V for approximately 85 min or until the 
appropriate resolution of the visible pre-stained protein standard was achieved.  
 
2.5.3 Coomassie stained SDS-PAGE gels  
For direct visualisation of protein after SDS-PAGE, the gel was stained with 
coomassie stain (0.1% (w/v) coomassie brilliant blue, 40% (v/v) methanol, 10% (v/v) 
acetic acid) for 1-2 h or overnight at room temperature, followed by destaining for 2-
6 h in 40% (v/v) methanol, 10% (v/v) acetic acid at room temperature. Gels were 
rinsed in distilled water and scanned using the Odyssey® Infrared Imaging System 
(LI-COR Biosciences) in the 700nm channel with a focus offset of 0.5mm.    
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2.5.4 Western blotting  
Following electrophoresis, protein from unstained SDS-PAGE gels was transferred to 
nitrocellulose membrane (Trans-blot transfer medium, 0.2mm pore size, Bio-Rad) 
using the Mini Trans-blot electrophoretic transfer cell (Bio-Rad). Proteins were 
transferred for 1 h at 75 V for a single gel or 85 V for two gels in transfer buffer (25 
mM Tris-base, 192 mM glycine, 1% (w/v) SDS, 20% (v/v) methanol). The 
membrane was blocked either for 1 h at room temperature or overnight at 4oC in 
TBST with 5% (w/v) dried skimmed milk powder. After blocking, the membrane was 
incubated for 1-2 h at room temperature or overnight at 4oC in primary antibody 
diluted at the required concentration (see Section 2.5.5) in 5-10 ml blocking solution. 
The membrane was washed with two 5 min washes in TBST and a final wash in 
blocking solution, before incubation with the secondary antibody (Section 2.5.5) 
diluted in 5-10 ml blocking solution. The secondary antibody was incubated at room 
temperature for 30 min (Alexa Fluor 680 or IRDye 800-conjugates) protected from 
light. Three additional 5 min washes with TBST were completed before detection.  
Fluorescent secondary antibodies were detected using the two-colour Odyssey® 
Infrared Imaging System (LI-COR Biosciences). 
 
2.5.5 Antibodies and stains 
A table of antibodies and stains used in this thesis is provided below with their 
individual uses and required dilutions. Abbreviations: WB; western blot, ICC; 
immunocytochemistry, HTRF; Homogenised time-resolved fluorescence, EuK; 
europium cryptate, DSHB; Developmental Studies Hybridoma Bank) 
 
Name Source Type Use and dilution 
Primary Antibodies 
TCF4 M03 Commercial (Abnova, M03) Mouse monoclonal WB (1:1000) 
SC35 Commercial (Abcam, ab11826) Mouse monoclonal ICC (1:5000) 
β-actin Commercial (AC-15, Sigma) Mouse monoclonal WB (1:1000) 
caspase 3 Commercial (Cell Signaling, 9662) Mouse monoclonal WB (1:1000) 
myc-EuK (conjugated) Commercial (Cisbio, 61MYCKLA) Mouse monoclonal  HTRF (1:400) 
HA-XL665 (conjugated) Commercial (Cisbio, 610HAXLA) Mouse monoclonal  HTRF (1:400) 
TCF4_01 In-house (anti-GST-TCF4) Rabbit polyclonal WB (1:250) 
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ICC (1:400) 
TCF4_02 In-house (anti-TRX-TCF4) Rabbit polyclonal 
WB (1:250) 
ICC (1:400) 
α-tubulin DSHB (Hybridoma, 12G10) Mouse monoclonal WB (1:20’000) 
myc DSHB (Hybridoma, 9E10) Mouse monoclonal 
WB (1:400) 
ICC (1:1000) 
Secondary Antibodies 
Alexa Fluor 546 Commercial (Invitrogen) Goat anti-rabbit ICC (1:2’000) 
Alexa Fluor 680 Commercial (Invitrogen) Donkey anti- rabbit WB (1:20’000) 
IRDye 800  Commercial (LI-COR) Donkey anti- mouse WB (1:20’000) 
Stains 
Alexa Fluor 488 
phalloidin 
Commercial (Invitrogen) N/A ICC (165nM) 
Hoechst 33342 Commercial (Invitrogen) N/A ICC (1µg/ml) 
 
 
2.6 Protein expression and purification 
2.6.1 Induction of protein expression using pET-32 or pGEX-4T system  
The TRX-TCF4 and GST-TCF4 recombinant plasmids were expressed in BL21 
(DE3) strain of E. coli. Cells containing expression plasmids were selected on LB 
agar containing ampicillin (Section 2.2.1) and a single colony used to inoculate 10ml 
LB media supplemented ampicillin. This was incubated overnight at 37oC, 200 rpm. 
500 µl of the overnight culture was used to inoculate 250ml LB media, which was 
incubated at 37oC, 200 rpm for approximately 3 h until an OD600 of approximately 
0.6. Expression of the fusion protein was induced by the addition of 1mM IPTG for a 
further 3-5 h at 37oC, 200 rpm. Cells were harvested at 12,000 rpm for 20 min. In 
some cases, the pellet was kept for long-term storage at –20oC. Pre-induction and 
post-induction aliquots were processed for SDS-PAGE and coomassie stained to 
verify successful induction (Section 2.5.1, 2.5.2 and 2.5.3).    
 
2.6.2 Purification of the TRX-TCF4 fusion protein 
Cell pellets were resuspended in 15 ml sonication buffer (20mM Tris pH 8.0, 100mM 
NaCl) and sonicated using a Vibra-Cell Ultrasonic Processor (Sonics). Samples were 
periodically chilled on ice to avoid heat-denaturation of fusion protein. Cells were 
harvested by centrifugation at 12,000rpm, 15 min at 4oC. Soluble proteins were found 
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in the supernatant; whereas insoluble proteins were extracted from the pellet by 
resuspension in 15ml sonication buffer containing 8M Urea, followed by 
centrifugation at 12,000rpm, 15 min, and 4oC to remove cell debris. The TRX-TCF4 
fusion protein in the soluble fraction was purified using immobilised metal affinity 
chromatography (IMAC) using TALON® Resin (Clontech). A 2ml bed volume was 
packed into an Econo-Pac® disposable chromatography column (Bio-Rad) and 
equilibrated with one column fill of sonication buffer. The fusion protein was then 
passed over the column for 1h. Unbound protein was drained and the affinity resin 
washed with a column fill of sonication buffer and a frit inserted just above the 
packed affinity resin. The recombinant protein was eluted from the TALON® column 
using sonication buffer plus 100mM imidazole and collected in 2ml fractions. The 
protein was typically present in the 2nd and 3rd fractions. Aliquots of pre-purification 
fractions and elutions were processed for SDS-PAGE and coomassie stained to verify 
successful purification (Section 2.5.1, 2.5.2 and 2.5.3). 
 
2.6.3 Purification of GST-TCF4 fusion protein 
Solubilisation of the GST-TCF4 fusion protein was performed in sonication buffer as 
described above for TRX-TCF4 (Section 2.6.2). The GST-TCF4 fusion protein in the 
soluble fraction was purified using Glutathione Sepharose 4B (Amersham 
Biosciences). A 0.5ml bed volume was packed into an Econo-Pac® disposable 
chromatography column (Bio-Rad) and equilibrated with one column fill of 
sonication buffer. The fusion protein was then passed over the column for 1h. 
Unbound protein was drained and the affinity resin washed with a column fill of 
sonication buffer and a frit inserted just above the packed affinity resin. The 
Glutathione Sepharose 4B column was washed with 10 column volumes of 50 mM 
Tris pH 8.0 prior to elution in 50 mM Tris pH 8.0 containing + 10 mM reduced 
glutathione. Elutions were incubated on the column for 5 min and collected in 0.5 ml 
fractions. Aliquots of pre-purification fractions and elutions were processed for SDS-
PAGE and coomassie stained to verify successful purification (Section 2.5.1, 2.5.2 
and 2.5.3). 
 
2.6.4 Antibody Production 
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Rabbit polyclonal antibodies were raised against the TRX-TCF4 and GST-TCF4 
fusion proteins obtained using the methods described above (Section 2.6.1-2.6.3). 
Immunisations were performed by Covalab (UK). Two New Zealand rabbits were 
immunised for each purified fusion protein using an 88 day protocol with four 
immunisations. 
 
2.6.5 Production of affinity purification columns 
The thioredoxin fusion protein used to produce antisera was desalted into reduction 
buffer (0.1 M sodium phosphate, 5 mM EDTA) using an Econo-Pac® 10DG desalting 
column (Bio-Rad) equilibrated with reduction buffer. 3 ml was allowed to enter the 
column, and was eluted with 4ml reduction buffer. This was reduced with 25 mM 
DTT at 37oC for 90 min in the dark. The Econo-Pac® 10DG desalting column was 
equilibrated with coupling buffer (50mM Tris pH 8.5, 5mM EDTA). 2 ml coupling 
buffer was added to the 4ml reduced fusion protein and 3ml added to the desalting 
column. The fusion protein was eluted with 4 ml coupling buffer, and the process 
repeated with the final 3 ml to give a final volume of 8 ml fusion protein in coupling 
buffer. This was coupled to 2ml packed (4ml slurry) of Sulfolink® Coupling Gel 
(Pierce) as per manufacturers’ instructions, and the resulting column used for the 
affinity purification of antibodies. Columns were stored at 4oC with the column bed 
equilibrated in phosphate buffered saline (PBS; 10mM phosphate buffer, 2.7mM 
KCl, 137mM NaCl, pH 7.4) plus 0.025% (v/v) sodium azide.    
 
2.6.6 Affinity purification of antisera 
Affinity chromatography columns were equilibrated with PBS. 5 ml of antiserum was 
diluted to 20 ml with PBS. The diluted antiserum from the TRX-TCF4 immunisation 
was passed over a thioredoxin column (kindly provided by Dr. C. Tinsley, DJ Blake 
Lab, Cardiff University) for 1h at room temperature to pre-absorb against thioredoxin 
specific antibodies in the antisera. The pre-absorbed antiserum was then repeatedly 
passed over the TRX-TCF4 affinity chromatography column for 1h. In the case of the 
antiserum from the GST-TCF4 immunisation, the diluted antiserum was directly 
passed over the TRX-TCF4 affinity chromatography column for 1h without pre-
absorbing. To purify non-specific IgG, 1 ml of pre-immune rabbit serum was diluted 
to 20 ml with PBS and passed over a Protein A agarose bead column with 2 ml bed 
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volume (provided by Dr. A. Waite, DJ Blake Lab, Cardiff University) for 1 h. 
Following antibody binding, columns were washed with 2 column fills of PBS and 
the bound antibodies eluted with ImmunoPure® IgG elution buffer (Pierce) in 1ml 
fractions and neutralised by the addition of 50 ml/ml 1 M Tris pH 9.0. Columns were 
regenerated by thorough washing with at least five column bed volumes of 
ImmunoPure® IgG elution buffer, followed by a column fill of PBS, and long term 
storage was maintained in PBS with 0.025% sodium azide at 4oC. 
 
2.7 Proteomics 
2.7.1 Cross-linking antibodies to protein A beads 
The TCF4_01, TCF4_02 and pre-immune IgG antibodies were coupled to protein A 
agarose beads (Invitrogen). 2 mg of affinity-purified antibody was coupled to 0.5 ml 
packed beads (equilibrated with PBS), rotating at room temperature for 2 h. The 
beads were spun down at 2,000 rpm for 5 min and washed twice with 5 ml 0.1M 
borate buffer (0.2 M di-sodium tetraborate, 0.2 M boric acid, pH 9.0). The bound 
antibody was cross-linked to the beads through incubation with 20 mM dimethyl 
pimelimidate dihydrochloride (DMP) in 9.5 ml borate buffer by rotating for 30 min at 
room temperature. The beads were spun down by centrifugation at 2,000 rpm for 5 
min and the reaction stopped by washing the beads in 5 ml 0.1M ethanolamine, pH 
8.0. Unreacted DMP was quenched by incubating the beads in 5 ml 0.1 M 
ethanolamine for 1 h at room temperature, before centrifugation (as above), washing 
in 5ml PBS and centrifugation again. To remove uncoupled IgG, the beads were 
washed with 5 ml of ImmunoPure® IgG elution buffer, followed by two PBS washes 
and transfer to a 1.5ml microcentrifuge tube. The beads were stored as a 50% slurry 
in PBS plus 0.05% sodium azide at 4oC. 
 
2.7.2 Immunoprecipitation (IP) 
SH-SY5Y cells were seeded at 5 × 106/dish in four 15 cm dishes (BD Bioscience) 
and grown for 48 h. Cells were washed twice with PBS, scraped into a 15 ml falcon 
tube (Corning) with 10 ml of PBS, and pelleted for 2 min at 2500 rpm and 4oC. PBS 
was removed, and the cells were solubilised in 4 ml of ice-cold RIPA buffer for 30 
min at 4oC. The sample was homogenised for 10 s using a POLYTRON® PT3100 
(Kinematica) and then placed on ice 30 s. Homogenisation was repeated two more 
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times. The sample was further homogenised by passage through a 23G needle six 
times. The lysate was divided into four 1.5 ml eppendorfs and clarified by 
centrifugation for 10 min at 13’000 rpm and 4oC. Samples were pooled into a 15cm 
falcon tube and a 50 µl sample (input) was taken prior to pre-clearing with 50 µl of 
packed protein A agarose beads (equilibrated with RIPA) for 1-2 h at 4oC with 
constant rotation. The beads were pelleted for 2 min at 2500 rpm (4oC) and the pre-
cleared lysate was divided into four samples (two controls, two IPs). For TCF4 IP, 
5µg of affinity purified TCF4_01 or TCF4_02 was added to the protein lysates. For 
control IPs, either 5 µg of affinity purified 9E10 antibodies or no antibody was added 
(no Ab). All samples were incubated overnight at 4oC with constant rotation. The 
following day, insoluble material was pelleted by centrifugation for 10 min at 13’000 
rpm (4oC) and the supernatants were transferred to new 1.5 ml eppendorf tubes. 
Antibody complexes were captured by the addition of 15 µl of packed protein A 
agarose beads (equilibrated with RIPA) to each tube and constant rotation for 1 h at 
22 rpm (4oC). Beads were spun down by centrifugation and a 50 µl sample was taken 
(post-IP) prior to washing the beads four times with 1 ml of RIPA buffer. RIPA 
buffer was removed and 70 µl of 2× SDS-sample buffer was added to the beads. 50 µl 
of 2× SDS-sample buffer was added to the ‘input’ and ‘post-IP’ samples. Samples 
were heated to 95oC for 5 min before resolution by SDS-PAGE (Section 2.5.2).  
 
2.7.3 Large-scale immunoaffinity purification (IAP) 
The following section describes the procedure for IAP with one TCF4 antibody and 
one control antibody. SH-SY5Y cells were seeded at 5 × 106 cells/dish in sixteen 15 
cm dishes (BD Bioscience) and grown for 48 h (approximately 2 × 108 cells after 
growth). Each dish was washed twice with ice-cold PBS, the cells were scraped and 
divided into two 50 ml polypropylene tubes (Corning). Tubes were filled to 50 ml 
with ice-cold PBS and the cells were pelleted for 2 min at 2500 rpm and 4oC before 
removal of the PBS. At this stage, cells could be stored at -80 oC. Frozen cells were 
thawed on ice prior to use. Fresh or thawed cells were solubilised in 10 ml of ice-cold 
RIPA buffer per 50 ml polypropylene tube for 30 min at 4oC. The lysed cells were 
homogenised for 10 s using a POLYTRON® (Kinematica) and then placed on ice 30 
s. Homogenisation was repeated two more times. The sample was further 
homogenised by passage through a 23G needle six times. The lysates were combined 
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and clarified by centrifugation for 10 min at 13’000 rpm (4oC) and a 50 µl sample 
(input) was taken. The lysate was pre-cleared with 300 µl of packed protein A 
agarose beads (equilibrated with RIPA buffer) in a 50 ml polypropylene tube for 3h 
at 4oC. The pre-cleared lysate was divided into two samples, one incubated with 50 µl 
of packed TCF4-protein A agarose beads (equilibrated with RIPA buffer), and the 
other 50 µl of IgG-protein A agarose beads (equilibrated with RIPA buffer). Samples 
were incubated under constant rotation for 3 h at 4oC. The following incubation, an 
unbound fraction was taken, beads were washed four times with 10 ml RIPA buffer 
followed by transfer to a 1.5 ml microcentrifuge tube. Proteins were eluted with 70ul 
of SDS-sample buffer, boiled at 95oC for 5 min, and cooled on ice. The eluted sample 
was pulse centrifuged before resolution on a 4-12% gradient NuPAGE® Novex Bis-
Tris gel (Invitrogen), run in 1× MOPS Running Buffer (Invitrogen) using an XCell 
SurelockTM Mini-Cell electrophoresis system (Invitrogen). Gels were run for 90 min 
at 150V before fixing for 15 min in 50% (v/v) methanol, 7% (v/v) acetic acid, diluted 
molecular grade water (Millipore). Gels were washed two times 5 min in molecular 
grade water prior to staining with 20 ml colloidal coomassie blue stain (Gelcode Blue 
Stain Reagent, Pierce) for 2 h, followed by de-staining with molecular grade water. 
Coomassie stained gels were scanned using the Odyssey® Infrared Imaging System 
and bands of interest excised with a clean scalpel blade, transferred to sterile 1.5 ml 
microcentrifuge tubes and sent for mass spectrometry. 
 
2.7.4 Mass spectrometry 
Excised gel plugs were sent to the Functional Genomics and Proteomics 
Laboratories, School of Biosciences, University of Birmingham to be processed and 
digested for mass spectrometry. The UltiMate® 3000 HPLC series (Dionex) was 
used for peptide concentration and separation. Peptides were eluted using a Triversa 
Nanomate nanospray source (Advion Biosciences) into a LTQ Orbitrap Velos ETD 
mass spectrometer (ThermoFisher Scientific). The data-dependent scanning 
acquisition was controlled by Xcalibur 2.1 software. Peptide data was matched 
against the NCBInr database using Mascot algorithm (Matrix Sciences) and software 
Proteome Discoverer 1.3 (ThermoFisher Scientific). The Mascot algorithm uses 
probability based scoring to identify proteins from the database. The cumulative 
protein score is based on summing the ion scores of the unique peptides identified for 
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that protein. If a peptide is redundantly identified, only the highest-scoring peptide is 
used. Scores are reported as –10 × Log10 (P), where P is the probability that the 
observed match is a random event. Variable modifications were deamidation (N and 
Q), oxidation (M) and phosphorylation (S, T and Y). 
 
2.8 Cell biology 
2.8.1 Immunocytochemistry  
Cells were grown on sterile glass coverslips (22mm x 22mm) in 6-well plates seeded 
with 5×104 COS-7 or 7.5×104 SH-SY5Y cells. Cells were grown for 24 h, 
transfected, and fixed 24 h later. COS-7 cells were transfected with 1 µg of plasmid 
DNA and 6 µl of FuGENE (Roche). SH-SY5Y were transfected with 3 µg of plasmid 
DNA and 10 µl of lipofectamine 2000 (Invitrogen). For siRNA treatment, cells were 
fixed after the 72 h knockdown protocol (Section 2.9.2). Cells were washed twice 
with PBS and fixed with 1ml of 4% paraformaldehyde (PFA) solubilised in PBS for 
15 min at room temperature. The PFA was removed and the cells permeabilised with 
2 ml PBS and 0.1% (v/v) Triton X-100 at 4°C for 15 min. Following 
permeabilisation, the cells were washed three times with PBS for 5 min with shaking. 
The cells were blocked with 1 ml of 10% (v/v) FCS for 20 min at room temperature. 
Blocking solution was removed and the primary antibody diluted in 1 ml PBS 
containing Heoscht stain (1ug/ml) was added to the cells for 1 h at room temperature 
with shaking. The cells were washed twice with PBS for 5 min and were incubated 
with the secondary antibody in 1 ml PBS at room temperature with shaking for 30 
min. The antibodies used in this study are presented in Section 2.5.5. Following a 
final set of three 5 min PBS washes, the coverslips were mounted onto glass slides 
with Aqua Poly/Mount (Polyscience, Inc.). Cells were visualised using a Leica SP5 
or Leica DM6000B confocal microscope with a 63x oil immersion objective lens. 
The images were assembled using ImageJ, Adobe Photoshop and Illustrator, in which 
images were cropped and adjusted for brightness and contrast but otherwise not 
manipulated. 
 
2.8.2 Homogeneous time resolved fluorescence (HTRF) 
Six well plates were seeded with HEK-293T cells at 5×105 cells/well. After 24 h, 1 
µg of the appropriate HA-tagged and myc-tagged constructs were transfected into a 
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6-well using FuGENE 6. Negative control experiments were also performed that 
consisted of either a transfection with only one of the epitope-tagged constructs or the 
empty pCMV-HA and pCMV-myc vectors. 24 h after transfection, the cells were 
washed with ice-cold PBS and lysed in 0.5 ml of chilled NP-40-containing buffer 
(50mM Tris pH 7.4, 150mM NaCl, 1% (v/v) NP-40, 0.1% (w/v) BSA, 100mM 
potassium fluoride) for 30min at 4°C and homogenised using a 23 G syringe needle. 
Lysates were clarified by centrifugation at 13’000 rpm for 10 min (4°C) and 100µl of 
clarified supernatant was diluted 1:1 in NP-40 buffer containing 0.5µl of anti-HA-
europium cryptate (Cisbio) and 0.5µl anti-9E10-XL665 (Cisbio) and incubated in a 
96-well microplate (Greiner Bio-one) overnight on a shaker at 4˚C. Three biological 
replicates and two technical replicates for each experimental condition were read on a 
dedicated HTRF reader (Berthold Artemis K-101) with a 100ms delay, 100ms 
integration time and flash number of 50. For each condition, the mean and standard 
error were calculated from at least three separate experiments. 
 
2.8.3 Luciferase assays 
HEK-293T cells were seeded at 104 cells/well on 96 well plates and left to grow for 
24 h. The pGL3-basic (luciferase reporter), pRL-CMV (Renilla reporter) and all 
reagents used were part of the Dual-Luciferase assay system (Promega). The design 
strategy for promoter regions cloned into pGL3-basic is described in Section 2.10.2. 
Each 96-well was transfected with one HA-tagged bHLH transcription factor 
construct (5-10 ng), one myc-tagged transcription factor (20 ng), a Renilla luciferase 
control (0.5 ng), and a luciferase reporter construct (pLuc-CNTNAP2 or pLuc-
NRXN1β) in total volume of 2 µl using FuGENE 6 (Roche) (see table below). 
Luciferase reporter constructs in the reverse direction (pLuc-CNTNAP2_R and pLuc-
NRXN1β _R) were used as negative controls for promoter activity. 24 h post-
transfection, cells were washed with 100 µl of PBS and lysed in 20 µl of passive lysis 
buffer for 15 min at room temperature with slow mixing on an orbital shaker. The 
fluorescent signal was read on a Berthold LB 96 V plate-reader with automatic 
injection dispensing 50 µl of LARII reagent followed by 50 µl of “stop and glow” 
reagent. Each measurement was integrated over 10s with 2s delay between 
measurements. Results represent the mean and standard error of experiments 
performed in quadruplicate. 
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Each transfected 96-well contained one construct of the following categories: 
Construct ng DNA 
1. HA-tagged bHLH protein 
    HA-TCF4, HA-ATOH1, HA-ASCL1, HA-NEUROD1, HA-ID2 5-10 
2. myc-tagged TCF4 or mutant 
    myc-TCF4, myc-G358V, myc-D535G, myc-R574P, myc-R580W, myc-A614V 20 
3. Promoter 
    pLuc-CNTNAP2_F or pLuc-CNTNAP2_R 100 
    pLuc-NRXN1β _F or pLuc-NRXN1β _R 75 
4. Renilla luciferase (transfection control) 
    pRL-CMV 0.5 
 
2.8.4 Cell viability and caspase assays 
SH-SY5Y cells were seeded at 104 cells/well in two 96 well clear bottom plates and 
left to grow for 24 h. 24 replicate wells were treated with the appropriate siRNA 
using the 72 h knockdown protocol (Section 2.9.2). Cell viability and caspase 3/7 
activation were measured in the same wells using the CellTiter-Fluor™ Cell Viability 
(Promega) and the Caspase-Glo® 3/7 (Promega) assays. 3 h prior to the start of the 
assays, 1 µl of staurosporine dissolved in DMSO (100µM stock) or 1 µl of DMSO 
was added to 24 previously untreated wells as a positive control and negative control 
respectively. For cell viability, 20 µl of a 5× concentrate of CellTiter-Fluor™ Cell 
Viability reagent was added to the 100 µl of each 96 well and mixed briefly by orbital 
shaking. The plates were incubated for 45 min at 37°C and the emitted luminescent 
signal was measured in 24 wells for each condition using the luminometer module of 
a FLUOstar OPTIMA microplate reader with a gain of 1000. After the first 
measurement, 120 µl of 1× Caspase-Glo® 3/7 reagent was added to 12 wells of each 
condition and mixed briefly by orbital shaking prior to incubation for a further 45 
min at 37°C. The emitted fluorescent signal was measured using the fluorometer 
module of a FLUOstar OPTIMA microplate reader. Readings were taken from the 
top of the wells with a gain of 4000. All data were normalised to the levels in the 
mock-transfected cells, and represented as the mean and standard error. t-tests were 
used to compare treatment groups. In addition to the microplate assays, caspase 3 
cleavage was assessed by western blotting. SH-SY5Y cells were seeded in 6 well 
plates and transfected with the appropriate siRNA using the 72 h knockdown protocol 
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(Section 2.9.2). After treatment, dead cells were collected from the media by 
centrifugation and lysed 100 µl RIPA buffer with the remaining live cells. The 
protein content was measured using a BCA assay (Pierce) and 15µg of each lysate 
was used for western blotting with caspase 3 and β-actin antibodies (Section 2.5.4). 
 
2.9 Gene expression analysis 
2.9.1 Short interfering RNA (siRNA) design 
27 nucleotide long blunt-ended RNA oligonucleotide duplexes (27mers) were used 
for all siRNA treatments. To knockdown TCF4, siRNAs were designed using 
predictive algorithms (siDESIGN Center, http://www.thermoscientificbio.com; 
siMAXTM Design Tool, http://www.eurofinsdna.com). Two non-overlapping 
sequences were selected according to predicted efficacy scores and homology to 
regions of interest. For siRNA sequences targeting the TCF4-A isoform, only one 
sequence (KDA2) was identified by the predictive algorithms due the limited length 
of the unique sequence in exon 1 therefore the second siRNA was designed manually 
(KDA1). The 27mer targeting GAPDH was designed from a 23 nucleotide sequence 
known to be effective for knocking down GAPDH provided by Dr. C. Tinsley (DJ 
Blake Lab, Cardiff University). The GAPDH siRNA was used in control experiments 
to identify transcripts that were altered by non-specific mechanisms related to the 
presence interfering RNA in cells. Lyophilised siRNA was reconstituted in siMAX 
Universal Buffer (30mM HEPES, 100mM KCl, 1mM MgCl2; pH 7.3) as a 50mM 
stock and stored at -80°C. Sequences of siRNA duplexes used in this thesis are 
provided in the table below: 
 
siRNA 
name 
siRNA 
binding site 
siRNA-mediated 
effect 
siRNA Sequence 
GAPKD 
GAPDH 
exon 1-2 
GAPDH Knockdown 5’- CGGAGUCAACGGAUUUGGUCGUAUUGG 
KD1 
TCF4-B  
exon 10-11 
Global TCF4 
knockdown 
5’-GGGACAGACAGUAUAAUGGCAAAUAGA 
KD2 
TCF4-B 
exon 17 
Global TCF4 
knockdown 
5’-AUAAUGACGAUGAGGACCUGACACCAG 
KDB1 
TCF4-B 
exon 1 
TCF4-B knockdown 
(long isoform) 
5’- GGGACGGACAAAGAGCUGAGUGAUUUA 
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KDB2 
TCF4-B 
exon 2-3 
TCF4-B knockdown 
(long isoform) 
5’-ACUGGCUCAAAUGUAGAAGACAGAAGU 
KDA1 
TCF4-A 
exon 1 
TCF4-A knockdown 
(short isoform) 
5’-ACTGCGCATACACAATCCCGGGCATGG 
KDA2 
TCF4-A 
exon 1 
TCF4-A knockdown 
(short isoform) 
5’-GCAACUCUUUGAUGUACUACUAUAAUG 
 
2.9.2 siRNA-mediated knockdown protocol 
SH-SY5Y were seeded at 2×105 cells per well in 6 well plates. 24h after seeding, 
cells were transfected with the required siRNA duplexes at a final concentration of 10 
nM using 4 µl of Lipofectamine® RNAiMAX (Invitrogen) or mock transfected with 
just the transfection reagent. For the 72 h knockdown protocol used in Chapter 4, the 
cells were re-transfected 48 h after the first transfection using the same conditions 
and cells from each condition were prepared for RNA and protein extraction the 
following day. Each transfection was performed in quadruplicate and three biological 
replicates were used for gene expression analysis whilst the remaining sample was 
used for western blotting. For the 48 h knockdown protocol used in Chapter 5, the 
cells were re-transfected 24 h after the first transfection using the same conditions 
and cells from each condition were prepared for RNA and protein extraction the 
following day. Each transfection was performed in five replicates and four biological 
replicates were used for gene expression analysis whilst the remaining sample was 
used for western blotting. In both protocols, cells were lysed in 350 µl of RLT buffer 
for RNA extraction (Section 2.9.3) and 100 µl of RIPA buffer for protein extraction 
(Section 2.5.1). The RNA and protein quantification was determined using qPCR 
(Section 2.9.4) and western blotting (Section 2.5.4) respectively. 
 
2.9.3 RNA extraction and cDNA synthesis 
Total RNA was prepared from SH-SY5Y cells using the RNeasy Plus Mini Kit 
(QIAGEN). Cells were lysed directly using 350 µl RLT buffer and homogenised 
using a syringe and 23 G needle. RNA quality and concentration was determined 
using a Nanodrop spectrophotometer (GE Healthcare). After RNA extraction, the 
samples were DNase I treated with the Ambion® TURBO DNA-free™ DNase I 
(Invitrogen) and the RNA stored at -80°C. 1st strand cDNA was generated by reverse 
transcription of 400ng to 1 µg of DNAse-free RNA using the ProtoScript® M-MuLV 
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First Strand cDNA Synthesis Kit (NEB). Oligo-dT priming was used in most 
instances although Oligo-dT and random hexamer primers were mixed together when 
quantifying 18S RNA. Control reactions with no reverse transcriptase (-RT) were 
performed to examine the levels of residual genomic DNA (gDNA). The –RT sample 
was prepared using pooled RNA from each condition. The cDNA products were 
diluted as required (at least 5 times) for quantitative or reverse transcriptase PCR 
(qPCR and RT-PCR). 
 
2.9.4 Quantitative PCR using SYBR Green 
SYBR® green was used to quantify the level of TCF4 and GAPDH transcripts after  
knockdown treatments. Gene expression was quantified using SensiMixTM SYBR 
No-ROX (Bioline) and a Qiagen Rotor-gene 3000 real time PCR machine (Qiagen) 
following the conditions outlined in the table below. Triplicate 25µl qPCR reactions 
were prepared on a Corbett robot (Corbett Robotics CAS1200/QIAGEN) in a 72-well 
ring. A typical PCR reaction mixture with cycling parameters is provided below. –RT 
controls and non-template controls (5 µl of water instead of DNA) were included in 
each qPCR run. The melt curve analysis was performed from 55°C to 95°C and 
inspected to ensure only one PCR product was being amplified. The threshold cycle 
(Ct) values were calculated by the Qiagen Rotor-Gene 3000 software after setting a 
manual threshold in linear phase of PCR amplification (usually 0.4). Relative 
quantification was used to determine gene expression and compare treatment groups 
(Section 2.9.8). 
 
Typical qPCR reaction mixture with and cycling parameters: 
Name  Volume (µl) Program  
SensiMix (2x master mix) 12.5 1. 95°C for 10 min  
Forward primer (100 µM)  0.75 2. 95°C for 15 s  
Reverse primer (100 µM)  0.75 3. 60°C for 15 s 
Molecular grade water 6 4. 72°C for 20 s 
cDNA (2ng/µl) 5 5. Go to step 2; 40 times  
 
 
2.9.5 Quantitative PCR using TaqMan assays 
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TaqMan® gene expression assays were used to validate gene expression changes 
after TCF4-knockdown in Chapters 4 and 5 (Applied Biosystems). Genes selected for 
validation had a fold change above or below 1.5 and represented important functional 
categories from the enrichment analyses. A list of TaqMan probe IDs and their 
associated genes are provided in Appendix II. 1 or 10ng of cDNA was used as 
template in 20µl reactions with the TaqMan® Fast Advanced Master Mix depending 
on transcript abundance (Applied Biosystems). All samples were run in triplicate 
according to the Fast Advanced Master Mix protocol using the ABI 7900HT Fast 
Real-Time PCR System (Applied Biosystems). In addition to the samples, a dilution 
series of template cDNA (0.1ng to 10ng or 1ng to 100ng) was used to determine 
amplification efficiency of each TaqMan assay (Section 2.9.7). Results were analysed 
on the RQ Manager 1.2 (Applied Biosystems) using manual Ct determination 
according to manufacturer’s guidelines. Background thresholds were set in the non-
amplifying phase of the PCR reaction and the Ct thresholds were set in the linear 
phase of PCR amplification. Relative quantification was used to determine gene 
expression and compare treatment groups (Section 2.9.8). 
 
2.9.6 Reverse transcriptase PCR (RT-PCR) 
RT-PCR was used to determine the expression of epithelial-to-mesenchymal (EMT) 
genes in a semi-quantitative manner. 10 ng of cDNA prepared from the RNA 
(Section 2.9.3) of each knockdown treatment group (Section 2.9.2) was amplified for 
30 cycles in a 25µl reaction with REDTaq® DNA Polymerase (Sigma) (Section 
2.3.3). The sequences of the gene-specific primer pairs are listed Appendix II. 20µl of 
the PCR reaction was separated on a 2.5% agarose gel containing ethidium bromide. 
PCR products were imaged with a GelDoc-It® TS Imaging System (UVP). 
 
2.9.7 Primer optimisation 
Primer sequences were designed to amplify short cDNA sequences between 50-150 
bp and cross-exon boundaries wherever possible to eliminate gDNA amplification. 
Primer sequences are provided in Appendix II. Prior to use, primer sets were 
evaluated at different concentrations (50 – 300 nM) on serial dilutions of template 
cDNA covering the required range of DNA being measured (usually 1 ng to 100 ng). 
The amplification efficiency was calculated from the standard curve generated from 
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plotting the Ct values acquired from qPCR analysis against the log of the 
corresponding amount of cDNA being measured in nanograms. Primer efficiencies 
were calculated from the following equation, efficiency = (10 -1 /slope -1) × 100. Only 
primers with amplification efficiencies between 90% and 110% were used in for 
relative quantification of gene expression (Section 2.9.8). 
 
2.9.8 Relative quantification of gene expression 
Relative quantification was determined using the comparative Ct method (ΔCt). 
Mean Ct values for each transcript were calculated from two or three technical 
replicates. The mean Ct value of the gene of interest was subtracted from the mean Ct 
value of a reference gene (ΔCt). Reference genes (often housekeeping genes) are 
genes that have a high and stable expression under the conditions tested. For the 
results in Chapter 4 the chosen reference was 18S rRNA and for results in Chapter 5 
the chosen reference was the average expression of the COX6A1 and NDUFA4 
genes. The COX6A1 and NDUFA4 genes were chosen from the microarray results 
obtained in Chapter 4, as both genes were highly expressed in SH-SY5Y cells and 
did not vary in between treatment groups. Logarithmic ΔCt values were converted to 
linear gene expression values (2 ΔCt). The linear gene expression values of at least 
three biological replicates were used to calculate the mean abundance and standard 
error of each transcript. The abundance of each transcript was reported as a 
percentage of the control group (usually pooled values from mock treated and 
GAPDH-knockdown treated cells) that was set as 100%. The standard error values 
were scaled to percentages for each group. A two-tailed t-test was performed on two 
groups of interest to determine if gene expression was statistically different. Genes 
were considered differentially expressed between groups if P < 0.05. 
 
2.9.9 Toray Microarray 
Gene expression profiling was performed on a Toray 3D-gene Human Oligo chip 25k 
(Toray Industries Inc.) by Central Biotechnology Services (CBS), Cardiff University 
according to manufacturer’s instructions. The Toray 3D-gene Human Oligo chip 
contains 24,267 probes that are mostly located at the 3’ end of transcripts. Three 
biological replicates from four treatment groups (TCF4 KD1and KD2, GAPDH KD 
and mock) were sent for analysis. The concentration and quality of the RNA for each 
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sample was assessed using the RNA 6000 Nano Kit and the Agilent 2100 bioanalyser 
(Agilent Technologies). These tools provided an RNA Integrity Number (RIN) for 
each sample prior to microarray analysis. 500 ng of total RNA was amplified and 
labelled using an Amino Allyl MessageAmp™ II aRNA Amplification kit (Life 
Technologies) and Cy™5 mono-Reactive Dye (GE Healthcare Life Sciences). 
Labelled aRNAs were hybridised onto 3D-Gene Human 25k oligo chips version 2.1 
(Toray Industries Inc).  The chips were stringently washed, and fluorescent signals 
were scanned with a 3D-GeneTM Scanner 3000 (Toray Industries Inc) and analysed 
using Toray Extraction and 3D-GeneTM Scanner 3000 software (Toray Industries 
Inc).  Hybridised probe spots with signal intensity greater than the mean intensity 
plus 2 standard deviations of the background signal were considered to be valid.  The 
background average was subtracted from the signal intensity and multiplied by the 
normalisation factor (25 divided by the medium signal intensity of all the subtracted 
background data) to generate the normalised data.  
 
The Toray microarray data provided by CBS was in the form of an excel file 
containing the normalised, background subtracted, signal intensity values with their 
corresponding gene and probe annotations. The data was imported manually into 
Partek Genomics Suite 6.6 (Partek Inc.) with all the probe relevant annotations. As 
there were only three replicates in each group, probe sets with more than one missing 
value in any group were removed from the analysis. Data from biological replicates 
were grouped into treatment categories. The clustering of treatment groups was 
assessed using principal component analysis (PCA). A one-way ANOVA comparing 
control (mock and GAPDH) and TCF4 knockdown (KD1, KD2) groups was then 
performed to identify differentially expressed genes. A false discovery rate (FDR) 
was used to correct for multiple testing (FDR < 0.01, 1204 differentially expressed 
genes; FDR < 0.05, 5374 differentially expressed genes). The FDR 0.01 corrected 
gene list was used for enrichment analysis (Section 2.10.3) although the FDR 0.05 
corrected gene list was used to identify additional signaling pathway components. 
The top 1204 differentially expressed genes (FDR < 0.01) were subjected to 
hierarchical clustering to confirm the validity of the experimental grouping in the 
one-way ANOVA. Gene expression changes from the array were validated using 
TaqMan assays (Section 2.9.5). The microarray data discussed in Chapter 4 has been 
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deposited in NCBI's Gene Expression Omnibus (GEO) and is accessible through 
GEO Series accession number GSE48367.  
 
2.9.10 Affymetrix Microarray 
Gene expression profiling was performed on a GeneChip® Human Gene 2.0 ST 
Array (Affymetrix Inc.) by Central Biotechnology Services (CBS), Cardiff 
University according to manufacturer’s instructions. The Human Gene 2.0 ST Array 
contains 988’528 probes and has a high coverage for each transcript. Probes are 
designed to bind across multiple exons of each gene, providing a gene-level summary 
of expression. Four biological replicates from six treatment groups (mock, GAPDH 
KD, TCF4B KD1, TCF4B KD2, TCF4A KD1, TCF42 KD2) were sent for analysis. 
The concentration and quality of the RNA for each sample was assessed using the 
RNA 6000 Nano Kit and the Agilent 2100 bioanalyser (Agilent Technologies). These 
tools provided an RNA Integrity Number (RIN) for each sample prior to microarray 
analysis. Sense strand cDNA was prepared using the Ambion WT Expression Kit 
(Applied Biosystems).  Sense strands were fragmented and terminally biotinylated 
using the GeneChip WT Terminal Labeling Kit (Affymetrix). Labelled cDNA 
samples were hybridised to the GeneChip Human Gene 2.0 ST Array then washed, 
stained and scanned according GeneChip Expression Wash, Stain and Scan Protocol. 
The chips were washed using the Fluidics Station 450 and scanned using the 
GeneChip Scanner 3000 (Affymetrix). 
 
The Affymetrix microarray data provided by CBS was in the form of .CEL files 
containing raw signal intensity information. The .CEL file for each sample was 
imported into Partek Genomics Suite v6.6 (Partek Inc.) with the appropriate probe 
and transcript annotations (HuGene-2_0-st-v1), downloaded automatically from the 
Affymetrix website. The robust multiarray averaging (RMA) algorithm was used to 
summarise the probe-level data to a single value for each probe set (Okoniewski and 
Miller, 2008). Adjustments were made for probe GC content on pre-background-
subtracted values. The exon-level probe sets were summarised to the gene-level using 
the probe set mean. Data from biological replicates were grouped into treatment 
categories. The clustering of treatment groups was assessed using principal 
component analysis (PCA). A one-way ANOVA was used to determine differentially 
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expressed genes between groups. To identify genes differentially expressed in TCF4-
B, a one way ANOVA was performed comparing the control (mock and GAPDH) 
and TCF4-B knockdown (KDB1 and KDB2) groups. To identify genes differentially 
expressed in TCF4-A, a one way ANOVA was performed comparing the control 
(mock and GAPDH) and TCF4-A knockdown (KDA1) groups. The KDA2 
knockdown group was omitted from the analysis due to a lack of gene expression 
generated by this siRNA. A false discovery rate (FDR) of 0.01 was used to correct 
for multiple testing and generate gene lists for enrichment analysis (Section 2.10.3). 
The most significant gene expression changes (FDR < 0.01) were subjected to 
hierarchical clustering to confirm the validity of the experimental grouping in the 
one-way ANOVA. Gene expression changes from the array were validated using 
TaqMan assays (Section 2.9.5). 
 
2.10 Bioinformatics  
2.10.1 General 
DNA and protein sequence homology searches were performed using the BLAST 
(Basic Local Alignment Search Tool) program. Gene and protein sequences were 
obtained using the NCBI’s CCDS (Consensus Coding Sequence) and Refseq 
(Reference Sequence) databases and the Ensembl database. Alignment of the 
nucleotide and protein sequences was performed with ClustalW 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). DNA to protein translation and 
molecular weight prediction was carried out using the ExPASy (Expert Protein 
Analysis System) proteomics server from the Swiss Institute of Bioinformatics 
(http://www.expasy.org/). Pair-wise linkage disequilibrium between single nucleotide 
polymorphisms (SNPs) was calculated using the SNAP (SNP Annotation and Proxy 
Search) tool (http://www.broadinstitute.org/mpg/snap/ldsearchpw.php). Graphics for 
genome wide association data were obtained using Ricopili tool with the “PGC SCZ 
GWAS (Sept. 2011)” data set (http://www.broadinstitute.org/mpg/ricopili/). The 
biological functions of genes were annotated using the BP_FAT option in DAVID 
v6.7 (Database for Annotation, Visualisation and Integrated Discovery) (Huang da et 
al., 2009) (http://david.abcc.ncifcrf.gov/home.jsp). For a broader classification of 
biological processes, GOSlim (Gene Ontology Slim) annotations were used from the 
AgBase GOSlimViewer (McCarthy et al., 2007) (http://www.agbase.msstate.edu/cgi-
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bin/tools/goslimviewer_select.pl). Gene and protein accession numbers were 
converted to Entrez gene IDs using the batch converter tool in DAVID v6.7. 
Prediction of phophorylation sites was performed with PhosphoMotif Finder 
(http://www.hprd.org/PhosphoMotif_finder). 
 
2.10.2 Design of promoter constructs  
The CNTNAP2 and NRXN1β promoter regions were identified using a 
bioinformatics approach. Mouse and human genomic DNA sequences up to 5 kb 
upstream of the predicted transcriptional starts for the CNTNAP2 and NRXN1β 
genes were compared the UCSC genome browser. Evolutionarily similar regions that 
also contained conserved E-box motifs were used to select the putative promoter 
sequences. The UCSC genome browser was used to verify the epigenetic marks 
(H4K3me3) indicative of transcriptional start sites. Using these methods a 2 kb and a 
600 bp region directly 5’ of the CNTNAP2 and NRXN1β transcriptional start sites 
were identified that would act as putative promoters in the luciferase assays (Section 
2.8.3). These genomic regions were amplified from human gDNA, sequence verified 
and subcloned into the pGL3-basic reporter construct (Promega). 
 
2.10.3 Process network and gene ontology (GO) enrichment Analysis 
Process network enrichment analysis was performed in MetaCoreTM (GeneGo, 
Thomson Reuters) using the enrichment analysis workflow. Biological process GO 
term enrichment analysis was performed using the GOTERM_BP_FAT option in the 
Database for Annotation, Visualisation and Integrated Discovery (DAVID ) v6.7 
(Huang da et al., 2009). Entrez Gene IDs were used for all analyses to avoid the 
redundancy of gene symbols. For enrichment analysis of microarray data, 
differentially expressed genes from high confidence lists of (FDR 0.01) were 
exclusively used unless otherwise stated. All gene lists were compared to a 
background list of genes related to the microarray type. For the Toray microarray, the 
background list consisted of Entrez Gene IDs from all genes that were detected by the 
array (18966 IDs). For the Affymetrix microarray, the background list consisted of all 
the probes on the array that had Entrez Gene IDs, since absolute gene expression 
values cannot be calculated in Partek Genomics Suite 6.6 for this array type (25957 
IDs).  
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The enrichment analysis categorises the input data into different process network 
(MetaCore) or biological process (DAVID) ontologies. The significance of the 
enrichment is evaluated based on the size of the intersection between the selected 
data and the entire ontology it has been categorised in. The resulting P value 
represents the probability that this intersection has occurred by chance, considering 
the numbers of genes in the input data, the background list of genes (see above) and 
the number of genes represented in the entire ontology term. An FDR correction of 
0.05 was used to determine significantly enriched ontology terms. The gene lists used 
in enrichment analyses are summarised below: 
 
List name N° genes Description Array type Analysis 
TCF4KD 1031 
All differentially expressed genes in 
global TCF4 knockdown experiment 
(FDR 0.01) 
Toray 
(Chapter 4) 
MetaCore 
TCF4KD_Up 425 
All upregulated genes in global TCF4 
knockdown experiment (FDR 0.01) 
Toray 
(Chapter 4) 
DAVID 
TCF4KD_Down 606 
All downregulated genes in global 
TCF4 knockdown experiment (FDR 
0.01) 
Toray 
(Chapter 4) 
DAVID 
KDB 386 
All differentially expressed genes in 
TCF4-B isoform knockdown 
experiment (FDR 0.01) 
Affymetrix 
(Chapter 5) 
MetaCore 
KDB_Down 287 
All downregulated genes in TCF4-B 
isoform knockdown experiment 
(FDR 0.01) 
Affymetrix 
(Chapter 5) 
MetaCore 
KDA1 1319 
All differentially expressed genes in 
TCF4-A isoform knockdown 
experiment (FDR 0.01) 
Affymetrix 
(Chapter 5) 
MetaCore 
KDA1_Down 830 
All downregulated genes in TCF4-A 
isoform knockdown experiment 
(FDR 0.01) 
Affymetrix 
(Chapter 5) 
MetaCore 
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Chapter 3 
 
Functional Analysis of TCF4 Missense Mutations that Cause Pitt-
Hopkins Syndrome 
 
 
3.1 Introduction 
As mentioned in Chapter 1, Pitt-Hopkins syndrome (PTHS) is a rare genetic disorder 
characterised by heterozygous loss-of-function of the TCF4 gene (Section 1.11). The most 
prominent symptoms of the disorder are severe intellectual disability, dysmorphic features 
and breathing abnormalities although many other symptoms have been described in patients 
including developmental delay with impaired speech, epilepsy, stereotypic movements 
constipation and ocular anomalies (Pitt and Hopkins, 1978; Amiel et al., 2007; Zweier et al., 
2007).  
 
There are currently 112 clinically diagnosed PTHS patients described in the literature and 
most have discrete mutations affecting different parts of the TCF4 gene. The spectrum of 
mutations includes whole gene deletions (23 patients) and partial gene deletions (10 patients) 
in addition to frameshift (33 patients), splice-site (6 patients), nonsense (18 patients) and 
missense mutations (22 patients) (Whalen et al., 2012a). The diversity of mutations found in 
patients and the lack of a genotype-phenotype correlation for the disorder strongly suggests 
haploinsufficiency is the pathological mechanism in PTHS.  
 
In addition to TCF4, recessive mutations in the genes encoding the neuronal cell adhesion 
molecules CNTNAP2 (OMIM 610042; contactin-associated protein like 2) and NRXN1 
(OMIM 614325; neurexin) have also been identified in cases with PTHS symptomatology 
but without TCF4 mutations (Zweier et al., 2009). Importantly, TCF4, NRXN1 and 
CNTNAP2 have also been implicated in the genetic etiology of several other neuropsychiatric 
disorders suggesting they are crucial for neurodevelopment (Stefansson et al., 2009; Blake et 
al., 2010; Penagarikano et al., 2011; Ripke et al., 2011). Rare deletions in NRXN1 have been 
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found in patients with schizophrenia and genetic variation in CNTNAP2 has been linked to a 
spectrum of neurodevelopmental disorders including schizophrenia, autism and attention 
deficit hyperactivity disorder (Alarcon et al., 2008; Friedman et al., 2008; Kirov et al., 2009; 
Elia et al., 2010). The overlap of these genetic loci in at least two separate disorders suggests 
a shared mechanism involving TCF4, NRXN1 and CNTNAP2 regulating key 
neurodevelopmental events (Blake et al., 2010). 
 
At the outset of this work, the functional analysis of PTHS-associated TCF4 mutations was 
limited. Characterisation of TCF4 mutations was restricted to assessing their impact on gene 
activation using synthetic promoter constructs containing multiple E-boxes. Two studies 
focused on truncating mutations (G232fsX25, S508fsX5, R385X, G500X) and missense 
mutations (R576W, R572G, R576Q) concluding that all mutants displayed a similar 
reduction in activity on these synthetic promoters (Zweier et al., 2007; de Pontual et al., 
2009). These studies were the first to report functional deficits related to PTHS-associated 
mutations although further characterisation is required to fully delineate the role of TCF4 
mutations in PTHS. 
 
To improve our understanding of TCF4 mutations in PTHS, I examined the effect of five 
discrete missense mutants using a range of complementary techniques (Zweier et al., 2007; 
de Pontual et al., 2009) (Figure 3.1). Missense mutations were investigated rather then 
truncating mutations as they offer additional insight into the different functional domains of 
the TCF4 protein. Each mutation was assessed for its effect on basic biochemical properties 
relating to TCF4 function namely: subcellular localisation, transcriptional activity and 
dimerisation with other bHLH proteins. 
 
The work described in this chapter has been published in Human Mutation,	  December 2012, 
vol. 33, issue 12, pages 1676-86 (Forrest et al., 2012). 
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Figure 3.1. TCF4 protein structure and location of PTHS-associated missense 
mutants characterised in this study. The illustration shows the conceptual organisation of 
the TCF4 protein. Triangles approximate positions of missense PTHS mutants according to 
domain architecture. The table below indicates the exonic location of each mutation, the 
nomenclature used for mutations and the original references where mutations were identified. 
Amino acid numbers and exons represent the positions on the full length coding sequence of 
TCF4-B+ (671 amino acids including RSRS insertion). Abbreviations: AD1, activation 
domain 1; AD2, activation domain 2; CE, CE repressor domain; NLS, nuclear localisation 
signal; Rep, Rep repressor domain; b, basic domain; HLH, helix-loop-helix domain; C, 
domain C. Illustration not to scale. 
 
 
 
 
 
 
Coding exon Amino acid Mutation Mutant name Reference 
13 358 Gly to Val G358V (Zweier et al., 2008b) 
16 535 Asp to Gly D535G (de Pontual et al., 2009) 
17 578 Arg to Pro R578P (Zweier et al., 2008b) 
17 580 Arg to Trp R580W (Zweier et al., 2008b) 
17 614 Ala to Val A614V (de Pontual et al., 2009) 
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3.2 Results 
 
3.2.1 Basic domain mutants have aberrant nuclear localisation 
Of the twelve different TCF4 missense mutations described in PTHS most cluster in the 
bHLH domain (Amiel et al., 2007; Zweier et al., 2007; de Pontual et al., 2009; Takano et al., 
2010; Whalen et al., 2012a). However some mutations (G358V and D535G) are found in 
other conserved regions of the protein where their effect on protein function is unknown. To 
examine the effect of different mutations on the function of TCF4, five distinct mutants were 
selected (G358V, D535G, R578P, R580W, A614V) which affect different regions of the 
protein (Figure 3.1). The sub-cellular localisation of wild type TCF4 and the PTHS-
associated missense mutants was determined using indirect immunofluorescence of 
transfected COS-7 cells expressing GFP-tagged proteins (Figure 3.2).  
 
Wild-type TCF4 was detected uniformly throughout the nucleus but was excluded from the 
nucleoli (Figure 3.2). The mutants G358V and D535G were also expressed in the nucleus 
with a pattern indistinguishable from the wild type. Unexpectedly, the mutants R578P, 
R580W and to a lesser extent A614V, were apparently mislocalised to small, spherical 
punctae that were dispersed throughout the nucleus and reminiscent of nuclear speckles 
(Figure 3.2). To determine whether these mutants were indeed present in nuclear speckles, 
transfected cells were co-stained with an anti-SC-35 antibody to detect this nuclear sub-
compartment (Mao et al., 2011). The data shows that SC-35 does not co-localise with the 
PTHS-mutants (Figure 3.2). Similar results were obtained when these mutants were 
transfected into the SH-SY5Y neuroblastoma cell line and when myc-tagged TCF4 mutants 
were transfected (data not shown). Therefore the R578P, R580W and A614V mutations 
affect the nuclear localisation of the protein. 
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Figure 3.2 Subnuclear localisation of wild type and mutant TCF4.  
COS-7 cells transiently expressing GFP-TCF4 or GFP-PTHS mutants were fixed and stained 
with an anti-SC-35 antibody that detects nuclear speckles (red). Wild-type TCF4 is found in a 
diffuse pattern throughout the nucleus but is excluded from the nucleolus. By contrast, he 
mutants R578P, R580W and to a lesser extent A614V form small, spherical punctae differing 
markedly from the distribution of wild type TCF4 and  the mutants G538V and D535G. SC-
35 staining does not appear to co-localise with R578P, R580W or A614V mutants indicating 
that the mutant proteins are not mislocalised to nuclear speckles (merged image). Scale bar, 
10µm. 
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3.2.2 Characterisation of the HTRF system to study bHLH dimerisation 
Homo- and hetero-dimerisation are intrinsic properties of bHLH transcription factors (Powell 
and Jarman, 2008). In common with many transcription factors, TCF4 dimerisation is 
essential for physiological activity and is considered to be a critical determinant of its 
biological function. To study this activity in cells, a homogenous time resolved fluorescence 
(HTRF) assay was developed for TCF4-dependent protein-protein interactions since E-
proteins and their binding partners can form stable heterodimers in solution and in the 
absence of DNA (Longo et al., 2008). This method combines fluorescence resonance energy 
transfer (FRET) with time-resolved measurements to provide a quantitative output for 
protein-protein interactions (Degorce et al., 2009). HTRF measures FRET between a donor 
(europium cryptate) and an acceptor molecule (XL665) only when the two fluorophores are 
in close proximity (5 to 10 nm) to each other (Figure 3.3). The intensity of the HTRF signal 
can be used as a measure of protein dimerisation because bHLH transcription factors are in 
close proximity when they dimerise (Ellenberger et al., 1994). In the following experiments 
the HTRF signal was measured at 665nm and then normalised to the value ∆F which 
represents the signal:noise ratio (665nm/620nm). ∆F can be used to compare across 
experimental conditions and time points making it a useful reference measure. 
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Figure 3.3 Principles of homogenous time-resolved fluorescence (HTRF). HTRF 
combines standard fluorescence resonance energy transfer (FRET) technology with time-
resolved measurement of fluorescence, eliminating short-lived background fluorescence. 
FRET is based on the transfer of energy between two fluorophores (donor and acceptor) 
when in close proximity. Conjugated antibodies can be used to direct the donor (europium 
cryptate, EuK) or acceptor (XL665) fluorophores to epitopes of interest. A) Interacting 
protein pairs that are in close proximity emit a FRET signal at 665 nm when excited. B) Non-
interacting proteins do not emit a FRET signal (665 nm) when excited and only emit a 
background signal (620 nm). Protein interactions can therefore be quantitatively measured by 
the intensity of the FRET emission signal. HTRF data is reported at as the ratio of between 
the FRET (665 nm) and the background (620 nm) signal (∆F). Abbreviations: HA, 
Hemagglutinin-epitope tag; Myc, c-myc-epitope tag. 
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In order to ensure a FRET signal between wild type TCF4 homo- and hetero- dimers was 
possible, a series of published TCF4 interactors were cloned into pCMV-HA (HA-TCF4, 
HA-ASCL1, HA-ATOH1, HA-NEUROD1, HA-ID2) and co-transfected individually with a 
myc-TCF4 construct in HEK 293T cells. 24 h after transfection, the cells were lysed in NP-
40 buffer, and the processed whole cell lysates were subsequently incubated with anti-HA 
XL665 and anti-myc europium cryptate antibodies. The binding of acceptor and donor 
fluorophores to each tag resulted in a 665nm emission signal from each condition and 
demonstrated that a robust signal could be detected for interacting pairs (Figure 3.4).  It is 
noteworthy that although the HA-TCF4, HA-ATOH1 and HA-ASCL1 constructs have a 
marked difference in their HTRF signal, each one was expressed at a similar level when 
visualised by western blotting (data not shown). In contrast, HA-NEUROD1 that had the 
strongest expression, and HA-ID2 that had the lowest expression, generated the highest and 
lowest HTRF signals respectively. These two observations suggest that both the identity and 
expression levels of each interactor contribute to the HTRF signal.  
 
 
 
Figure 3.4 Characterisation of wild type TCF4 homo- and hetero- dimers by HTRF 
Myc-tagged wild type TCF4 was co-transfected with a series of HA-tagged binding partners 
(TCF4, ASCL1, NEUROD1, ATOH1, ID2) in HEK-293T cells to assess the strength of the 
HTRF signal for TCF4 dimerisation. The acceptor and donor fluorophore-conjugated 
antibodies, which recognise the epitope tags, generated a signal significantly over 
background (mock) for each interaction, confirming the close proximity of proteins in the 
dimer. This data substantiates HTRF as a tool to measure bHLH dimerisation. The mock 
sample consists of mock transfected cell lysates incubated with the acceptor and donor 
antibodies. Data is reported as the mean of 4 replicates  ± standard error of the mean. 
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3.2.3 Impact of PTHS-associated mutations on homodimerisation 
Once the protocol for wild type TCF4 dimerisation was established, DNA for mutant TCF4 
sequences were cloned into pCMV-myc vectors and expressed in HEK-293T cells to ensure 
they generated a viable protein product (Figure 3.5). Although there was variability in the 
expression of each construct, each of the six transfected vectors was efficiently translated to a 
protein of the same size. As each of the five mutant sequences all originated from the same 
sequence and vector, the observed differences in expression are likely to be a direct 
consequence of the mutations’ effect on protein stability.  
 
 
 
 
Figure 3.5 Relative expression of wild type and mutant TCF4 constructs. 
Wild type TCF4 and its associated PTHS mutants were cloned into pCMV-myc and 
expressed for 24h in HEK-293T cells. The cells were subsequently lysed and the proteins 
were separated on a 12% polyacrylamide gel before western blotting. (Top) Relative 
expression of wild type (WT) and mutant TCF4 constructs. Band intensities for all TCF4 
constructs and for α-tubulin were measured with the LI-COR odyssey software. The relative 
expression of each construct was calculated by normalising TCF4 expression to α-tubulin 
(see western blot). (Bottom) Western blot of the wild type TCF4 and mutant TCF4 
constructs. Detection of α-tubulin was used as a loading control and to calculate relative 
expression. 
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To examine the effect of these mutants on homodimerisation with TCF4, HA-tagged wild 
type protein was co-expressed with myc-tagged TCF4 and the mutants thereof (myc-G358V, 
myc-D535G, myc-R578P, myc-R580W and myc-A614V) in HEK-293T cells.  This 
experimental design essentially replicates the situation in PTHS patients, with one mutant 
allele and one wild type allele contributing to the total amount of TCF4 protein. In these 
experiments, all the mutants generated a reduced FRET signal in comparison to the wild 
type/wild type interaction (Figure 3.6). Since a robust signal was previously observed from 
the wild type TCF4 interaction, ΔF was expressed as a percentage of the wild type TCF4 
signal for comparative purposes. The largest change in FRET signal was observed with the 
mutants R578P, R580W and A614V, where the ΔF was reduced to less than 20% of the wild 
type TCF4 homodimer (Figure 3.6). Importantly, the FRET signal was not abolished by 
mutations in the bHLH domain indicating that some homodimerisation could still occur 
between wild type and mutant TCF4. By contrast, the mutations G358V and D535G 
produced FRET signals that were reduced to approximately 80% of wild type levels (Figure 
3.6). Whilst this change is statistically significant, these data suggest that the G358V and 
D535G mutations do not have a dramatic impact on homodimer formation. 
 
 
 
Figure 3.6 HTRF analysis of homodimerisation between TCF4 and PTHS-associated 
mutants. HEK-293T cells were co-transfected with HA-tagged wild type TCF4 and a panel 
of myc-tagged PTHS mutants. The association between the protein pairs was measured by 
HTRF. The 665nm/620nm ratio (ΔF) was recorded for each interaction and expressed as a 
percentage of wild type activity. Data are expressed as the mean %ΔF ± SEM for three 
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biological replicates. P-values for Student’s t-test results comparing the PTHS-associated 
mutants to wild type TCF4 are indicated thus; * p<0.05; ** p<0.001; *** p<0.0001. 
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3.2.4 Impact of PTHS-associated mutations on heterodimerisation 
The HTRF assay was used to examine the effect of the different PTHS-associated missense 
mutations on the interaction of TCF4 with other bHLH transcription factors, ie. heterodimer 
formation. Specifically, the association of TCF4 with three proneural proteins ASCL1, 
ATOH1, NEUROD1 and one inhibitory factor, ID2 was examined. In these experiments 
quantitative deficits in association for all TCF4 heterodimers tested were detected (Figure 
3.7). The damaging effects of these mutations were variable however, dependent both on the 
identity of the mutant and the binding partner. 
 
 
 
Figure 3.7 HTRF analysis of heterodimer formation between, PTHS-associated 
mutants and bHLH proteins. HEK-293T cells were co-transfected with HA-tagged bHLH 
proteins (ATOH1, ASCL1, NEUROD1 or ID2) and a panel of myc-tagged PTHS mutants. 
The interaction between the two proteins was measured by HTRF and normalised to the wild 
type signal as previously mentioned (see Figure 3.6). P-values for Student’s t-test results 
comparing the PTHS-associated mutants to wild type TCF4 are indicated thus; * p<0.05; ** 
p<0.001; *** p<0.0001. 
 
The association of TCF4 with ATOH1 was largely similar to the effects observed with the 
TCF4 homodimer (Figure 3.7). Whilst, the mutations G358V and D535G generated a modest 
change in FRET intensity, mutations affecting the bHLH region of the protein reduced the 
FRET signal to less than 20% that of wild type TCF4 (Figure 3.7). Similarly, the bHLH 
mutations caused a large reduction in the FRET signal between TCF4 and ASCL1 (Figure 
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3.7). However, whilst the G358V mutation resulted in a statistically significant reduction in 
the FRET signal between the TCF4 mutant and ASCL1, the D535G mutation only reduced 
the FRET signal by approximately 5% of wild type (Figure 3.7). HTRF analysis of TCF4 
binding to NEUROD1 showed that all TCF4 mutations resulted in significant reduction in the 
FRET signal (Figure 3.7). As before, the more distal mutations produced the largest reduction 
in FRET signal although in this instance, the two mutations in the bHLH domain R578P and 
R580W only reduced the FRET signal by approximately 40%. Thus, it can be concluded that 
each TCF4 mutant can associate with NEUROD1 although the weaker FRET signal suggests 
that the mutations may reduce the affinity of this interaction. These data are important to 
consider when interpreting the transactivation of gene expression described below (Section 
3.2.5).  
 
In addition to examining the interaction between TCF4 and the proneural genes, the same 
HTRF assay was used to determine whether TCF4 mutants could interact with ID2, a potent 
negative regulator of gene expression (Rothschild et al., 2006). Interestingly, the N-terminal 
mutants essentially behaved like wild type TCF4 and showed almost no difference in FRET 
signal (Figure 3.7). By contrast, the two most distal mutations, mutations R580W and A614V 
appeared to abolish the interaction with ID2, whereas the mutant R578P reduced the FRET 
signal to approximately 20% of wild type (Figure 3.7). These results suggest that residues 
R580 and A614 are particularly important for ID2 interactions. 
 
 In summary, PTHS-mutations have significant effects on the association of TCF4 with a 
selection of bHLH transcription factors however the mutations differentially affect each 
interaction. 
 
3.2.5 TCF4 activates the putative CNTNAP2 and NRXN1β  promoters 
E-proteins such as TCF4 are potent regulators of gene expression that act on E-box-
containing promoters. Previous studies on PTHS-mutants have used synthetic multimerised 
E-box sequences cloned upstream of a reporter to assess TCF4 activity (Zweier et al., 2007; 
de Pontual et al., 2009). These types of constructs have very little resemblance to in vivo 
promoter structures making comparisons to physiological gene regulation difficult. 
Sequences flanking E-boxes are crucial to their activity and participate in recruiting specific 
transcription factor complexes to individual regulatory elements (Castro et al., 2006; Powell 
and Jarman, 2008). To examine the effect of the PTHS mutations on transcriptional activity, 
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the mutant’s properties were characterised on physiological promoters that may be relevant to 
PTHS. It was hypothesised that TCF4 may regulate the expression of the NRXN1 and 
CNTNAP2 genes since genetic variation in TCF4, NRXN1 and CNTNAP2 can result in 
similar neuropsychiatric disorders including PTHS. 
 
To predict the location of the NRXN1 and CNTNAP2 promoters, several bioinformatic tools 
were used to identify characteristic elements upstream of the transcriptional start site (TSS).  
The first strategy was to search for highly conserved regions anywhere 5000bp upstream of 
the TSS, because cross-species conservation is an indicator of functionally important DNA 
elements. E-box sequences appear frequently within the genome therefore putative promoter 
sequences were selected if they contained E-box sequences that were conserved between the 
human and the mouse genome. This approach made it more likely that the promoters 
contained functional E-boxes. For the NRXN1 gene, which encodes two main isoforms 
(NRXN1α and NRXN1β), putative sequences upstream of both isoforms were identified. 
NRXN1α is the longer of the two isoforms and is the most affected by copy number variation 
in schizophrenia patients (Kirov et al., 2009). Although a conserved region was found 
upstream of the NRXN1α TSS, no conserved E-boxes were present in this sequence. In 
contrast, the sequence directly upstream of NRXN1β contained a conserved E-box. Hence, the 
NRXN1β promoter region was chosen for transcriptional assays over the NRXN1α promoter 
region. A region approximately 600bp upstream of the NRXN1β gene and a region 
approximately 2500bp upstream of the CNTNAP2 gene were selected (Figure 3.8). Each of 
these sequences was highly conserved across species and contained at least one E-box 
conserved between the human and the mouse genomes. Putative promoter regions were then 
overlaid with epigenetic information from the UCSC human genome browser. H3K4me3 
methylation sites were specifically selected as these are indicative of active promoter 
elements. The data from the UCSC genome browser provided additional evidence that these 
sequences were functional promoter elements (Figure 3.8) however it remained to be 
determined whether these sequences could be transactivated by TCF4. 
 
To examine the effects of TCF4 on the putative NRXN1β and CNTNAP2 promoters, each 
region of gDNA was amplified by PCR and cloned bi-directionally in to the pGL3-basic 
vector to drive the expression of a luciferase reporter. Robust basal transcription was 
observed only when the putative promoter was in the forward orientation as opposed to the 
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reverse configuration (Figure 3.9). To determine whether the proneural genes were able to 
activate these promoters, each transcription factor was expressed alone and in combination 
with TCF4. Whilst each proneural gene was found to weakly drive luciferase expression, co-
transfection of TCF4 strongly activated expression of the forward promoter sequences, 
consistent with these factors requiring an E-protein for full activation (Figure 3.9). 
Comparatively, total activation was higher for the NRXN1β promoter (a maximum of 1.2 
RLU) compared to CNTNAP2 (a maximum of 0.35 RLU) (Figure 3.9). The luciferase activity 
for both promoters was dependent on the levels of TCF4 in the transfection (Figure 3.10). 
Together, these experiments indicate that TCF4 is able to regulate the selected CNTNAP2 and 
NRXN1β promoter regions in vitro. 
 
Chapter 3: Functional Analysis of TCF4 Missense Mutations that Cause Pitt-Hopkins Syndrome 
	   76 
 
 
 
Figure 3.8. Genomic view of the NRXN1β and CNTNAP2 promoters.  
Large black boxes delineate the region cloned into the pGL3-basic vectors to create the 
luciferase reporter constructs. The medium sized black boxes represent regions of homology 
between human and mouse genomes. The small boxes represent layout of conserved (black) 
and non-conserved (white) E-boxes (CANNTG) across the promoter. The dinucleotides 
above each E-box correspond to the variant residues in the E-box consensus. ASCL1 has a 
preference for GC at the variable position of the E-box consensus as indicated in red (Castro 
et al., 2011). In addition to ASCL1, E-protein homodimers are known to bind to E-boxes 
containing CC at the variable position (Henthorn et al., 1990). Two of these E-boxes are 
located in the NRXN1β promoter and may mediate the potent dose-dependent transactivation 
of this promoter when co-expressed with TCF4 (Figures 3.9 and 3.10). Consensus sequences 
for the other HLH factors used in this study are poorly characterised and have not been 
annotated. Arrows indicate the location of start of transcription and beginning of the first 
coding exon (black) downstream of the 5’ untranslated region (grey box). The exact size of 
each promoter is shown at the top right of the illustration. The chromosomal position of the 
cloned region is also shown. “Your sequence from Blat search” identifies the promoter for 
each gene in UCSC genome browser. The screen capture depicts the mammalian 
conservation plot and the location of H3K4me3 histone modification indicative of active 
promoters. *For clarity the E-box sequences in the NRXN1β promoter are written 5’to 3’. 
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Figure 3.9 Characterisation of the NRXN1β and CNTNAP2 promoters: directionality 
and activation by bHLH factors. Luciferase assays in HEK-293T cells were used to 
determine whether bHLH factors co-expressed with TCF4 could activate the NRXN1β and 
CNTNAP2 promoters. ATOH1, ASCL1, NEUROD1 or ID2 were expressed with either the 
forward or reverse orientations of the putative NRXN1β or CNTNAP2 promoters in the 
presence or absence of TCF4. ATOH1, ASCL1 and NEUROD1 enhanced luciferase 
expression at both promoters. ID2 had little effect on the NRXN1β promoter but was able to 
augment luciferase expression from the CNTNAP2 promoter by a factor of approximately 1.5 
fold. As expected, each bHLH factor resulted in minimal transactivation of the NRXN1β and 
CNTNAP2 promoters in the reverse configuration. Data are expressed as the mean relative 
luciferase units (RLU) ± SEM for four biological replicates. 
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Figure 3.10 TCF4 dose-dependent transactivation of the NRXN1β and CNTNAP2 
promoters. Luciferase assays in HEK-293T cells were used to determine whether TCF4 
could activate transcription of the putative NRXN1β and CNTNAP2 promoters in a 
unidirectional manner. Increasing amounts of TCF4 construct were transfected together with 
the forward (5’-3’) and reverse (3’-5’) orientations of the putative NRXN1β or CNTNAP2 
promoters upstream of a luciferase reporter. Both forward promoter sequences demonstrated 
TCF4 dose dependence whereas sequences in the opposite orientation were not as sensitive to 
activation. Data are expressed as the mean relative luciferase units (RLU) ± SEM for four 
biological replicates. 
 
3.2.6 PTHS mutants have deficits in promoter transactivation that are context-
dependent 
Having shown that the CNTNAP2 and NRXN1β promoters were responsive to TCF4, the 
PTHS-associated missense mutants were compared to wild type TCF4 in luciferase assays 
with homodimer and heterodimer configurations (Figure 3.6 and 3.7). For comparative 
purposes, each assay was normalised to the activity of wild type TCF4 (expressed as a 
percentage) for each condition (Figures 3.11 and 3.12). Expressing normalised luciferase 
activity in this way allows direct comparison between the different co-transfected binding 
partners and between promoters.  
 
Using the NRXN1β promoter, the most damaging effects on transactivation were observed 
with the DNA-binding mutants R578P and R580W (Figure 3.11). When co-expressed with 
wild type TCF4, R578P and R580W reduced luciferase activities to approximately 70% 
compared to the control (Figure 3.11A). This reduction in luciferase activity was statistically 
significant (P < 0.001), whereas the mutants G358V and A614V had no statistically 
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significant effect on promoter activity. Intriguingly, D535G increased luciferase expression 
when co-expressed with wild type TCF4.  
 
Co-expression of ATOH1 with each mutant resulted in a significant reduction in luciferase 
activity for every construct when compared to wild type TCF4 (Figure 3.11B). bHLH 
mutations had the most damaging effects on promoter transactivation resulting in a reduction 
of approximately 55% of wild type activity when ATOH1 and R578P were co-expressed 
(Figure 3.11B). Similar results were also seen with ASCL1, however, G358V appeared to 
behave as wild type (Figure 3.11C). Co-transfection of NEUROD1 with TCF4 and the 
PTHS-associated mutants had surprisingly little effect on the NRXN1β promoter. The only 
statistically significant reduction in luciferase activity was observed with the R578P mutant 
(Figure 3.11D). Importantly, NEUROD1 and TCF4 were already shown to enhance basal 
expression of the NRXN1β promoter, confirming activity at this promoter (Figure 3.9). These 
data suggest that some of the PTHS-associated missense mutations may retain partial activity 
at certain promoters highlighting the importance of promoter context in assaying loss of 
function. It is interesting to note that each TCF4 mutant is able to associate with NEUROD1 
(Figure 3.7) potentially explaining the activity of the mutant heterodimers on the NRXN1β 
promoter. Similarly, ID2 had little effect on the activity of TCF4 and its mutants at the 
NRXN1β promoter (Figure 3.11E). Co-transfection of ID2 with G358V or R580W resulted in 
a modest but statistically significant decrease and increase in luciferase activity respectively 
(Figure 3.11E). 
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Figure 3.11 Effect of PTHS mutants on NRXN1β transactivation.  
Luciferase assays were performed to assess the ability of the PTHS mutants to activate 
transcription from the NRXN1β promoter with different bHLH binding partners. Each bHLH 
protein (TCF4 (A), ATOH1 (B), ASCL1 (C), NEUROD1 (D) or ID2 (E)) was co-transfected 
with the PTHS mutants and the NRXN1β reporter construct. Activity is measured in relative 
luciferase units (RLU) and is converted to percentage of wild type TCF4 activity. Results are 
reported as the mean ± SEM of four biological replicates. Student’s t-test results comparing 
the mutants to wild type TCF4 are indicated thus, * p<0.05; ** p<0.001; *** p<0.0001. 
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In addition to the NRXN1β promoter, the effects of the different PTHS mutants on the 
CNTNAP2 promoter when co-expressed alongside the different bHLH transcription factors 
were also examined (Figure 3.12). Several important differences between the effects of the 
PTHS mutants on the two different promoters were observed. D535G increased luciferase 
expression from the CNTNAP2 promoter whereas the R578P and R580W mutants reduced 
luciferase activities to approximately 80% of the wild type homodimer, as was the case with 
TCF4 activation of the NRXN1β promoter (Figure 3.12A). The luciferase activity profile of 
the PTHS mutants co-expressed with wild type TCF4 or ATOH1 were remarkably similar to 
those seen with the neurexin promoter (Figure 3.12B). Co-transfection of ATOH1 with 
R578P and R580W reduced luciferase expression to approximately 40% of wild type TCF4, 
whereas the other mutants had modest effects on promoter transactivation that was only 
significant for G358V (Figure 3.12B). Co-expression of ASCL1 with TCF4 and its mutants 
resulted in a robust, statistically significant reduction in luciferase activity for each construct. 
These data differ markedly from the previous experiment where ASCL1 and TCF4 were co-
transfected with the NRXN1β promoter (Figure 3.12C). Co-expression of the A614V mutant 
with ASCL1 had the most deleterious effect on the CNTNAP2 promoter activity consistent 
with the weakest FRET signal indicative of an impaired association between A614V and 
ASCL1 (Figure 3.7).  
 
Paradoxically, the PTHS-associated TCF4 mutants had very similar effects on the CNTNAP2 
promoter when co-expressed with NEUROD1 or ID2 (Figure 3.12D and E). Whilst G358V 
and D535G were essentially indistinguishable from wild type TCF4, the DNA-binding 
domain mutants caused an increase in luciferase activity from the CNTNAP2 promoter. These 
data suggest that R578P and R580W function as transcriptional activators at the CNTNAP2 
promoter. By contrast, A614V resulted in a modest reduction in luciferase activity when co-
expressed with NEUROD1 whereas it strongly activated the CNTNAP2 promoter when co-
expressed with ID2. As mentioned previously, each of the mutants retained the ability to 
associate with NEUROD1 in the HTRF assay (Figure 3.7). This data suggests that mutations 
in the DNA-binding domain of TCF4 can potentially activate transcription when co-
expressed with certain bHLH factors at an appropriate promoter. It is also possible that, in 
certain heterodimer contexts, the DNA-binding mutants remove inhibitory co-factors that 
participate in the regulation of the CNTNAP2 promoter. Whilst it is beyond the scope of this 
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data to speculate about the mechanism for these effects, these experiments highlight clear, 
context-dependent differences between the PTHS-associated mutants and wild type TCF4. 
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Figure 3.12 Effect of PTHS mutants on CNTNAP2 transactivation. Luciferase assays 
were performed to assess the ability of the PTHS mutants to activate transcription from the 
CNTNAP2 promoter following the scheme described in Figure 3.11. Each bHLH protein 
(TCF4 (A), ATOH1 (B), ASCL1 (C), NEUROD1 (D) or ID2 (E)) was co-transfected with 
PTHS mutants and the CNTNAP2 reporter construct. Data were analysed as described in 
Figure 3.11. Student’s t-test results comparing the mutants to wild type TCF4 are indicated 
thus, * p<0.05; ** p<0.001; *** p<0.0001. 
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3.3 Discussion 
 
Autosomal dominant PTHS is caused by mutations in the TCF4 gene that are thought to lead 
to haploinsufficiency. Although most PTHS-associated missense mutations alter basic amino 
acids in the bHLH domain of the TCF4 protein, their impact on the function of the protein 
has not been extensively studied. To further examine the molecular consequences of PTHS-
associated missense mutations on cellular localisation, dimerisation and transactivation, the 
TCF4 mutants were characterised using several complementary techniques. In addition to the 
previously described defects in promoter transactivation, TCF4 mutations were found to 
affect subcellular localisation and association with other bHLH transcription factors. The data 
presented in this chapter also provides the first evidence to suggest that TCF4 may regulate 
the expression of the NRXN1β and CNTNAP2 genes that are mutated in a PTHS-like 
syndrome, potentially defining an important neurodevelopmental regulatory network. The 
discussion presented below will summarise the main findings of this chapter and contrast the 
results to similar work which was published by Sepp et al. soon after the completion of these 
experiments (Sepp et al., 2012a). 
 
3.3.1 TCF4 localisation 
Unexpectedly, the mutants R578P, R580W and to a lesser extent A614V were found to alter 
the subnuclear localisation of the mutant protein. These mutants formed discrete punctae 
within the nucleus that clearly differed from wild type TCF4 (Figure 3.2). Although these 
punctae resembled nuclear speckles their failure to co-localise with the nuclear speckle 
marker SC35 indicated that they must reside in a different compartment in the nucleus. 
Interestingly, a recently described missense mutation (R244C) in the DNA-binding domain 
of the forkhead box G1 gene (FOXG1), that causes a variant of Rett syndrome, also results in 
nuclear mislocalisation of the mutant protein; in this case the mutant formed speckles that co-
localised with SC35 (Le Guen et al., 2011). 
 
In contrast, Sepp and colleagues did not find that DNA-binding mutants formed nuclear 
speckle-like structures in transfected cells. This may be explained by methodological 
differences between the two studies. Sepp et al. used an anti-TCF4 antibody to detect the 
protein (recombinant and endogenous) in transfected cells whilst here, EGFP-tagged 
constructs were used to differentiate between endogenous and transfected TCF4 (Sepp et al., 
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2012a). To confirm that the mislocalisation observed with the EGFP-tagged constructs was 
due to mutations in TCF4 and not due to an artefact of the EGFP tag, experiments were 
repeated with the equivalent myc-TCF4 mutants used for HTRF. Immunostaining with anti-
myc antibodies resulted in exactly the same mislocalisation observed in the EGFP-tagged 
constructs (data not shown). Interestingly, a commercial anti-TCF4 antibody (M03, Abnova) 
was not able to detect the speckle-like punctae in cells transfected with the DNA-binding 
mutants R578P, R580W (data not shown). 
 
3.3.2 TCF4 mutations affect protein:protein interactions 
Dimerising proteins interact with close proximity and should therefore emit a FRET signal 
when labeled with appropriate fluorophores and excited (Figure 3.3). The HTRF technique 
was therefore used to quantitatively assay dimerisation in pairs of interacting bHLH proteins 
(Figure 3.4). A clear signal was obtained from co-transfecting TCF4 with known binding 
partners therefore the effects of PTHS-mutations on these interactions was measured using 
HTRF 
 
The HTRF technique was used to demonstrate that mutants can potentially impair 
protein:protein interactions, either as a homodimer (with wild type TCF4) or through 
heterodimerisation with proneural or inhibitory bHLH transcription factors (Figure 3.6 and 
3.7). FRET was detectable for each pair of interacting wild type proteins (Figure 3.4) 
however mutations in the bHLH domain were associated with a significant reduction in 
FRET intensity suggesting a strong effect on protein:protein interactions (Figure 3.6 and 3.7). 
 
The effect of each mutant could be ranked according to its impact on FRET signal, as the 
HTRF technique provides a quantitative measure of association between proteins. Within the 
series of mutations modeled, the A614V mutation, located in the HLH domain, had the most 
deleterious effect on protein:protein interactions. These observations are consistent with the 
HLH domain being a major determinant of homo- or hetero- dimerisation between bHLH 
family members (Voronova and Baltimore, 1990). These results differed from mutations N-
terminal to the bHLH domain that had a marginal impact on protein association but remained 
significantly different to wild type in certain heterodimer configurations (Figure 3.6 and 3.7).  
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In comparison, Sepp et al. found that most TCF4 mutants did not have appreciable effects on 
homo- and heterodimerisation (Sepp et al., 2012a). These observations may be attributable to 
the nature of the technique used to qualify the interactions. The HTRF technique used herein 
provides a quantitative measure of protein:protein association by an indirect measurement of 
FRET between two fluorophores (Wang et al., 2006a). The data from these HTRF 
experiments demonstrated that TCF4 mutations impair but do not abolish protein:protein 
interactions in both homo- or heterodimer configurations. Sepp et al. used a nuclear 
redirection assay to infer homo- and heterodimerisation of wild type and mutant TCF4 in live 
cells, which were then fixed and imaged. The assay is based on the “piggy-back mechanism” 
which is used by certain bHLH proteins without a nuclear localisation signal (NLS) to 
relocate to the nucleus.  In this assay, mutants lacking their N-terminal region (including the 
NLS) were fused to EGFP and co-transfected with a wild type bHLH protein containing a 
NLS (ASCL1 or NEUROD2) to establish whether mutants could be trafficked to the nucleus 
by associating (or “piggy-backing”) with a wild type protein. Using this assay, Sepp and 
colleagues concluded that all PTHS-associated mutants could be redirected to the nucleus, 
implying that they were all capable of homo- and hetero- dimerisation. The data in this 
chapter is in broad agreement with this conclusion since most TCF4 mutations (homo- or 
hetero- dimer) produced a FRET signal (with the exception of ID2 that was not tested by 
Sepp). However, the quantitative nature of HTRF meant differences were still identified 
between TCF4 mutants which would be much more difficult to assess using qualitative 
nuclear redirection assays.  
 
3.3.3 PTHS mutations affect transcriptional activity in a context-dependent manner 
To date, three previously published studies have examined how PTHS-associated TCF4 
mutants affect transcriptional activity. These studies used multimerised E-box-containing 
reporter constructs from the pTα enhancer of the Herpes simplex thymidine kinase promoter 
(Zweier et al., 2007), the Delta1 enhancer (de Pontual et al., 2009) and the µE5 
immunoglobulin enhancer (Sepp et al., 2012a). These studies found that most TCF4 
frameshift and truncation mutations, as well as missense mutations in the basic domain, 
attenuate or abolish transcriptional activity when co-expressed with ASCL1 (Zweier et al., 
2007; de Pontual et al., 2009; Sepp et al., 2012a). Similarly, the data presented here 
demonstrates that TCF4 missense mutations attenuate gene expression of a reporter construct 
driven by the putative NRXN1β and CNTNAP2 promoters when co-expressed with an 
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accessory bHLH transcription factor (Figures 3.11 and 3.12). However, it must be 
highlighted that the deficits in transactivation reported here are more subtle then in previously 
published data, which is an aspect discussed below (de Pontual et al., 2009; Sepp et al., 
2012a). 
The bHLH domain is an essential determinant of DNA-binding specificity and dimerisation 
(Davis et al., 1990; Voronova and Baltimore, 1990). In agreement with these previous 
studies, the data indicates that missense mutations (R578P and R580W) in the basic region of 
TCF4 attenuate transcriptional activity and are the most damaging mutants modeled (Zweier 
et al., 2007; Sepp et al., 2012a). This effect is reproducible with the majority of conditions 
tested and on both the NRXN1β and CNTNAP2 promoters. The remaining mutants (G358V, 
D535G, A614V) had a weaker effect on luciferase expression, although each mutant was 
shown to impair transcription in a particular context. These general conclusions are broadly 
similar to those of Sepp and colleagues, however some differences are apparent which may 
be important in understanding TCF4 function. 
 
The most salient difference is that promoter context is particularly important to the activating 
properties of bHLH dimers. In the study published by Sepp and colleagues, the effect of 
PTHS mutants on transcriptional activation is measured using a synthetic construct composed 
of 12 E-boxes (CACCTG). Using ASCL1 as a co-activator, Sepp and colleague found that 
most mutations in the basic, DNA-binding region of the bHLH domain abolished 
transcription whereas the other mutations have little impact on this function. The data in this 
chapter shows that the DNA-binding domain mutants show a significant reduction in activity 
at the NRXN1β promoter when co-expressed with ASCL1, however none of the mutants 
completely abolished transcriptional activity (Figure 3.11C). Residual transcriptional activity 
in the DNA-binding mutants is also observed in previously published studies that use slightly 
different synthetic promoters (Zweier et al., 2007; de Pontual et al., 2009). The absolute 
effect of mutations in the DNA-binding domain on transcriptional activity is therefore highly 
dependent on promoter sequence and structure. Interestingly, at the CNTNAP2 promoter all 
PTHS-associated TCF4 mutants were found to significantly reduce promoter transactivation 
when co-expressed with ASCL1 (Figure 3.12C), including mutants G358V, D535G and 
A614V that were unaffected in Sepp’s experiments. This is one of the only contexts where 
mutations outside the basic domain have a substantial effect on transcriptional activity and 
this may be related to the presence of an ASCL1 favoured E-box adjacent to the 
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transcriptional start site of the CNTNAP2 gene (Figure 3.8). The TCF4 mutations may be 
expected to have similar damaging effects in physiological conditions as each mutation is 
assumed to be the cause of PTHS in patients. Thus it may be concluded that synthetic 
promoters are useful to interpret the general properties of a mutation, but they cannot be used 
to infer deficits in vivo which are likely to be much more subtle due to the presence of 
multiple interacting proteins and complex promoter structures. 
 
The transactivation experiments also demonstrate that some mutations can elicit opposing or 
variable effects depending on the co-expressed binding partner. For example, R578P and 
R580W increased luciferase expression from the CNTNAP2 promoter when co-expressed 
with NEUROD1 (Figure 3.11D) but had little effect on the NRXN1β promoter. This effect 
may reflect the highly context-specific functions of bHLH factors (Castro et al., 2006; Powell 
and Jarman, 2008). The gene expression analysis performed on TCF4-knockdown cells in 
chapters 4 and 6 would suggest that TCF4 can activate or repress transcription and thus may 
interact with co-activators and co-regulators as has already been proposed (Zhang et al., 
2004; Bayly et al., 2006). Consequently, TCF4 mutants may differentially affect the ability of 
homo and hetero- dimers to recruit regulatory complexes to promoters, depending on the 
surrounding DNA sequence. In this view, the R578P/NEUROD1 and R580W/NEUROD1 
heterodimers may cause aberrant activation of the CNTNAP2 promoter by recruiting 
additional co-activating complexes that do not interact on the NRXN1β promoter (Figures 
3.11D and 3.12D). The R578P/NEUROD1 and R580W/NEUROD1 heterodimers may also 
sequester repressive complexes specifically affecting the CNTNAP2 promoter leading to an 
increased activation (Figures 3.11D and 3.12D). The differential recruitment of co-regulators 
may also explain the opposing effects observed between the R578P/ID2 and R580W/ID2 
heterodimers on the NRXN1β and CNTNAP2 promoters (Figures 3.11E and 3.12E). This data 
underscores the potentially complex regulatory mechanisms governing gene regulation by 
bHLH transcription factors and their context dependence. The exact regulatory mechanisms 
operating on these promoters may be interesting to investigate further if the NRXN1β and 
CNTNAP2 promoter regions used in this study can be validated as physiological TCF4 
binding sites. 
 
Although it is clear that the mutants R578P, R580W and A614V affect the well characterised 
bHLH domain, it is less certain how the other mutants alter TCF4 function. In addition to the 
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bHLH domain, TCF4 contains at least two identifiable activation domains as well as two 
repressor domains (CE repressor and Rep domain) defined by their function in transcriptional 
assays (Section 1.5.2). The G358V mutation resides in AD2 whereas D535G is located in the 
Rep domain (Figure 3.1). As a result of their location, these mutations may interfere with the 
regulation of TCF4 though the AD and Rep domains of the protein. Consistent with the 
context dependence of these mutants, the Rep domain has already been proposed to behave in 
a manner that is dependent upon the composition of the dimer (Markus et al., 2002a). 
Interestingly, the D535G appears to have an augmented activity as a homodimer with the 
wild type protein when compared to TCF4 and the other mutants in luciferase assays. This 
relatively weak increase in activity was found with both the NRXN1β and CNTNAP2 
promoters even though the D535G reduced the propensity of the mutant to form homodimers 
in the HTRF assay (Figure 3.6). Similarly, Sepp et al., also found that that D535G mutant 
was more active than wild type TCF4 in luciferase assays using a synthetic promoter 
construct. Furthermore, using electrophoretic mobility shift analysis (EMSA) Sepp et al., also 
found that D535G had a preference for homodimerisation over heterodimer formation with 
ASCL1 (Sepp et al., 2012a). Thus, the D535G mutation may augment transcriptional activity 
of the mutant protein at certain promoters possibly through de-repression (Figure 3.1). These 
data suggest that PTHS-mutations can dysregulate gene expression by upregulating and 
downregulating target genes. 
 
In summary, the results suggest that mutations R578P and R580W and other DNA binding 
mutants have the most pervasive effects on TCF4 function and are the most damaging in 
vitro. This may be the reason why these are the most common missense mutations in PTHS. 
The A614V mutation seems to specifically disrupt homo- and hetero- dimerisation over other 
aspects of function whilst the impact of the G358V and D535G mutations are more subtle 
and highly dependent on particular contexts. The data presented in this chapter define a 
molecular phenotype for five PTHS-associated missense mutations. In addition, the 
transactivation experiments on the CNTNAP2 and NRXN1β promoters raise the intriguing 
possibility these genes may be regulated by TCF4, defining a regulatory network in PTHS. 
These data provide an important insight into the function of TCF4 and construct a conceptual 
framework to understand the role of TCF4 in PTHS and related neurodevelopmental 
disorders.
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Chapter 4 
 
Knockdown of TCF4 and Gene Expression Profiling 
 
 
4.1 Introduction 
TCF4 is associated with an increased risk of schizophrenia – a common psychiatric disorder 
affecting approximately 1% of the population (Section 1.11). The largest genome-wide 
association studies to date have repeatedly implicated common DNA variation in the TCF4 
gene to schizophrenia susceptibility. TCF4 was initially associated to schizophrenia in large 
meta-analysis of GWAS with 12,945 schizophrenia cases 34,591 controls (P = 4.1×10-9; OR 
1.23) (Stefansson et al., 2009). Independent studies have since found additional evidence that 
variants near TCF4 confer risk to schizophrenia (Ripke et al., 2011; Steinberg et al., 2011; 
Aberg et al., 2013) (Figure 1.5). Although the functional implications of these common DNA 
variants are often unclear, many SNPs are found in regulatory DNA elements that can affect 
gene expression (Kavanagh et al., 2013). Consistent with this hypothesis TCF4 expression 
levels in the frontal cortex and the thalamus of healthy patients were significantly associated 
to cis-acting SNPs proximal to the TCF4 gene (Kim et al., 2012). Variation in SNPs at 
regulatory elements around the TCF4 gene may therefore differentially regulate TCF4 
expression and lead to subtle changes in critical neurodevelopmental pathways. Support for 
this hypothesis is already emerging as increased TCF4 expression has been identified in the 
peripheral blood of psychotic patients (Wirgenes et al., 2012). It is therefore plausible that 
altered expression of TCF4 leads to an unbalanced transcriptional program that contributes to 
the etiology of schizophrenia and PTHS. 
 
To date, the genome-wide effects of TCF4 on neuronal transcription are unknown. TCF4 
function and its transcriptional program have been comprehensively investigated in the 
context of the immune system but comparable understanding of its neural function is lacking 
(de Pooter and Kee, 2010; Reizis, 2010). In order to improve our understanding of TCF4 
function and the cellular networks it regulates, a neuronal cell line expressing high levels of 
endogenous TCF4 was used to investigate the TCF4-regulated transcriptional program. RNA 
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interference (RNAi) was used to knockdown TCF4 transcripts in SH-SY5Y cells and the 
effect on the neuronal transcriptome was measured using microarrays combined with 
pathway analysis and manual curation of the data. Together, these experiments demonstrate 
that knockdown of TCF4 has a direct impact on global transcription and is associated with 
robust gene expression changes in multiple, convergent signaling pathways. This data offers 
unique insight into gene expression networks potentially dysregulated in schizophrenia and 
PTHS and establishes a framework to understand TCF4 function the brain. 
 
The work described in this chapter has been published in PLoS One, August 2013, vol. 8, 
issue 8, e73169 (Forrest et al., 2013). 
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4.2 Results 
 
4.2.1 Knockdown of TCF4 in SH-SY5Y cells 
The silencing of particular mRNA targets can be achieved through RNAi, a mechanism by 
which double stranded RNA (dsRNA) triggers the sequence-specific suppression of mRNA 
through the RNA-induced silencing complex (RISC) (Fire et al., 1998). This technique is 
now widely used for studying gene function and can be combined with microarrays to study 
genome wide transcriptional changes.  
 
The TCF4 gene contains at least 20 coding exons and has complex splicing architecture 
resulting in multiple transcripts with alternative 5’ exons (Sepp et al., 2011). In order to 
knockdown all published TCF4 transcripts, bioinformatics tools were used to design siRNAs 
matching the sequence of core exons shared by all transcripts. High-scoring siRNA duplexes 
complementary to exon 12 (TCF4 KD1) and exon 19 (KD2) of the TCF4 sequence were 
selected for their predicted efficacy. To control for non-specific effects of siRNA treatment, a 
siRNA duplex against GAPDH transcripts was also designed and used along side a mock 
transfection control in the experiments. In each case, blunt-ended RNA duplexes 27 
nucleotides in length (27-mers) were preferred to conventional 21-mer siRNAs as they can be 
up to 100-fold more potent and can be used at lower concentrations (Kim et al., 2005). 
Knockdown of GAPDH was predicted to be a useful control as it is an enzyme that 
participates in central metabolism and is not predicted to cause acute gene expression 
changes if depleted (Appendix III). In addition, the GAPDH siRNA can control for gene 
expression changes induced by the interferon and the RNAi responses that cells activate non-
specifically in the presence of dsRNA. The mock transfected and GAPDH siRNA transfected 
control groups can therefore be used for background correction in these experiments.  
 
After designing the siRNAs, each duplex was transfected individually in SH-SY5Y cells to 
test for their sequence-specific efficacy. The knockdown protocol performed in biological 
triplicates and was scheduled over 72h, to ensure a strong, reproducible depletion. This 
protocol validated the use of the SH-SY5Y model as each siRNA was efficiently transfected 
and achieved a robust knockdown of the target gene (Figure 4.1A). Knockdown efficiency 
was evaluated by quantitative PCR (qPCR) for both GAPDH and TCF4. The TCF4-silencing 
duplexes reduced transcript levels to 20% of mock (TCF4 KD1) and 38% of mock (KD2) 
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(Figure 4.1A). Knockdown of GAPDH reduced transcript levels reduced to 15% of mock-
transfected cells (data not shown).  
 
 
 
 
Figure 4.1 siRNA-mediated knockdown of TCF4 in SH-SY5Y cells. SH-SY5Y cells 
were transfected with siRNA oligonucleotides targeting TCF4 (KD1 and KD2) or GAPDH. 
After 72h, RNA and protein were extracted to assess the knockdown efficiency. (A) Primers 
complimentary to a constitutive exon present in all TCF4 isoforms (exon 13) were used to 
measure overall transcript abundance by qPCR in three biological replicates. TCF4 
knockdown efficiency was similar with both KD1 and KD2 whereas the control GAPDH KD 
did not affect TCF4 transcript levels. (B) Western blots of protein lysates prepared from 
siRNA-treated SH-SY5Y cells demonstrated that KD1 and KD2 reduced TCF4 levels whilst 
wild type (WT), GAPDH knockdown (G), and mock (M) treatment cells had no apparent 
effect. α-tubulin was used as a loading control and for normalization. (C) LI-COR 
quantitation of TCF4 protein levels in siRNA-treated cells. The levels of TCF4 in each 
experiment were quantified and normalised to α-tubulin. In agreement with the qPCR results, 
siRNA treatment reduced TCF4 levels to approximately 20% of mock treated cells. 
 
Importantly, siRNAs targeting GAPDH and mock transfection had no significant effect on 
the level of the TCF4 transcripts (Figure 4.1). In addition to qPCR, quantification of the 
knockdown treatment was also verified by semi-quantitative western blotting. A clear 
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reduction in TCF4 protein was visible for the TCF4 knockdown samples KD1 and KD2 
compared to controls (Figure 4.1B). Knockdown of TCF4 with KD1 and KD2 resulted in a 
greater than 80% reduction in proteins levels with both duplexes (Figure 4.1C). Although 
similarly reduced, KD2 was less effective than KD1 at knocking down the TCF4 protein 
reflecting the qPCR data. As a final assessment, the SH-SY5Y cells were imaged by confocal 
microscopy to observe any overt treatment effects on cellular morphology. The TCF4-
depleted cells had reduced expression of TCF4 in their nuclei compared to controls although 
no obvious morphological differences were observed (Figure 4.2) 
 
 
Figure 4.2 Cellular imaging of siRNA-treated SH-SY5Y cells. SH-SY5Y cells were 
treated with siRNAs for 72h as described above. Fixed cells were stained with Alexa Fluor 
488 phalloidin (F-actin, green), Hoescht-33342 (nuclei, blue) and with an anti-TCF4 
polyclonal antibody (red). Although there is a marked reduction in TCF4 immunoreactivity in 
TCF4 KD cells, no apparent morphological differences are observed between treatment 
groups after 3 days knockdown. A few condensed pyknotic nuclei, indicative of apoptosis 
were observed after TCF4 KD treatment (arrow heads). 
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4.2.2 Data processing and quality control of microarray experiments 
After successful validation of the gene-specific knockdown, the quality of the RNA from 
each sample was measured using an Agilent Bioanalyzer. Each RNA sample had a RNA 
integrity number (RIN) of 10, the maximum score for this instrument, indicating the extracted 
RNA was of high quality. To ensure that any of the reported gene expression changes were 
reproducible, three of the previously validated biological replicates from each group were 
used for microarray analysis, a total of 12 samples. Each of the samples were converted to 
cDNA, amplified, labeled and hybridised to a Toray microarray for genome-wide transcript 
analysis (Section 2.9.9).  
 
The processed microarray data received from CBS consisted of an Excel spreadsheet with 
background-corrected signal intensities for each gene annotated on the Toray microarray 
platform. The Toray microarray has a unique probe for each gene that is designed to capture 
the majority of transcripts described in public databases (approximately 25,000 probes). The 
annotated gene information and signal intensity data for each of the 12 samples (3 mock, 3 
GAPDH, 3 TCF4 KD1, 3 TCF4 KD2) was imported manually into Partek Genomics Suite 
6.6, log transformed to fit normal distribution and quantile normalised so that the distribution 
ranges of each sample was similar. As there were relatively few replicates in each condition 
(n=3), probes with more than 1 missing values across all groups were ignored.  
The success of the experimental treatments was measured using principle component analysis 
(Figure 4.3.2). This graphical display summarises the microarray data for each sample onto 
three principle components and demonstrates how the experimental samples relate to one 
another. The quality of the experiment can be assessed by the clustering biological replicates 
within a treatment group and the segregation of samples between treatments. It is interesting 
to note that although each treatment group clusters in a distinct area of the graph (indicating 
distinct treatment effects), the replicates in the KD2 treatment group (light green) are much 
closer to the control samples compared to the KD1 (dark green) (Figure 4.3.2).  
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Figure 4.3.1. Comparison of gene expression signatures between TCF4 knockdown 
groups. The microarray data for TCF4 KD1 and TCF4 KD2 was used to generate two lists of 
transcripts that were differentially expressed compared to mock treated cells. The lists were 
generated by performing a one-way ANOVA between the TCF4 knockdown group (KD1 or 
KD2) and the mock treated group. The lists were compared to determine the number of 
shared gene expression changes (illustrated in the overlap). The total and shared number of 
differentially expressed transcripts are indicated. The size of each circle is representative of 
the number of gene expression changes but is not to scale. 
 
The similarity between the TCF4 KD1 and TCF4 KD2 treatments were subsequently 
compared in terms of their effect on gene expression compared to mock treated cells. A one-
way ANOVA comparing the signal intensities from the TCF4 KD-treated groups to the mock 
treated group was performed to establish two list of differentially expressed; one for TCF4 
KD1 and one for TCF4 KD2. A false discovery rate (FDR) 0.01 was applied to each list to 
remain in agreement with downstream analysis (see section 4.2.3). After FDR-correction, 
comparison of the differentially expressed genes in TCF4 KD1 and TCF4 KD2 revealed an 
overlap of 69%, indicating similarity in the effects of each treatment on gene expression 
(Figure 4.3.1). 
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Figure 4.3.2 Principle component analysis of microarray samples. The genome-wide 
expression data from each sample is reduced to three principle components that capture 
60.2% of the variation in the data. The principle components (PC) are plotted against 3 axes: 
PC1; X-axis, PC2; Y-axis, PC3; Z-axis. The percentage variance captured by each PC is 
displayed next to each axis label (PC1; 37%, PC2; 12.9%, PC3; 10.3%). Two different 
viewpoints of the graph are presented to fully appreciate the distribution of data points in 
dimensional space.  For clarity, treatment groups have been colour-coded (see key above 
graph: Mock; dark blue, GAPDH KD; light blue, TCF4 KD1; dark green, TCF4 KD2; light 
green) 
 
4.2.3 Overview of differentially expressed genes in TCF4 knockdown cells 
In order to identify genes differentially expressed between the TCF4 KD groups and the 
control groups a one-way ANOVA was performed on the pooled control (mock and GAPDH 
KD; 6 samples) and pooled TCF4 (TCF4 KD1 and KD2; 6 samples) knockdown groups. To 
correct for multiple testing, a false discovery rate (FDR) based approach was applied which is 
appropriate for microarray analysis (Reiner et al., 2003). Decreasing the threshold of FDR 
correction decreases the number of significant genes in the ANOVA analysis. In our analysis, 
an FDR correction of 0.05 generated a list of 5376 differentially expressed genes and this list 
was reduced to 1204 genes when the correction was reduced to 0.01. To select the most 
robust gene expression changes and reduce the number of genes in the list, an FDR correction 
of 0.01 was used for all downstream enrichment analysis, as a moderately sized gene lists 
(between 500 and 2000 genes) are recommended for an informative enrichment analysis 
(Huang da et al., 2009).  
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Figure 4.4 Hierarchical clustering of the top differentially expressed genes. The top 
1204 differentially expressed genes (FDR 0.01) cluster by treatment group as evident from 
the dendrogram to left of the heatmap. Samples from the control treatments (mock and 
GAPDH KD) and TCF4 KD treatment (KD1 and KD2) are shown to cluster into defined 
groups (white and black respectively). The top section of the heat map displays differential 
expression relative to controls: up-regulated genes are shown in red while down-regulated 
genes are coloured blue. 
 
Hierarchical clustering was used to visualise the top gene expression changes in the FDR 
0.01 list. The top gene expression changes clustered with the experimental treatment 
indicating control and TCF4 KD groups had distinct gene expression signatures (Figure 4.4).  
This clustering analysis also displays that there is a higher portion of downregulated (710) 
compared to upregulated genes (494) (Figure 4.4). The top 40 up- and downregulated genes 
ranked by fold change are illustrated in Figure 4.5A. Initial examination of the most robust 
gene expression changes in TCF4-knockdown cells (Figure 4.5A) appeared to suggest a role 
for TCF4 in apoptosis or inflammasome function (up-regulation of CASP1 and CASP4), cell 
signaling (down-regulation of IGF2, BMP7 and LEFTY1) and neurodevelopment (down-
regulation of NEUROG2, ASCL1 and MEF2C). Furthermore, several of the major gene 
expression changes in TCF4-knockdown cells involved transcription factors including 
ASCL1 and NEUROG2 that interact directly with TCF4 at E-boxes (Zweier et al., 2007; 
Forrest et al., 2012; Li et al., 2012b; Sepp et al., 2012b). Finally, a number of imprinted 
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genes, IGF2, H19 and CDKN1C were prominent amongst the most significantly 
downregulated genes in TCF4-knockdown cells (Figure 4.5A). 
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A 
 
 
B   Functional Classification of Differentially Expressed Genes 
 
 
 
Figure 4.5 Overview of differentially expressed genes after TCF4 knockdown 
(A) Top 40 upregulated (upper panel) and downregulated (lower panel) genes after FDR 
correction (0.01) ranked by fold change. (B) Functional characterization of all differentially 
expressed genes (upregulated and downregulated) (FDR 0.01) using GOSLIM annotations. 
All annotation categories representing less than 4% of the gene list were grouped and labeled 
as “other”. 
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To confirm the gene expression changes detected on the microarray, qPCR was used to 
independently validate the results. 5 up- (FAS, NTRK1, CASP8, NOTCH1, CASP1) and 5 
down- regulated genes (IGF2, CDKN1C, NEUROG2, BMP7, CDK6) were selected that had a 
fold change above or below 1.5. The genes were also designated on the basis of their known 
importance to developmental processes and their recurrent appearance in the downstream 
enrichment analyses (Tables 4.2 and 4.3). Transcript abundance was measured from the same 
RNA samples used on the microarray, allowing a direct comparison of the inferred changes. 
In addition, TaqMan probes were selected to match the exons targeted on the microarray. The 
qPCR analysis confirmed that each of the 10 selected genes were differentially expressed and 
each had similar a fold change to that detected on the microarray (Table 4.1). 
 
Table 4.1 qPCR validation of differentially expressed genes. Ten differentially 
expressed genes belonging to various functional categories were chosen for qPCR validation. 
All the genes selected for validation had similar fold changes by qPCR to that seen on the 
microarray. In both cases, the presented P values represent the statistical significance 
(Student’s t-test) between the pooled control (mock treated, GAPDH KD) and TCF4 KD 
(KD1, KD2) groups. 
 
Gene 
Microarray qPCR 
Fold change P value Fold change P value 
FAS 1.9 2.88E-05 2.9 3.58E-05 
NTRK1 3.8 1.53E-05 4.1 3.58E-05 
CASP8 3.0 1.38E-05 10.4 2.40E-03 
NOTCH1 2.3 1.02E-04 2.9 6.03E-05 
CASP1 15.7 6.13E-05 9.8 8.06E-03 
IGF2 -5.2 1.52E-06 -4.2 2.51E-05 
CDKN1C -2.4 2.36E-06 -2.3 1.02E-03 
NEUROG2 -3.0 1.50E-05 -3.6 8.30E-07 
BMP7 -3.7 1.34E-04 -2.4 5.46E-05 
CDK6 -2.9 2.87E-07 -2.6 3.71E-06 
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4.2.4 Enrichment analysis of differentially expressed genes in TCF4-depleted cells 
Initial functional annotations associated with the 1204 differentially expressed genes in 
TCF4-knockdown cells were found to span a range of biological functions that cluster around 
the broad themes of metabolism, development and cell signaling (Figure 4.5B). To ascertain 
whether any biological functions were enriched in the high confidence gene list, all genes 
with Entrez gene IDs were selected for enrichment analysis to avoid the redundancy 
associated to using gene names. Of the 1204 genes that passed FDR correction of 0.01, 1031 
had corresponding Entrez IDs (425 upregulated, 606 downregulated). The 1031 genes were 
subsequently tested for GO annotation enrichment using the Database for Annotation, 
Visualization and Integrated Discovery (DAVID) (Huang da et al., 2009). Functional 
annotations from up- and downregulated genes were compared separately to a background 
list of genes consisting of all expressed genes detected on the microarray. This analysis 
identified several biological processes that were significantly enriched (FDR 0.05) in TCF4 
knockdown cells. These terms included non-coding RNA metabolic processes, apoptosis and 
regulation of NF-κB signaling (Table 4.2). Importantly, up- and down- regulated genes 
seemed to cluster by distinct functional annotations (Table 4.2). For example, regulation of 
the NF-κB and apoptotic signaling cascades and were significantly enriched in the 
upregulated genes whereas annotations relating to non-coding RNA metabolism, ribosome 
biogenesis and protein folding were downregulated as a consequence of TCF4 knockdown. 
Although not all the GO annotations listed in the downregulated gene category passed 
multiple test correction, they were nominally significant by DAVID’s EASE score (P < 0.05) 
and functionally linked. In this context it is important to note that DAVID recommends using 
p-values simply as a ranking tool without the need for statistical cut offs to be set, as they 
may be arbitrary (Huang da et al., 2009). 
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Table 4.2 GO term enrichment analysis using DAVID. The Entrez Gene IDs of 
upregulated and downregulated genes were analyzed separately for biological process 
enrichment using DAVID. Enriched GO terms are ranked in order of decreasing significance. 
The genes in each GO category are listed as wells as the corrected (FDR) and uncorrected P 
values. For clarity redundant terms were removed. *Pass FDR correction of 0.05. 
 
 GO annotation Genes P value FDR 
Upregulated genes (423 DAVID IDs) 
1 
GO:0043122~regulati
on of I-kappaB 
kinase/NF-kappaB 
cascade 
CD40 TFG, TNFSF10, CASP1, TBK1, PLK2, TRIM38, NOD1, 
RHOC, HTR2B, WLS, CARD8, SHISA5, TRADD, ZDHHC17 4.87E-07 0.001
* 
2 GO:0042981~regulation of apoptosis 
MEF2C, LOC100289713, NGFRAP1, ARHGEF6, NOTCH1, 
SH3GLB1, TNFSF13B, B4GALT1, TNFSF10, IDO1, BNIP3, 
APH1A, NOD1, ADAM17, CARD8, NGFR, SOCS3, KALRN, 
TRADD, SOX9, MSX2, AEN, CADM1, BARD1, CASP4, 
CREB1, CD38, CASP1, AKT1, CASP3, MCL1, JAK2, DPF2, 
TXNIP, FAS, TIA1, ANGPTL4, EYA1, YWHAZ, NTRK1, SIRT1, 
BCL2L13 
1.10E-05 0.019* 
3 
GO:0009967~positiv
e regulation of signal 
transduction 
CD40, BMPR1A, TFG, HIF1A, FKBP8, TNFSF10, CASP1, 
JAK2, TBK1, PLK2, TRIM38, NOD1, HTR2B, ADAM17, JAG1, 
RHOC, WLS, RICTOR, SMAD4, SHISA5, TRADD, ZDHHC17 
1.18E-05 0.021* 
4 
GO:0043065~positiv
e regulation of 
apoptosis 
LOC100289713, NGFRAP1, ARHGEF6, NOTCH1, SH3GLB1, 
B4GALT1, TNFSF10, BNIP3, APH1A, NOD1, NGFR, KALRN, 
TRADD, MSX2, AEN, CADM1, BARD1, CASP4, CD38, 
CASP1, AKT1, CASP3, JAK2, DPF2, FAS, TXNIP, TIA1, 
BCL2L13 
1.28E-05 0.022* 
5 GO:0006915~apoptosis 
MEF2C, LOC100289713, NGFRAP1, ARHGEF6, SH3GLB1, 
FKBP8, TNFSF10, BNIP3, CSRNP1, APH1A, NOD1, CSRNP2, 
CARD8, NGFR, KALRN, TRADD, AEN, CADM1, CASP4, 
RNF34, DAPL1, CASP1, AKT1, CASP3, JAK2, MCL1, DPF2, 
FAS, ELMO1, TIA1, SHISA5, GULP1, SIRT1, BCL2L13 
1.29E-05 0.022* 
6 
GO:0043067~regulati
on of programmed 
cell death 
MEF2C, LOC100289713, NGFRAP1, ARHGEF6, NOTCH1, 
SH3GLB1, TNFSF13B, B4GALT1, TNFSF10, IDO1, BNIP3, 
APH1A, NOD1, ADAM17, CARD8, NGFR, SOCS3, KALRN, 
TRADD, SOX9, MSX2, AEN, CADM1, BARD1, CASP4, 
CREB1, CD38, CASP1, AKT1, CASP3, MCL1, JAK2, DPF2, 
TXNIP, FAS, TIA1, ANGPTL4, EYA1, YWHAZ, NTRK1, SIRT1, 
BCL2L13 
1.29E-05 0.023* 
7 
GO:0043068~positiv
e regulation of 
programmed cell 
death 
LOC100289713, NGFRAP1, ARHGEF6, NOTCH1, SH3GLB1, 
B4GALT1, TNFSF10, BNIP3, APH1A, NOD1, NGFR, KALRN, 
TRADD, MSX2, AEN, CADM1, BARD1, CASP4, CD38, 
CASP1, AKT1, CASP3, JAK2, DPF2, FAS, TXNIP, TIA1, 
BCL2L13 
1.39E-05 0.024* 
 
 
 
Continued… 
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Downregulated genes (598 DAVID IDs) 
1 GO:0034660~ncRNA metabolic process 
CARS2, FARSB, POP7, TSEN2, WDR12, EXOSC1, DUS3L, 
TARSL2, ADAT2, RPL35A, PDCD11, PIWIL1, IMP4, QTRTD1, 
TRMT10C, PUS3, EXOSC7, FTSJ1, MKI67IP, RPL7, DIMT1 
2.42E-05 0.041* 
2 
GO:0022613~ribonuc
leoprotein complex 
biogenesis 
WDR12, GEMIN6, RRS1, EXOSC1, NCBP1, SURF6, RPL35A, 
TSR1, IMP4, PDCD11, GEMIN5, EXOSC7, FTSJ1, NUFIP1, 
MRTO4, RPL7, BYSL, DIMT1 
3.72E-05 0.064 
3 GO:0042254~ribosome biogenesis 
WDR12, RRS1, EXOSC1, SURF6, RPL35A, TSR1, IMP4, 
PDCD11, FTSJ1, EXOSC7, MRTO4, RPL7, BYSL, DIMT1 8.01E-05 0.14 
4 GO:0034470~ncRNA processing 
WDR12, TSEN2, POP7, EXOSC1, DUS3L, ADAT2, RPL35A, 
IMP4, PDCD11, QTRTD1, TRMT10C, PUS3, EXOSC7, FTSJ1, 
RPL7, DIMT1, SMAD2 
1.94E-04 0.33 
5 GO:0006457~protein folding 
BAG2, DNAJC12, SEC63, RUVBL2, FKBP7, GRPEL1, APCS, 
SACS, PFDN6, HSPBP1, PPIF, PPID, CCT6A, URI1, PPIH 7.06E-04 1.20 
6 GO:0016072~rRNA metabolic process 
WDR12, EXOSC1, EXOSC7, MKI67IP, FTSJ1, RPL35A, 
PDCD11, RPL7, IMP4, DIMT1 2.72E-03 4.55 
7 GO:0007005~mitochondrion organization 
MRPL12, TIMM8A, TIMM13, PPIF, OXA1L, PTCD2, BID, 
GRPEL1, TIMM9, RNASEH1, FAXC, MYC 4.45E-03 7.36 
     
 
 
 
 
 
 
Chapter 4: Knockdown of TCF4 and Gene Expression Profiling 
	   105	  
To determine whether the apoptotic cell death pathway was indeed activated in TCF4-
depleted cells, cell viability and caspase activation after treatment with the different siRNAs 
was examined (Figure 4.6). TCF4-knockdown was associated with significantly reduced cell 
viability compared to the control groups (P = 2.8x10-16). Reduced cell viability was also 
associated with increased caspase 3/7 activity (P = 1.3x10-3) in TCF4-depleted cells (Figure 
4.6A). Caspase-3 cleavage, which occurs in cells undergoing apoptosis, was also detected by 
western blotting in TCF4-depleted cells (Figure 4.6B). Interestingly, cells treated with TCF4 
KD2 showed more evidence of apoptotic cell death and reduced viability compared to TCF4 
KD1. In control experiments, acute staurosporine-treatment was associated with a robust 
increase in apoptotic cell death in untransfected SH-SY5Y cells. Although no gross 
differences in cellular morphology were evident between siRNA-treated cells and controls, 
condensed pyknotic nuclei were frequently observed in TCF4-depleted cells (Figure 4.2). 
 
 
 
Figure 4.6 Knockdown of TCF4 induces apoptosis in SH-SY5Y cells. Cells were 
treated with siRNAs for 72h after which cell viability and caspase activity were measured 
(A). In addition to the siRNA treatment groups, untransfected SH-SY5Y cells were exposed 
to staurosporine (1µM in DMSO) and vehicle for 3h to induce apoptosis. Knockdown of 
TCF4 leads to a significant reduction in cell viability (P = 2.8x10-16, white). Furthermore, 
TCF4-knockdown is also associated with an increase in caspase 3/7 activity compared to 
controls (P = 1.3x10-3, black bars). Although GAPDH knockdown is associated with reduced 
cell viability and elevated caspase 3/7 activity compared to mock-treated cells, both assays 
showed statistical significant differences between the control groups (mock and GAPDH) 
compared to TCF4-knockdown (TCF4 KD1 and KD2) supporting the microarray data. As 
expected, staurosporine treatment also reduced cell viability and increased caspase 3/7 
activity in untransfected cells. Western blot analysis of caspase 3 processing after 72h 
knockdown shows that caspase 3 cleavage products are detected in siRNA treated cells (B). 
β-actin was used as a loading control for all treatment groups. 
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4.2.5 Differential expression of genes in the TGF-β  signaling and EMT pathways in 
TCF4-knockdown cells 
To refine the analysis of downstream gene expression changes due to TCF4 knockdown, the 
MetaCoreTM (GeneGo) analytical suite was utilised which provides a manually curated 
database of “process networks” which detail more specific biological processes than GO 
annotations. In this analysis, the full list of up- and downregulated genes with Entrez IDs 
(1031 genes) were interrogated to reveal the concerted function of the top differentially 
expressed genes. This analysis identified a number of cellular processes in TCF4-knockdown 
cells including TGF-β signaling, epithelial to mesenchymal transition (EMT), hedgehog 
signaling, apoptosis and neurogenesis (Table 4.3). These data corroborate the findings using 
DAVID, as process networks relating to apoptosis (“Death Domain receptors and caspases in 
apoptosis” and “Apoptosis stimulation by external signals”) appeared in the list (Table 4.3). 
 
Novel terms relating to particular signal transduction pathways and developmental processes 
were identified using MetaCore (Table 4.3). Specifically, three process networks passed 
stringent FDR correction (FDR 0.05). In the signal transduction category, process networks 
associated with “TGF-β, GDF and activin signaling” and “BMP and GDF signaling” were 
found to be over-represented. These terms refer to signaling through the TGF-β superfamily 
of ligands (Massague, 2012). TGF-β ligands operate through the activation of transmembrane 
serine-threonine receptor kinases that phosphorylate SMAD proteins to coordinate cell-type 
specific gene expression. MetaCore analysis revealed that several elements of the TGF-β 
signaling pathway where differentially expressed after TCF4 knockdown. Differentially 
expressed genes included two ligands of the TGF-β family (INHBA and BMP7), the 
BMPR1A receptor, and several of the SMAD transcription factors (SMAD2, SMAD4, 
SMAD7), demonstrating that each level of the pathway was affected (Table 4.4). 
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Table 4.3 Process network enrichment in MetaCore. The Entrez gene IDs derived 
from the high-confidence list of 1031 differentially expressed genes in TCF4-knockdown 
cells were analyzed for enrichment using MetaCoreTM. Each term is presented with its 
functional category, network and corresponding P value. *Pass FDR correction of 0.05. 
 
Category Process Network Genes P value FDR 
Signal 
Transduction 
TGF-β, GDF and Activin 
signaling 
PTPRK, PTGER2, CREB1, GATA3, 
CCND1, INHBA, SMAD4, FOS, SP1, 
SMAD2, HIF1A, ATF2, SMAD7, 
LEFTY1, MYC, TOB1, NOTCH1, CDK6 
3.54E-04 0.044* 
Signal 
Transduction BMP and GDF signaling 
CREB1, MSX2, BMPR1A, AKT1, BMP7, 
SMAD4, TLE1, ATF2, SMAD7, MYC, 
NODAL, SOX9, TOB1, CDK6 
8.02E-04 0.044* 
Development 
Regulation of epithelial-
to-mesenchymal 
transition 
NOTCH1, CREB1, ACTA2, JAK2, 
BMP7, TRADD, SMAD4, FOS, SP1, 
SMAD2, HIF1A, ATF2, ABBP1, JAG1, 
SMAD7, ADAM17, SNAI2, IGF2, TJP1, 
SOX9 
8.38E-04 0.044* 
Development Regulation of telomere length 
TINF2, MAX, TEP1, SP1, HNRNPC, 
MYC, PTGES3, CDK6 5.35E-03 0.190 
Development Hedgehog signaling 
NOTCH1, CREB1, HESX1, CCND1, 
SIRT1, INHBA, AKT1, BMP7, RBX1, 
SMAD4, ASCL1, ZIC1, SP1, ROCK2, 
PBX1. CDKN1C, HES1, JAG1, MYC, 
ADAM17, SOX9 
6.06E-03 0.190 
Apoptosis 
Death Domain receptors 
and caspases in 
apoptosis 
NGFRAP1, NGFR, TRADD, CD40, 
TIMP3, TNFSF10, CASP1, TRAF4, 
NOD1, PDCD5, CASP3, BIRC8, FAS, 
CASP4, CARD8 
7.26E-03 0.190 
Apoptosis Apoptosis stimulation by external signals 
NGFRAP1, JAK2, BID, NGFR, NTRK1, 
TRADD, SMAD4, TNFSF10, FOS, 
SMAD2, ADAM17, CASP3, FAS, BID 
9.66E-03 0.217 
Development Neurogenesis in general 
NOTCH1, CREB1, HESX1, GFRA3, 
INHBA, RCAN1, ASCL1, ZIC1, PBX1, 
NEUROG2, HES1, JAG1, ADAM17, 
CHRM3, MEF2C, SERPINI1 
1.24E-02 0.237 
DNA 
damage Checkpoint 
YWHAQ, CCND1, TLK2, BRIP1, 
CCND3, RUVBL2, ATF2, ATF3, RAD1, 
BARD1, MYC, YWHAZ, CDK6 
1.51E-02 0.237 
Cardiac 
development 
BMP and TGF-β 
signaling 
MSX2, ISL1, BMPR1A, BMP7, SMAD4, 
PDLIM3, MYH7, SMAD2, SMAD7, 
NODAL, SNAI2, SOX9, MEF2C 
1.51E-02 0.237 
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Table 4.4 Gene expression changes associated with TGF-β  and Notch signaling 
pathways in TCF4-knockdown cells. Gene expression changes in manually curated 
signaling pathways in TCF4-knockdown cells. The data are presented as statistically 
significant (FDR 0.01) gene expression changes (fold change) for the genes in the TGF-β and 
Notch signaling pathways. *Pass FDR correction of 0.05. 
 
Gene Fold Change P value Description 
TGF-β  signaling pathway 
BMP7 -3.94 1.34E-04 BMP Ligand 
BMPR1A 2.46 1.81E-05 Tyrosine kinase receptor (BMP) 
SMAD2 -2.15 4.38E-04 R-SMAD (TGF/Nodal) 
SMAD4 1.49 4.71E-04 co-SMAD 
SMAD7 1.38 3.97E-04 I-SMAD 
SMAD6 1.23 1.04E-02* I-SMAD 
SMAD1 1.28 9.59E-03* R-SMAD (BMPR1) 
NODAL -1.25 2.27E-04 Ligand (Nodal) 
INHBA -2.38 2.68E-07 Ligand (Activin A) 
LEFTY1 -2.81 3.37E-04 Ligand (Inhibitor of Nodal) 
Notch signaling pathway 
NOTCH1 2.40 1.02E-04 Ligand receptor 
NOTCH2 -1.43 8.48E-03* Ligand receptor 
JAG1 2.59 4.61E-04 Ligand receptor (inhibitor of Notch) 
ADAM17 1.44 3.83E-04 metallopeptidase (Notch-cleavage) 
APH1A 1.64 1.57E-04 γ-secretase complex (Notch-cleavage) 
HES1 1.65 4.67E-05 Notch effector 
HES7 -1.54 6.40E-03* Notch effector 
 
The third term that remained statistically significant after FDR correction was in the 
development category and relates to EMT (Table 4.3). EMT is a developmental process 
whereby cells loose their adhesive properties and become more motile. EMT is essential for 
neural tube formation and is thought to be a key step regulating cancer cell metastasis 
(Acloque et al., 2009). Two important EMT regulators, SNAI2 and DEC1 (BHLHB2 in Figure 
4.5A) are differentially expressed in response to TCF4 depletion. SNAI2 promotes EMT and 
is downregulated in TCF4-knockdown cells whereas DEC1 is upregulated in TCF4-
knockdown cells (Figure 4.5A). It is also noteworthy that differentially expressed genes 
associated to the EMT category are also of general importance to development as they 
include elements of the Notch, BMP and IGF signaling pathways (Tables 4.3, 4.4 and 4.5). 
RT-PCR was used to gain further support for the differential expression of EMT genes in 
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TCF4-depleted cells (Figure 4.7). These data confirm the gene expression changes detected 
on the microarray and show that in addition to SNAI2, SNA11 is also downregulated in TCF4-
depleted cells. Importantly, expression of the closely related class I bHLH gene TCF3 
(E12/E47) was unaltered in TCF4-depleted cells suggesting the alterations in the EMT gene 
expression pathway occurred independently of E47 activity. 
 
 
Figure 4.7 Semiquantitative RT-PCR analysis of EMT-regulating transcription 
factors in TCF4-knockdown cells. RT-PCR was used to confirm differential expression of 
several transcription factors that drive EMT. SNAI1 and SNAI2 transcripts are down-
regulated in TCF4-knockdown cells whereas BHLHE40 (DEC1) and MEF2C transcripts are 
up-regulated. These data also show that TCF4 homologue TCF3 (E47), a known regulator of 
EMT, is unaltered in TCF4-depleted cells. Note that alterations in SNAI1 were not evident on 
the microarray possibly due to its low expression in SH-SY5Y cells. 
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The IGF-signaling pathway also appears to be altered in TCF4-depleted SH-SY5Y cells 
(Fernandez and Torres-Aleman, 2012). Specifically, IGF2 and GRB14 are among the most 
significantly downregulated genes whereas IGFBP5 and the genes encoding other IGF-
binding proteins are upregulated in our dataset (Figure 4.5 and Table 4.5). These alterations 
in gene expression are also evident in downstream elements of the IGF-signaling pathway 
and include down-regulation of several kinases and adaptor molecules such as AKT1 and 
RPS6KB1 that encodes the p70 ribosomal S6 kinase (Table 4.5).  
 
Table 4.5 Gene expression changes associated with the IGF signaling pathway in 
TCF4-knockdown cells. Gene expression changes in the manually curated IGF signaling 
pathway in TCF4-knockdown cells. The data are presented as statistically significant (FDR 
0.01) gene expression changes sorted by fold change for the genes in the IGF signaling 
pathway (Fernandez and Torres-Aleman, 2012). *Pass FDR correction of 0.05. 
 
Gene Fold change P value Description 
IGF2 -5.22 1.52E-06 IGF ligand 
IGFBP5 4.90 2.35E-05 IGF carrier protein 
IGFBP3 1.28 1.17E-02* IGF carrier protein 
IGFBP4 2.59 3.09E-03* IGF carrier protein 
GRB14 -3.08 1.79E-05 Receptor-bound protein (inhibitor) 
GRB7 -1.22 1.95E-04 Receptor-bound protein (inhibitor) 
PIK3CG -1.75 9.67E-03* Signal transduction (kinase) 
PIK3CA 1.58 6.16E-04* Signal transduction (kinase) 
PIK3C2B -1.45 5.42E-03* Signal transduction (kinase) 
PIK3CD -1.30 7.37E-03* Signal transduction (kinase) 
PDPK1 (PDK1) -1.98 8.88E-05 AKT inhibition (kinase) 
AKT1 1.36 3.53E-04 Signal transduction (kinase) 
YWHAG -1.97 7.64E-05 Regulatory co-factor 
YWHAZ 1.26 3.63E-04 Regulatory co-factor 
FOXO1A 1.60 3.75E-03* Transcription factor 
FOXO3B -1.72 3.65E-03* Transcription factor 
RPS6KB1 (S6K1) -1.28 3.83E-03* Ribosomal subunit kinase 
RPS6KC1 1.78 4.15E-03* Ribosomal subunit kinase 
RPS6KA3 1.47 6.83E-03* Ribosomal subunit kinase 
RPS6KA1 -1.32 2.57E-03* Ribosomal subunit kinase 
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4.2.6 Dysregulation of neurogenic and neurological disease genes in TCF4-depleted 
cells 
Human genetic studies implicate TCF4 in neurological and neuropsychiatric disorders. In 
accordance with these findings, our data supports a role for TCF4 in regulating genes 
important for neurodevelopment. The proneural genes ASCL1 and NEUROG2 were found to 
be downregulated in TCF4-depleted cells (Figure 4.5A). In addition, a number of genes 
implicated in rare Mendelian forms of mental retardation were differentially expressed in 
TCF4 knockdown cells (Table 4.6). Interestingly, these differentially expressed genes are 
mutated in disorders that resemble Rett syndrome and have phenotypic similarities to PTHS. 
For example, MEF2C is found in the top 40 most significantly upregulated genes in TCF4-
knockdown cells (Figure 4.5A). Furthermore, UBE3A (mutated in AS) is downregulated in 
TCF4 knockdown cells whereas the MWS gene and EMT regulator ZEB2, is upregulated 
(Table 4.6).  
 
Table 4.6 Dsyregulation of several genes associated with intellectual disability in 
TCF4-knockdown cells. Data presented are the fold change (FC) and the corrected P value 
(FDR 0.01) derived from the microarray. *Pass FDR correction of 0.05, **pass FDR 
correction of 0.1. Abbreviations: PTHS, Pitt-Hopkins syndrome; AS, Angelman Syndrome; 
MWS, Mowat-Wilson syndrome, AD; autosomal dominant. 
 
Gene Disease OMIM Inheritance FC P value Reference 
TCF4 PTHS 610954 AD -3.10 2.02 E-05 
(Peippo and Ignatius, 
2012) 
MEF2C Syndromic MR 613443 AD 3.73 1.37 E-05 
(Zweier and Rauch, 
2012) 
UBE3A AS 105830 
Loss or mutation 
of maternal allele 
-1.39 1.56 E-03* (Mabb et al., 2011) 
ZEB2 MWS 235730 AD 1.48 3.60 E-03* 
(Garavelli and 
Mainardi, 2007) 
FMR1 FXS 300624 X-linked 1.94 1.51 E-02** (Bhakar et al., 2012) 
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4.3 Discussion 
 
It is now well established that rare, highly penetrant TCF4 alleles are associated with 
neurodevelopmental phenotypes whereas common variants are associated with disorders such 
as schizophrenia (Amiel et al., 2007; Brockschmidt et al., 2007; Zweier et al., 2007; 
Stefansson et al., 2009; Talkowski et al., 2012). Recent cognitive and imaging studies have 
also shown that TCF4 is important for normal brain function (Blake et al., 2010; Navarrete et 
al., 2013). However, knowledge of TCF4-regulated genes and pathways in the brain is 
comparatively sparse. Using genome-wide transcriptional profiling of SH-SY5Y cells, 
experiments in this chapter demonstrate that silencing TCF4 affects the expression of genes 
involved in cell signaling, cell survival and neurodevelopment. By deconstructing the top 
gene expression changes, it is apparent that genes controlling apoptosis tend to be 
upregulated whilst genes that support processes involving non-coding RNA metabolism are 
downregulated. Process network enrichment analysis also suggests that the TGF-β, NOTCH 
and IGF signaling pathways may converge on the EMT pathway in TCF4-depleted cells.  
 
4.3.1 GO enrichment analysis implicates TCF4 in apoptosis and non-coding RNA 
metabolism 
Several bioinformatics tools were used to search for processes and pathways that may be 
altered in TCF4-depleted cells. Initial results from GO term enrichment analysis using 
DAVID showed that apoptosis and NF-κB signaling were statistically significant processes 
among the upregulated genes. Shared terms in GO categories between NF-κB signaling and 
cell death categories show that many of the genes in each pathway are the same, indicating 
some degree of convergence between NF-κB signaling and apoptosis (Table 4.2). In neurons, 
NF-κB regulates the expression of genes participating in seemingly diverse aspects of 
neurodevelopment, learning and memory (Gutierrez and Davies, 2011). NF-κB signaling has 
also been implicated in enhancing neuronal apoptosis associated with neurodegenerative 
disease, brain injury and inflammatory conditions (Qin et al., 2007). Similarly in neurons, 
caspase activation is known to be important for axon pruning and synapse elimination and 
can mediate some of the chronic neuropathological events associated with brain injury or 
neurodegeneration (Hyman and Yuan, 2012). Since acute knockdown of TCF4 over a period 
of 72h reduced cell viability and increased caspase 3/7 activity, up-regulation of some 
caspases and components of the NF-κB pathway in TCF4-depleted cells may induce cell 
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death (Figure 4.6). It is therefore possible that TCF4 may regulate the expression of some 
caspase genes and other components of the pro-apoptotic signaling pathway in SH-SY5Y 
cells. 
 
4.3.2 TCF4-knockdown affects genes in the TGF-β  signaling pathway 
To gain further insight in to TCF4-regulated pathways, MetaCore was utilised to identify 
network processes that were altered in TCF4-depleted cells. Enrichment analysis on the top 
1031 differentially expressed genes, demonstrated that several components of the TGF-β 
signaling pathway are affected. Specifically, robust down-regulation of the TGF-β 
superfamily of ligands (BMP7, NODAL, LEFTY1 and INHBA) was observed, as well as 
altered expression of several downstream components of the TGF-β signaling cascade 
including BMPR1A, and some of the SMAD transcription factors (Table 4.4). TGF-β 
signaling regulates many aspects of cell proliferation, differentiation, migration and apoptosis 
(Massague, 2012). In the nervous system, TGF-β signaling regulates neural crest formation 
and in also required for neurogenesis, neurite outgrowth and synaptogenesis (Panchision et 
al., 2001; Bond et al., 2012). Interestingly, Bmp7 regulates the survival and proliferation of 
neural progenitor cells in the developing neocortex of mice and maintains Ngn2 (the murine 
orthologue of NEUROG2) in ventricular and subventricular zones of the cortex (Segklia et 
al., 2012). Notably, both BMP7 (FC, -3.93) and NEUROG2 (FC, -3.10) are robustly 
downregulated in TCF4-depleted cells suggesting that TCF4 may coordinately regulate each 
gene (Figure 4.5A). 
 
4.3.3 TCF4-knockdown affects EMT regulators 
In addition to driving developmental programs, TGF-β signaling is also involved in EMT. 
Process network enrichment identified genes in the EMT pathway to be differentially 
expressed in TCF4-knockdown cells compared to controls (Table 4.3). This pathway governs 
the transition between epithelial and mesenchymal phenotypes known to be important during 
development and in cancer metastasis (Nieto, 2011).  In this process, TGF-β has been shown 
to activate SNAI1 through SMAD3/4 signaling that results in repression of critical epithelial 
cell genes such as CDH1 (E-cadherin) allowing activated cells to switch to the mesenchymal 
phenotype (Massague, 2012). There are a variety of EMT markers that are commonly used to 
detect an induction of the epithelial or mesenchymal phenotype. Epithelial cells can be 
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identified by a variety of cell-cell and cell-basal lamina junction proteins including CDH1 (E-
cadherin), TJP1 (ZO-1), DSP (desmoplakin, desmosomes) or LAMA1 (laminin-1, basal 
lamina). Mesenchymal cells tend to be recognised by markers such as CDH2 (N-cadherin), 
VIM (Vimentin) or FN1 (Fibronectin) (Kalluri and Weinberg, 2009). A selection of these 
markers are shown to be differentially expressed on the array in TCF4-knockdown cells 
including FN1, TJP1, LAMA-1 and CDH2 (Table 4.3 and data not shown).  
 
In addition to components of the TGF-β signaling pathway and cell adhesion markers, 
transcriptional regulators of the EMT pathway SNAI1/2, ZEB2, BHLHB2 (DEC1) and 
TWIST1 were differentially expressed in TCF4-knockdown cells (Figure 4.5A, Figure 4.7, 
and data not shown). SNAI1 and 2 are transcriptional repressors that bind to E-boxes in the 
promoter regions of genes including CDH1 (Cobaleda et al., 2007). ZEB2 is an E-box-
binding homeobox protein that induces EMT by repressing a variety of genes involved in 
epithelial cell–cell junctions. ZEB2 has also been implicated in interneuron subtype 
specification in the developing brain (McKinsey et al., 2013). DEC1 is another transcriptional 
repressor that regulates EMT in pancreatic cancer cells in response to TGF-β stimulation (Wu 
et al., 2012). TWIST1 is repressor of E-protein activity and an important mediator of EMT 
(Spicer et al., 1996; Yang et al., 2004). Together this data establishes that knockdown of 
TCF4 regulates a complex assortment of genes related to EMT, consistent with findings in 
other cell types where E-proteins are shown to have an important role in this pathway (Bolos 
et al., 2003; Moreno-Bueno et al., 2006; Sobrado et al., 2009). 
 
The function of the EMT has been well characterised in embryonic development and cancer 
however its function in neuronal cells is unclear. Mechanistically, aspects of EMT can be 
likened to neural stem and progenitor cell delamination, a critical step in early neurogenesis 
(Pacary et al., 2012). During cortical development, neural stem cells have a distinctive 
polarity and are anchored to the basal membrane of the ventricular zone, forming the 
neuroepithelium. During neurogenesis, neural precusors delaminate from the basal lamina 
and migrate into the cortex to form new neurons in a process similar to EMT. Repression of 
N-cadherin (CDH2), a marker of EMT, promotes this detachment from the neuroepithelium 
and regulates the subsequent migration of neural progenitors (Jossin and Cooper, 2011; 
Rousso et al., 2012). These early steps in neurogenesis are initiated by NEUROG2 that in 
turn activates FOXP2 and FOXP4 to repress N-cadherin expression (Heng et al., 2008; 
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Rousso et al., 2012) and allows cells to adopt a migratory character. Interestingly, 
NEUROG2 (FC -3.10, FDR0.01) and FOXP2 are downregulated (FC -1.2, FDR0.05) in the 
TCF4-knockdown data set, and N-cadherin is upregulated (FC 1.8, FDR0.05), consistent with 
molecular characteristics of cells remaining in the neuroepitheium. This observation suggests 
that if an analogous situation were to occur in neuronal stem cells, TCF4 expression may 
promote delamination and neurogenesis in an EMT-like process. This mechanism has already 
been proposed for snail family members SCRT1 and SCRT2, advocating a role for EMT 
regulators in early neurogenesis and migration (Itoh et al., 2013). 
 
4.3.4 Gene expression changes in the IGF signaling pathway 
In addition to changes in gene expression associated with the TGF-β and NODAL signaling, 
TCF4-knockdown also alters the expression of components of the IGF signaling pathways 
(Table 4.5). TCF4-knockdown is associated with a 5.2 fold down-regulation of IGF2 and up-
regulation of the genes encoding IGF binding proteins, IGFBP3, -4 and -5 (Figure 4.5A and 
Table 4.5). In the brain, IGF2 is required for memory consolidation and enhancement (Chen 
et al., 2011), adult hippocampal neurogenesis (Bracko et al., 2012), synapse formation and 
dendritic spine maturation (Schmeisser et al., 2012). Since IGF2 has a role in learning and 
memory and PTHS patients have profound intellectual disability (Van Balkom et al., 2012), 
TCF4 regulation of IGF2 expression may be a determinant of cognitive dysfunction. IGF1 
treatment has been shown to reverse some of the neurophysiological abnormalities in a 
mouse model of Rett Syndrome lacking methyl CpG-binding protein 2 (Mecp2, (Tropea et 
al., 2009)). Because IGF1 and IGF2 activate the same receptor, IGF2 may have some utility 
in reversing some of the cognitive deficits in PTHS patients. Another component of the IGF 
pathway RPS6KB1 (encoding a member of the ribosomal protein S6 kinase family), is also 
downregulated in TCF4-depleted cells (Table 4.5). RPS6KB1 may be particularly important 
in the context of neurodevelopment because genetic ablation of this gene rescues multiple 
physiological and behavioural phenotypes in a mouse model of fragile X syndrome, caused 
by aberrant synaptic translation (Bhattacharya et al., 2012). 
 
4.3.5 Altered expression of neurodevelopmental genes in TCF4-knockdown cells 
ASCL1 and NEUROG2 are important neurogenic bHLH transcription factors that interact 
directly with TCF4 and appear among the top downregulated genes in TCF-depleted cells 
(Figure 4.5A). Since both of these proneural genes are downregulated, this may indicate that 
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as well as regulating proneural activity through protein:protein interactions, TCF4 may also 
regulate proneural gene expression. In addition to ASCL1 and NEUROG2, other 
neurodevelopmental transcriptional regulators such as, MEF2C (syndromic mental 
retardation) and ZEB2 (MWS) were also differentially expressed in TCF4-depleted cells. 
 
PTHS, MWS and AS are sometimes classified as Rett-like syndromes because of their 
similar clinical presentation and genetics (Armani et al., 2012; Peippo and Ignatius, 2012). 
Furthermore, haploinsufficiency of MEF2C also results in a form of severe mental 
retardation, with absent speech, hypotonia and epilepsy (Le Meur et al., 2010; Zweier and 
Rauch, 2012). Importantly, genes for each of these phenotypically similar disorders (MEF2C, 
ZEB2 and UBE3A) were differentially expressed in TCF4-depleted cells (Table 4.6). From a 
mechanistic perspective it is interesting to note that, TCF4, ZEB2 and MEF2C can all 
regulate E-box activity in the promoters of certain genes (Molkentin and Olson, 1996; 
Remacle et al., 1999). These data, allied with the phenotypic overlap between these disorders, 
suggest that each of these genes may participate in a similar neurodevelopmental 
transcriptional pathway. Thus, alterations in the activity or levels of TCF4 as seen in PTHS, 
and possibly and schizophrenia, may be associated with dysregulation of several transcription 
factors that control neurodevelopmental gene expression programs at E-box containing 
promoters. 
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Chapter 5 
 
Proteomic Analysis of TCF4 Isoforms 
 
 
5.1 Introduction 
The TCF4 locus is particularly complex, encoding multiple transcripts with different 
N-termini and at least two major protein isoforms (Figure 1.2, Figure 5.1, Table 5.1). 
The evidence to support the existence of most protein isoforms is largely based upon 
conceptual translation of different transcripts generated by RT-PCR (Sepp et al., 
2011). The lack of isoform specific antibodies or antibodies with epitopes in specific 
exons has impeded the confirmation of their existence in cells and tissues. 
 
The transcriptional architecture of the TCF4 gene has already been extensively 
characterised in humans (Sepp et al., 2011). Expression of TCF4 is widespread in 
different tissues and is particularly high in the brain where most of the alternatively 
spliced transcripts exist. The vast array of alternatively splice forms in humans 
consequently raises questions about TCF4 protein diversity and function in the brain. 
Originally, two highly related protein isoforms were proposed to exist in cells (TCF4-
B and TCF4-A) although three distinct protein isoforms have been detected in 
Neuro2A cell extracts (Skerjanc et al., 1996; Sepp et al., 2011).  
 
The TCF4-B isoform is considered the full-length canonical protein and contains the 
two conserved activation domains, AD1 and AD2 (Figure 5.1 and Appendix IV). In 
contrast, TCF4-A is a truncated isoform that contains an N-terminus devoid of the 
AD1 and the nuclear localization signal (NLS) (Figure 5.1 and Appendix IV). It is 
widely thought that TCF4 can interact with a number bHLH proteins that regulate its 
DNA binding properties and transcriptional activity (Sections 1.4 and 1.9.1). E-
proteins have also been shown to interact with chromatin modifying proteins through 
the AD1 and AD2 domains (Section 1.5.1). Although the N-terminal AD1 and AD2 
domains are highly conserved among E-proteins, the interactions with chromatin 
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modifiers have only been extensively demonstrated for TCF3 (E2A) and TCF12 
(HEB) and there is a paucity of evidence for these interactions in neuronal cells 
(Bayly et al., 2004; Zhang et al., 2004; Guo et al., 2009; Denis et al., 2012). 
 
 
 
 
Figure 5.1 Structure of the TCF4-B and TCF4-A Isoforms. This illustration 
shows TCF4 isoforms and the organization of their functional domains. TCF4-B 
contains a set of 183 N-terminal amino acids that is specific to long isoforms. TCF4-
A lacks the N-terminal sequences encoding the AD1 domain and NLS but contains a 
unique 5’ exon (blue) that allows it to be distinguished from other short isoforms. For 
clarity, repressor domains were omitted from the illustration. Abbreviations: AD1, 
activation domain 1; AD2, activation domain 2 (putative leucine zipper); NLS, 
nuclear localization signal; RSRS, RSRS amino acid insertion sequence; bHLH, basic 
helix-loop-helix domain. Illustration not to scale. 
 
To gain further insight into the function of TCF4 in SH-SY5Y cells, immunoaffinity 
purification (IAP) and mass spectrometry (MS) were used to isolate and identify 
TCF4 and its associated proteins. To efficiently purify TCF4 from SH-SY5Y cells, 
polyclonal anti-TCF4 antibodies were generated. Immunoaffinity purified TCF4 
isoforms were unequivocally identified by MS. Finally, MS data was used to 
determine TCF4 phosphorylation sites and identify potentially novel interacting 
proteins that co-purified with TCF4. 
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Table 5.1  List of TCF4 isoforms in the NCBI database ordered by predicted 
molecular weight. The NCBI protein database entry for TCF4 is provided along with 
the corresponding names from the Sepp et al. 2012 publication. Schematics of 
transcript structure are depicted in Figure 1.1. Isoforms that contain unique peptide 
sequences are indicated. The presence of unique peptide sequences allows isoforms to 
be unambiguously identified by MS. 
 
TCF4 
Isoform 
NCBI Reference 
Sequence 
Number of 
amino acids 
Predicted 
MW (kDa) 
Sepp et al. 
2012 
Unique 
peptides 
Isoform c NP_001230155   773 83.4 TCF4-J yes 
Isoform e NP_001230157  677 72.4  - yes 
Isoform a NP_001077431  671 71.8 TCF4-B+ no 
Isoform b NP_003190  667 71.3 TCF4-B- no 
Isoform f NP_001230159 664 71.2 TCF4-E yes 
Isoform d NP_001230156 647 69.1 TCF4-C no 
Isoform g NP_001230160    625 67.0 TCF4-F yes 
Isoform h NP_001230161 600 64.6 TCF4-G yes 
Isoform i NP_001230162 537 57.4 TCF4-D no 
Isoform j NP_001230163 511 54.6 TCF4-A+ yes 
Isoform l NP_001230165     507 54.2 TCF4-I yes 
isoform k NP_001230164 507 54.1 TCF4-A- yes 
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5.2 Results 
 
5.2.1 TCF4 antibody design and characterization 
There are three E-protein paralogues in humans each with at least two distinct protein 
isoforms – TCF3 (E2A), TCF4 (E2-2), TCF12 (HEB). In order to generate a specific 
TCF4 antibody, care was taken to find amino acids unique to TCF4.  A multiple 
sequence alignment was used to determine a suitable amino acid sequence that was 
present in all human TCF4 isoforms and that was sufficiently divergent to other E-
proteins. A sequence corresponding to amino acids 361-554 in the full length TCF4-B 
sequence was identified. This 193 amino acid region had approximately 40% 
sequence similarity to TCF3 and 60% sequence similarity to HEB (data not shown). 
The nucleotide sequence corresponding to the selected amino acids (exons 14-18 in 
full length TCF4-B mRNA) was cloned into two different bacterial expression vectors 
in order to generate thioredoxin (TRX-TCF4) and GST (GST-TCF4) fusion proteins. 
Each protein was synthesised in bacterial cells and affinity purified before being 
injected into rabbits. The rabbits were immunised four times over a period of 88 days 
to produce a robust immune response. Following the immunization protocol, serum 
was extracted from the rabbits and the TCF4-specific antibodies were immunoaffinity 
purified using the cognate antigen linked to a column. 
 
The purified TCF4 antibodies isolated from the GST-TCF4 (TCF4_01) and TRX-
TCF4 (TCF4_02) immunizations were subsequently characterised for their ability to 
detect the TCF4 protein. To determine whether the TCF4 polyclonal antibodies could 
detect denatured TCF4 epitopes, the antibodies were tested by western blotting using 
extracts from SH-SY5Y and HEK-293T cells (Figure 5.2). Both antibodies were 
capable of detecting over-expressed TCF4 and endogenous TCF4 isoforms of 
approximately 71kDa and 54kDa (Figure 5.2A, lane 1 and 2). Similar results were 
obtained with both polyclonal antibodies, so only the data for TCF4_01 is presented. 
To ensure the bands detected in the SH-SY5Y cell extract were TCF4-specific, an 
extract from SH-SY5Y knockdown cells (Section 4.2.1) was included on the blot 
(Figure 5.2A, lane 3). Both bands from this extract were depleted confirming that the 
two bands on the blot were TCF4 isoforms. Identical blots were also incubated with 
the commercial anti-TCF4 antibody (Abnova, M03) used in Chapter 4  (Figure 4.1B). 
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This experiment demonstrated that Abnova, M03 only detected full length TCF4 
(71kDa). 
 
Figure 5.2 Characterization of anti-TCF4 polyclonal antibodies 
The TCF4 polyclonal antibody TCF4_01 was used to detect over-expressed or 
endogenous TCF4 in different cells lines (A). HEK-293T cells were transfected with 
1µg of myc-tagged TCF4 constructs and cellular lysates were prepared 24h after 
transfection. SH-SY5Y cells were either left untreated (lane 1) or transfected with 
siRNAs targeted against all TCF4 transcripts before preparing cellular lysates (lanes 1 
and 3 respectively). (B) Two-channel western blotting imaging of SH-SY5Y cellular 
lysates either left untreated (lane 1) or transfected with 1ug of various E47 (TCF3) or 
TCF4 constructs for 24h (lanes 2-5). Western blots were incubated with anti-myc 
(9E10, green channel) and anti-TCF4 polyclonal antibodies (TCF4_01, red channel). 
TCF4 antibodies detect endogenous and overexpressed TCF4 (myc-TCF4, GFP-
TCF4) and do not detect overexpressed E47 (pcDNA-E47, myc-E47). Anti-myc 
antibodies are able to detect the overexpressed myc-E47 and myc-TCF4 proteins. The 
myc-TCF4 construct can be recognised both the anti-myc and anti-TCF4 antibodies 
(yellow).  
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Western blotting was also used to determine whether the anti-TCF4 antibodies cross-
reacted with other E-proteins.  Another western blot was performed with SH-SY5Y 
cell extracts from cells overexpressing TCF4 and the TCF4 paralogue E47 (TCF3). 
The TCF4 antibodies were able to detect over-expressed TCF4 and did not detect the 
E47 protein, even when highly over-expressed (red channel, Figure 5.2B). Anti-myc 
antibodies were used to confirm the expression of each myc-tagged fusion protein in 
transfected cells (green channel, lanes 3 and 4, Figure 5.2B). These experiment 
indicated that the TCF4 polyclonal antibodies specifically detect TCF4 and not E47 
on western blots. 
 
To further validate the antibody, immunocytochemistry was used to detect native 
TCF4 in untransfected SH-SY5Y cells (Figure 4.2). Each TCF4 polyclonal antibody 
confirmed the nuclear localization of the TCF4 that had been established by the over-
expression of TCF4 constructs (Figure 3.2). The nuclear signal was diminished in 
siRNA treated cells demonstrating the specificity of the antibodies in these 
experiments (Figure 4.2). 
 
5.2.2 Immunoprecipitation of TCF4 and characterization of isoforms in SH-
SY5Y cells 
Immunoaffinity purification combined with mass spectrometry (IAP-MS) were used 
to confirm the identity of the two TCF4 isoforms previously detected by western 
blotting (71kDa and 55kDa) in SH-SY5Y cells (Figure 5.2). Initially, small scale 
immunoprecipitations (IPs) were used to enrich each TCF4 isoform. Proteins were 
solubilised from SH-SY5Y cells in RIPA buffer prior to incubation with TCF4_01 
and TCF4_02.  Following overnight incubation with the primary antibody, immune 
complexes were captured on protein A beads.  The beads were washed stringently 
with RIPA buffer to eliminate non-specific binding of proteins to the protein A beads. 
The antibody-TCF4 complexes were denatured in SDS loading buffer and the samples 
were resolved by western blotting (Figure 5.3).  This experiment demonstrated the 
TCF4_01 and TCF4_02 antibodies efficiently immunoprecipitated TCF4 from SH-
SY5Y cells.  The IP protocol efficiently depleted TCF4 from the cellular extracts 
(lanes 4 and 5) and the TCF4-antibody complexes were strongly enriched on the 
protein A beads (lanes 8 and 9) (Figure 5.3). Importantly, TCF4 did not precipitate on 
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the protein A beads or with a non-specific antibody (anti-myc), as no TCF4 protein 
was detected in the control IPs (lanes 6 and 7).   
 
 
 
 
 
 
Figure 5.3 Characterization of TCF4 polyclonal antibodies by 
immunoprecipitation. Western blotting was used to show that the TCF4 polyclonal 
antibodies could immunoprecipitate TCF4 from SH-SY5Y cells. Cellular extracts 
were incubated with TCF4 antibodies (TCF4_01 and TCF4_02) overnight and TCF4-
antibody complexes were subsequently captured on protein A agarose beads. The 
eluted TCF4 complexes were resolved by SDS-PAGE and detected by western 
blotting (IP, lanes 8 and 9). A mock immunoprecipitation (IP) with no antibody (no 
ab) and a negative control IP with an irrelevant antibody (anti-myc) was also 
performed to ensure TCF4 did not precipitate non-specifically (IP, lanes 6 and 7). The 
cellular extracts were also sampled before (Input, lane 1) and after the IPs (post-IP, 
lanes 2-5) to demonstrate the extent of TCF4 depletion in each experiment. Asterisk 
shows the position of the IgG heavy chain. 
 
Having established that both antibodies were suitable for IP, a large-scale IAP 
experiment was performed with cross-linked antibody beads (TCF4_01) to enrich 
sufficient amounts of TCF4 for MS. The immunoprecipitated complexes were 
separated on a 4-12% polyacrylamide gel that was subsequently stained with colloidal 
Coomassie blue (Figure 5.4). Several bands were visible after staining, including 
proteins potentially corresponding to the approximate molecular mass of the two 
TCF4 isoforms previously identified. Seven gel plugs were excised and sent for 
analysis by MS (bands 1-7, Figure 5.4). 
Chapter 5: Proteomic Analysis of TCF4 Isoforms 
	  124 
 
 
 
 
 
Figure 5.4 Immunoaffinity purification of TCF4 for isoform detection by 
mass spectrometry. TCF4 was immunoaffinity purified from SH-SY5Y cell extracts 
using protein A beads cross-linked to TCF4_01. A mock IAP was also performed 
with no antibody. TCF4 was eluted from the beads and resolved on a 4-12% gradient 
gel by SDS-PAGE. Gel slices were excised as indicated on the image (bands 1-7) and 
analysed by mass spectrometry to identify TCF4 isoforms. Approximate molecular 
weight is provided on the image in kilodaltons (kDa). 
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A total of 497 TCF4 peptides were identified by MS. Although TCF4 peptides were 
present in multiple bands, the highest peptide count  was found in band 4 (142 
peptides) spanning 70% of TCF4-B protein (Table 5.2, Figure 5.4). To search for 
specific TCF4 isoforms present in the data, unique peptides were defined from TCF4 
protein sequences in the NCBI database (12 isoforms, Table 5.1).  Eight of the twelve 
TCF4 isoforms in the NCBI database had at least one unique peptide, meaning they 
could be unambiguously identified from the MS data. Unique peptides are mainly 
found in the first 5’ exon of each isoform, such as with TCF4-A (blue exon, Figure 
5.1), therefore there are only a very limited number of unique peptides that can be 
generated. Manual examination of the MS data identified two unique peptides for the 
TCF4-A isoform (NCBI isoform j/k) and one unique peptide for the isoform l (Table 
5.2). Most of the TCF4-A associated peptides were found in bands 5 and 6 of the 
polyacrylamide gel (Figure 5.4). 
 
The MS data also confirmed the presence of long TCF4 isoforms. Peptides derived 
from the N-terminal fragment of TCF4-B (amino acids 1-183) that are absent in the 
TCF4-A isoform were readily detected in the data (Figure 5.1, Table 5.2). The TCF4-
B isoform does not contain a unique 5’ exon therefore it cannot be unambiguously 
distinguished from other long isoforms of similar molecular weight using MS 
(isoforms d-f, Table 5.1). However, the MS data did not contain evidence for the long 
isoforms e and f that do have unique peptide sequences.  
 
In addition to each N-terminal isoform, there was extensive evidence of specific 
peptides relating to the presence (+) and absence (-) of the RSRS amino acid insertion 
sequence (Table 5.2). The RSRS insertion is present in a region of the protein shared 
across all isoforms (coding exon 17 of TCF4-B). Both TCF4-A and TCF4-B have 
previously been reported to contain the + and – RSRS isoforms (Sepp et al., 2011). 
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Table 5.2 Identification of TCF4 and isoform-specific peptides in SH-SY5Y 
cells. Protein complexes obtained from IAP of TCF4 from SH-SY5Y cells were 
analysed by MS to characterise TCF4 isoforms (Figure 5.4, bands 1-7). TCF4 
peptides were identified in all bands (a total of 497 peptides) with the highest 
abundance of TCF4 peptides being identified in band 4 (protein score 1640, 70% 
coverage of full length TCF4-B protein). Non-unique and unique TCF4 peptides are 
presented. Band 4 contained evidence for the TCF4-B isoform, covering the first 183 
amino acids of the TCF4-B sequence that are absent in TCF4-A. However, the TCF4-
B protein sequence does not contain any unique peptides and shares much of its 
sequence with other long isoforms. Unique isoform-specific peptides relating to the + 
and – RSRS isoforms and well as the short isoforms TCF4-A (Isoform j/k) and 
Isoform l were identified in the data. The characteristics and nomenclature of 
particular isoforms is summarised in Table 5.1. 
 
Isoform Peptide sequence Total  # peptides 
Highest peptide 
abundance 
Isoforms without unique peptide sequences  
 
TCF4 
(all isoforms) 
C-terminal peptides (amino acids 184-671) 
 
NGGQASSSPNYEGPLHSLQSR 
GSGAAGSSQTGDALGK 
LDDAIHVLR 
SGTNHYSTSSCTPPANGTDSIMANR 
LLILHQAVAVILSLEQQVR 
ALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSR 
GMPPGLQGQSVSSGSSEIK 
GMPPGLQGQSVSSGSSEIKSDDEGDENLQDTK 
LSYPSHSSADINSSLPPMSTFHR 
GSHSLLPNQVPVPQLPVQSATSPDLNPPQDPYR 
VSSEPPPLSLAGPHPGMGDASNHMGQM 
MVQLHLK 
DINEAFKELGR 
DINEAFK 
HSLMVGTHREDGVALR 
 
497 Band 4 
 
TCF4-B 
(and other long 
isoforms) 
N-terminal peptides (amino acids 1-183) 
 
NGPTSLASGHFTGSNVEDR 
DLGSHDNLSPPFVNSR 
NYGDGTPYDHMTSR 
ESNLQGCHQQSLLGGDMDMGNPGTLSPTKPGSQYYQYSSNNPR 
SSSGSWGNGGHPSPSR 
ELSDLLDFSAMFSPPVSSGK 
KVPPGLPSSVYAPSASTADYNR 
VPPGLPSSVYAPSASTADYNR 
 
Isoforms with unique peptide sequences 
+ RSRS SSNNDDEDLTPEQK 29 Band 6 
– RSRS SITSNNDDEDLTPEQK 51 Bands 4/5 
TCF4-A 
(Isoform j/k) 
MYCAYTIPGMGGNSLMYYYNGK 4 Band 6 
AVYAPSASTADYNR 13 Bands 5/6 
TCF4 
(Isoform l) AEVYAPSASTADYNR 1 Band 5 
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5.2.3 Phosphoproteomic analysis of TCF4 
MS is also able to give precise information about amino acid modifications such as 
phosphorylation and acetylation. Many of these fixed modifications can be inferred 
from peptide mass data derived from the Orbitrap experiments (Taus et al., 2011). For 
example, phosphorylation increases the mass of a peptide by approximately 80Da 
(Larsen et al., 2001). Phosphorylation is a particularly interesting post-translational 
modification to investigate because it is known to modify the DNA binding activity of 
bHLH proteins (Johnson et al., 1996). The TCF4 peptide information was therefore 
filtered to obtain a list of all the phosphorylated peptides. In total, ten phosphoserine 
and three phosphothreonine residues were consistently observed in the data (Table 
5.3).  
 
Table 5.3 TCF4 phosphopeptides identified by mass spectrometry. TCF4 
peptides generated by IAP-MS were filtered to obtain a list of phosphopeptides. The 
phosphorylated residue within each peptide sequence is indicated with a lower case 
letter. The position of the phosphorylated residues was determined relative to full 
length TCF4-B protein sequence (671 amino acids, Figure 5.5).  
 
Peptide sequence TCF4-B residue 
MAALGTDKELSDLLDFSAMFsPPVSSGK S27 
SSSGSWGNGGHPsPSR S66 
DLGSHDNLsPPFVNSR S92 
ESNLQGCHQQSLLGGDMDMGNPGTLsPTKPGSQYYQYSSNNPR S140 
SGTNHYSTsSCTPPANGTDSIMANR S294 
GSGAAGSsQTGDALGK S318 
ALASIYSPDHTNNSFSSNPSTPVGsPPSLSAGTAVWSR S351 
NGGQASSsPNYEGPLHSLQSR S372 
GMPPGLQGQSVSSGSsEIKSDDEGDENLQDTK S511 
GMPPGLQGQSVSSGSSEIKsDDEGDENLQDTK S515 
ESNLQGCHQQSLLGGDMDMGNPGTLSPtKPGSQYYQYSSNNPR T142 
SGTNHYSTSSCtPPANGTDSIMANR T297 
SItSNNDDEDLTPEQK T545 
 
The phosphopeptides were subsequently aligned to the TCF4 protein sequence to 
establish the positioning of the phosphorylated residues in relation to TCF4’s 
functional domains (Figure 5.5). These sites were distributed across the coding 
sequence including three sites within AD1 (S27, S66, S92) and two within AD2 
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(S351, S372) (Figure 5.5, Table 5.3). Interestingly, the amino acid T545 was only 
phosphorylated in the – (minus) isoform that does not contain the RSRS sequence 
immediately adjacent to the bHLH domain. 
 
Having identified a number of potential TCF4 phosphorylation sites in SH-SY5Y 
cells, the full length TCF4 sequence was screened for known kinase phosphorylation 
motifs using PhosphoMotif Finder (Section 2.10.1). This database defines motifs 
based on manual curation of published experimental data and provides a list of 
putative kinases that are capable of phosphorylating a given residue within an amino 
acid motif. The database predicts phosphorylation sites for an array of kinases that 
collectively regulate diverse processes such as growth and differentiation, cell cycle 
regulation, DNA repair and synaptic plasticity (Table 5.4) (Unger et al., 2004; 
Knippschild et al., 2005; O'Driscoll and Jeggo, 2006; Hur and Zhou, 2010; Kim and 
Choi, 2010; Rebola et al., 2010; Lim and Kaldis, 2013).  
 
 
 
 
Figure 5.5 TCF4 phosphorylation sites in SH-SY5Y cells. This illustration 
depicts the location of TCF4 phosphorylation sites identified by MS. Serine (S) and 
threonine (T) phosphorylation sites are presented with their amino acid positions 
relative to the full length TCF4-B+ sequence. The approximate amino acid positions 
of functional domains are indicated as well as the region of the protein shared with 
TCF4-A. The triangle demonstrates the approximate location of the RSRS insertion 
sequence. Asterisk: The T545 phosphorylation site is only present in the  – isoforms 
that lack the RSRS insertion sequence. For clarity, repressor domains were omitted 
from the illustration. Abbreviations: AD1, activation domain 1; AD2, activation 
domain 2; NLS, nuclear localization signal; RSRS, RSRS amino acid insertion 
sequence; bHLH, basic helix-loop-helix domain. Illustration not to scale. 
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Table 5.4 Phosphorylated residues in the TCF4 amino acid sequence and 
their predicted kinases. The location of phosphorylated residues in TCF4 are 
indicated. The numbering of amino acid residues and exons are in relation to the full 
length coding sequence of TCF4-B+ (671 amino acids). The residues were predicted 
to be phosphorylated by specific kinases using PhosphoMotif Finder. The T545 
phosphorylation site was only observed on unique peptides corresponding to TCF4 
isoforms that lack the RSRS insertion. Abbreviations: S, Serine; T, Threonine; AD1, 
activation domain 1; AD2, activation domain 2; GSK3B, glycogen synthase kinase 
3B; ERK1, extracellular-signal-regulated kinase 1; ERK2, extracellular-signal-
regulated kinase 2; MAPKAPK2, mitogen-activated protein kinase-activated protein 
kinase 2; CDK1, cyclin-dependent kinase 1; CDK2, cyclin-dependent kinase 2; 
CDK4, cyclin-dependent kinase 4; CDK5, cyclin-dependent kinase 5; CDK6, cyclin-
dependent kinase 6; PRKDC , DNA-activated protein kinase; CKI, casein kinase I; 
CKI, casein kinase II; GRK1, G protein-coupled receptor kinase 1; ATM, ataxia 
telangiectasia mutated; PKA, cAMP-dependent protein kinase,; PKC , protein kinase 
C. 
 
Phospho Residue Exon Domain Predicted phosphorylating kinase 
S27 2 AD1 GSK3B, ERK1, ERK2, CDK5, MAPKAPK2 
S66 3 AD1 GSK3B, ERK1, ERK2, CDK5, PRKDC, CDK1, CDK2, CDK4, CDK5, CDK6 
S92 4 AD1 GSK3B, ERK1, ERK2, CDK5, CKI 
S140 6 - GSK3B, ERK1, ERK2, CKII, CDK1, CDK2, CDK4, CDK5, CDK6 
T142 6 - PRKDC 
S294 10 - GRK1 
T297 10 - GSK3B, ERK1, ERK2, CDK5 
S318 11 - PRKDC, ATM 
S351 12 AD2 GSK3B, ERK1, ERK2, CDK5, CKI 
S372 13 AD2 GSK3B, ERK1, ERK2, CDK5 
S511 16 - MAPKAPK2 
S515 17 - CKI, CKII 
T545 18 – isoform PKA, PKC 
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5.2.4 Proteomic analysis of TCF4 binding proteins 
In addition to providing important information concerning post-translational 
modification of TCF4, IAP-MS can be used to identify TCF4-associated proteins. E-
proteins regulate cell differentiation through interacting with an assortment of tissue-
specific bHLH transcription factors. Furthermore, the E-proteins have been 
demonstrated to interact with co-activators and co-repressors that bind to their N-
terminal activation domain (Massari et al., 1999; Zhang et al., 2004). These 
interactions have been essential in understanding the function of TCF4 within the cell 
however the repertoire of proteins that specifically interact with TCF4 is sparse.  
 
In order to further characterise the TCF4 interactome, IAP-MS was used to isolate 
and identify proteins that bind to TCF4 in SH-SY5Y cells. In this experiment, TCF4 
complexes were isolated using two different polyclonal antibodies (TCF4_01 and 
TCF4_02) to minimise the discovery of false positive interactions due cross-reactivity 
of the antibodies. In addition, one negative control antibody was used that consisted 
of IgG purified from pre-immunised rabbit serum. Each of the three antibodies was 
cross-linked separately to protein A beads and subsequently incubated with protein 
extracts from SH-SY5Y cells (Section 2.7.1). The beads were stringently washed and 
the captured TCF4 complexes were eluted in SDS-containing buffer. Resolving the 
TCF4-associated protein complexes on a gradient gel confirmed that a range of 
proteins had been immunoprecipitated with each antibody (Figure 5.6). The 
distribution of immunoprecipitated proteins resolved by SDS-PAGE seemed to 
suggest the reactivity profiles of the antibodies were different (Figure 5.6). Multiple 
(equivalent) regions of the gel were excised and processed for MS as described above 
(bands 1-8, Figure 5.6). As an additional negative control, a mock IAP-MS 
experiment was performed with no antibody to try and identify proteins that bind to 
the agarose gel matrix; this is commonly known as the bead proteome. Protein 
complexes in this experiment were eluted in RapiGest reagent and analysed directly 
by MS. This experiment generated a background list of proteins that could be used in 
downstream data processing to filter out non-specific interactions (Table 5.5). 
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Figure 5.6 Co-immunoprecipitation of TCF4 binding proteins for analysis by 
mass spectrometry. Protein A beads were cross-linked with either TCF4 polyclonal 
antibodies (TCF4_01, TCF4_02) or pre-immune IgG (IgG) and used to co-
immunoprecipitate TCF4 complexes from SH-SY5Y cell extracts. TCF4 complexes 
were eluted from the beads and resolved on a 4-12% gradient gel by sodium dodecyl 
sulfate polyacrylamide gel electrophoresis (SDS-PAGE). Gel slices were excised as 
indicated on the image (IgG; bands A1-A8, TCF4_01; bands B1-B8, TCF4_02; bands 
C1-C8) and analysed by mass spectrometry to detect potential TCF4-interacting 
proteins. Approximate molecular weight is provided on the image in kilodaltons 
(kDa). 
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Table 5.5 SH-SY5Y agarose bead proteome. This is a list of proteins that bind 
non-specifically to protein A agarose beads and represent a common source of false-
positive interactions in IAP-MS experiments. The protein names are presented with 
their individual protein scores generated by the Mascot software package. The 
number of peptides identified by MS for each protein is presented with the % amino 
acid coverage this represents compared to the full length protein sequence (# peptides, 
% coverage). 
 
♯ Gene 
Protein 
score % coverage # peptides 
1 KRT10 747.3 41.27 20 
2 KRT1 497.01 26.55 15 
3 MB21D2 326.57 23.93 13 
4 KRT2 301.86 26.13 16 
5 HSPA9 221.42 15.19 8 
6 KRT14 167.07 10.81 5 
7 KRT5 150.18 14.31 8 
8 KRT9 123.27 16.45 6 
9 HIST1H2AJ 122.66 28.91 3 
10 ACTG1 113.76 18.32 5 
11 HSPA8 110.96 16.59 7 
12 DPYSL2 70.2 7.32 4 
13 PCMT1 69.22 18.52 3 
14 ALB 65.32 9.83 4 
15 RBM39 63.45 2.97 1 
16 CDC23 57.1 7.1 4 
17 H3F3A 56.25 17.65 3 
18 H3F3B 56.25 17.65 3 
19 H3F3AP4 56.25 17.65 3 
20 H3F3AP6 56.25 17.65 3 
21 HSPA5 56.07 10.02 6 
22 DUT 52.45 5.67 1 
23 PZP 52.29 3.94 1 
24 C4A 51.17 12.55 4 
25 GRN 48.87 3.2 1 
26 HIST1H1D 44.8 17.19 4 
27 ANAPC7 36.83 4.39 2 
28 RPL35 34.93 8.13 1 
29 RPL35P1 34.93 8.13 1 
30 RPL35P2 34.93 8.13 1 
31 SNRPD1 32.55 16.81 1 
32 DDX3X 32.14 5.64 2 
33 ITPR1 31.92 0.96 3 
 
Chapter 5: Proteomic Analysis of TCF4 Isoforms 
	  133 
The IAP-MS experiments with the TCF4_01 and TCF4_02 antibodies resulted in a 
robust enrichment of TCF4 peptides, covering approximately 37% of the full length 
TCF4-B sequence in both cases (Table 5.6). The majority of the TCF4 peptides 
analysed by MS were found in bands 3 and 4 for both antibodies (Figure 5.6). 
Interestingly, two proteins with the highest peptide scores in the TCF4_01 IAP 
(YLPM1 and LUZP1, band 1) were absent in the TCF4_02 IAP, indicating these were 
probably cross-reactive proteins. The combined peptide data from all of the excised 
bands was searched and filtered to generate a list of putative TCF4-interacting 
proteins as outlined in Figure 5.7. Initially, proteins that were present in both 
TCF4_01 and TCF4_02 IAPs were exclusively selected to redress the possibility that 
each TCF4 antibody may have cross-reactive proteins. A threshold protein score of 20 
was initially applied to the MS data to remove the lowest confidence proteins from 
the list. Proteins that had immunoprecipitated non-specifically with the pre-immune 
IgG IAP were subsequently removed. In the final step, proteins in the bead proteome 
were removed from the analysis (Table 5.5). The filtering process generated a list of 
72 TCF4-associated proteins that spanned an array of biological functions.  
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Figure 5.7 Flowchart of the quality control process used to establish potential 
TCF4-interacting proteins. The schematic illustrates the data processing steps used 
to generate the list of TCF4-associated interactions presented in Table 5.6. Bands 
excised from the polyacrylamide gel in Figure 5.6 were analysed by mass 
spectrometry (MS) and the data was processed in five steps. 1. Proteins cross-reacting 
with either antibody were avoided by generating a list of co-immunoprecipitated 
proteins that appeared in both TCF4_01 and TCF4_02 IAP experiments. 2. Low 
confidence protein predictions from MS data were eliminated by applying a threshold 
protein score of 20. 3. Proteins that bound non-specifically to pre-immune IgG 
antibodies in the negative control IAP experiment were removed. 4. Proteins that 
precipitated non-specifically onto the agarose bead matrix were removed (Table 5.5). 
The filtering process created a list of 72 TCF4-associated proteins (Table 5.6). 5. 
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Potential TCF4-interacting proteins were annotated in three ways (Section 5.2.5). i) 
Proteins with high confidence protein prediction scores (score >100) in both IAPs 
were highlighted. ii) E-protein interaction datasets from the Human Protein Research 
Database (HPRD) and Biological General Repository for Interaction Datasets 
(BioGRID) public databases were searched to identify published E-protein 
interactions. iii) Top biological processes were identified using DAVID v6.7 
(BP_FAT) (Table 5.7). 
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Table 5.6 TCF4-associated proteins determined by mass spectrometry. The 
proteins in this list were identified in IAP-MS experiments using the TCF4_01 and 
TCF4_02 antibodies. Probable false-positive interactions were removed using the 
filtering process outlined in Figure 5.7. The protein score (prot. score), percentage 
amino acid coverage (% coverage) and number of peptides (# peptides ) associated to 
each co-precipitated protein is displayed in the table for each antibody. The proteins 
are ranked in descending order according to the score generated from the TCF4_02 
IAP. Proteins that have a score >100 for both IAPs are highlighted in orange. These 
form the list of high confidence interactors. Known E-protein interactions for either 
TCF3 (E47) or TCF12 (HEB) are marked in bold. Official HUGO gene names of 
proteins have been used. The indicated protein prediction scores were generated by 
the Mascot software (Section 2.7.4). 
 
# Gene TCF4_01 Prot. score 
TCF4_01 
% coverage 
TCF4_01 
# peptides 
TCF4_02 
Prot. score 
TCF4_02 
% coverage 
TCF4_02 
# peptides 
1 TCF4 224.65 37.85 21 292.88 36.66 21 
2 HIST2H2AC 160.81 58.14 5 177.09 58.14 5 
3 GPHN 30.38 7.23 4 172.64 30.84 17 
4 DOCK7 35.78 3.57 6 144.6 13.95 27 
5 NCOR1 136.98 9.06 17 139.56 13.44 27 
6 DHX9 98.51 15.2 15 131.97 13.94 16 
7 TBL1XR1 103.82 27.63 11 128.71 32.68 11 
8 PABPC1 108.92 32.46 12 127.51 21.24 7 
9 PKM 228.38 34.17 11 119.63 28.57 9 
10 OSBPL8 66.06 17 11 109.74 27.56 20 
11 TUBB2C 172.39 32.95 11 101.55 27 9 
12 HDAC3 39.74 12.4 4 99.39 17.25 5 
13 SLC25A13 146.47 16.74 9 93.37 12 7 
14 FASN 86.29 5.97 11 92.88 4.9 11 
15 H2AFX 36.13 16.78 2 79.6 47.55 4 
16 ILF2 129.84 39.2 9 77.39 20.17 5 
17 FAM98B 26.68 7.33 1 77.31 8.94 2 
18 SSBP1 55.98 34.09 3 77.06 37.88 4 
19 KIAA1429 58.2 2.96 4 76.31 6.81 10 
20 USP7 59.64 8.56 8 69.28 8.29 8 
21 PRPF8 101.98 5.13 13 69.24 4.01 10 
22 NUP205 61.36 2.63 5 64.62 1.64 3 
23 ARHGEF2 160.8 19.1 15 62.5 19.42 17 
24 TWIST2 31.59 13.13 2 61.7 13.13 2 
25 PTCD3 31.18 3.48 2 60.28 17.79 3 
26 SYNCRIP 84.81 23.02 9 59.87 11.03 4 
27 LGALS1 111.07 60 6 59.82 40.3 4 
28 SNRPD3 32.33 15.83 2 59.67 33.33 3 
29 NAGK 89.22 21.8 7 58.38 23.84 6 
30 BUB3 50.68 23.15 7 56.69 16.05 5 
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31 TMEM33 58.93 4.86 1 56.6 4.86 1 
32 HNRNPD 77.2 22.33 4 52.22 10.23 2 
33 FARSA 62.46 5.24 2 52.2 5.24 2 
34 TJP1 52.91 4.38 6 50.59 8.45 13 
35 SNRPD2P1 59.81 29.66 4 48.67 46.61 6 
36 TIFA 56.31 29.89 2 47.96 45.98 3 
37 PRDX2 33.98 21.31 5 46.71 31.15 6 
38 PSMD11 49.59 10.19 4 45.66 11.15 3 
39 CRMP1 341.56 30.74 13 45.26 8.91 4 
40 SSBP2 50.41 10.42 1 45.26 10.42 1 
41 MTPN 39.95 14.41 1 44.72 14.41 1 
42 RTL1 97.53 5.89 8 44.65 4.49 6 
43 TCF3 33.32 8.33 1 44.54 8.33 1 
44 NPM1P42 35.73 10.57 3 42.11 31.32 5 
45 SESTD1 30.47 4.24 1 41.98 7.61 5 
46 EIF4A1 57.94 10.04 2 41.75 10.04 2 
47 DHX15 54.4 5.41 2 41.74 7.27 1 
48 TRA2B 47.03 21.38 6 41.51 25 4 
49 HADHB 59.17 8.85 3 40.99 5.31 2 
50 PPP2R1A 72.4 15.81 7 40.25 5.17 1 
51 HAND2 55.86 25.37 3 39.19 8.96 1 
52 SRSF7 35.44 13.86 1 39.19 20.79 2 
53 SEC23B 28.95 5.26 3 37.89 5.93 3 
54 PPP2R4 23.59 5.83 2 37.84 10.25 2 
55 DDX1 42.93 10.13 5 35.98 8.36 4 
56 CENPV 66.61 13.55 2 35.18 4.8 1 
57 EXOSC9 40.42 5.92 2 34.17 2.82 1 
58 FLOT1 39.4 4.35 1 34.09 4.64 1 
59 CCT4 75.44 11.59 4 33.43 5.4 2 
60 RPL23 52.38 20.9 2 31.8 39.55 4 
61 MCCC2 69.64 12.08 6 30.37 3.01 1 
62 CHTF8 32.38 5.73 3 28.89 5.73 3 
63 MYEF2 72.18 6.22 3 27.44 4.45 1 
64 DCAF7 109.93 21.64 6 27.32 10.23 3 
65 CAD 92.89 3.21 6 26.02 1.08 2 
66 MCM7 322.11 42.56 24 25.92 5.56 3 
67 PSMD14 56.05 6.45 2 25.64 14.84 3 
68 MCM4 541.51 44.59 32 25.33 2.92 2 
69 KPRP 32.88 6.22 4 25.25 1.73 1 
70 ARID1A 236.86 14.22 27 24.93 2.55 4 
71 PCMTD2 59.92 10.53 4 24.84 9.57 3 
72 BLVRA 37.3 6.16 2 22.66 3.42 1 
73 POLDIP2 20.77 12.63 3 37.1 10.29 1 
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5.2.5  Functional annotation of TCF4-associated proteins 
To establish whether any of the TCF4-associated proteins identified by IAP-MS were 
known to interact with E-proteins, the list from Table 5.6 was compared to a 
combined set of E-protein (TCF4, TCF3, TCF12) interactions obtained from the 
Human Protein Reference Database (HPRD), and the Biological General Repository 
for Interaction Datasets (BioGRID) database. This analysis revealed that several of 
the proteins identified by IAP-MS were reported to interact with TCF3 (E47). The 
TCF3-interacting proteins in the list included the bHLH proteins TCF3 (self 
association), HAND2 and TWIST2, the DNA binding protein SSBP1, the splicing 
factor PRPF8 and the co-repressor NCOR1 (El Ghouzzi et al., 2000; Murakami et al., 
2004; Murayama et al., 2004; Teachenor et al., 2012). In addition, HAND2 was 
already reported to interact with TCF4 (Jogi et al., 2002; Murakami et al., 2004). Each 
of these proteins is highlighted in bold in Table 5.6. 
 
TCF4-associated proteins identified by IAP-MS were functionally annotated using 
biological process annotations in DAVID v 6.7 (Section 2.10.1). Three distinct 
biological processes were identified from these annotations; RNA splicing, chromatin 
modification and the cell cycle (Table 5.7). 
 
Table 5.7 Biological process annotations for TCF4-associated proteins 
identified by mass spectrometry. The top biological process annotations related to 
proteins identified Table 5.6. Biological process annotations (BP_FAT) were 
determined in DAVID. The percentage of genes in each annotation is relative to the 
total number of genes in Table 5.6 (72 genes). 
 
Function % Genes 
RNA splicing 18 DDX1, DHX9, DHX15, HNRNPD, PPP2R1A, SRSF7, TRA2B, SNRPD3, SYNCRIP, PRPF8, KIAA1429, SNRPD2P1, PABPC1 
Cell cycle 17 CHTF8, H2AFX, ARHGEF2, CENPV, HDAC3, MCM4, MCM7, NCOR1, NPM1P42, PSMD11, PSMD14, TCF3 
Chromatin 
organization 11 
H2AFX, ARID1A, HIST2H2AC, HDAC3, NCOR1, TBL1XR1, 
CENPV, NPM1P42 
 
Among the RNA splicing proteins are two members of the spliceosome; the catalytic 
RNA-protein complex responsible for pre-mRNA splicing. DEAH (Asp-Glu-Ala-His) 
box polypeptide 15 (DHX15) is an RNA helicase-like protein and is involved in 
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spliceosome disassembly (Arenas and Abelson, 1997). The pre-mRNA processing 
factor 8 homolog (PRPF8) is a protein in the catalytic core of the spliceosome that 
participates in assembling the catalytic RNAs for splicing events (Galej et al., 2013). 
Interestingly, PRPF8 was also co-immunoprecipitated with E47 (TCF3) in a similar 
IAP-MS experiment performed in HEK cells (Teachenor et al., 2012).  
 
The chromatin organization annotation contains histones (H2AFX, HIST2H2AC) and 
chromatin modifiers such as AT-rich interactive domain-containing protein 1A 
(ARID1A), histone deacetylase 3 (HDAC3), nuclear receptor co-repressor 1 
(NCOR1) and transducin beta-like 1 X-linked receptor 1 (TBL1XR1). ARID1A forms 
an essential part of the SWI/SNF (SWItch/Sucrose NonFermentable) chromatin-
remodeling complex; an ATP-dependent nuclear protein complex that rearranges 
nucleosomes to modulate transcription. Remarkably, NCOR1, HDAC3 and 
TBL1XR1 were all co-purified and together form the nuclear co-repressor complex, 
functioning with transducin beta-like 1 (TBL1) to repress gene expression (Yoon et 
al., 2003). NCOR1 and TBL1XR1 are two of the few co-precipitated proteins with 
high scores in both IAP experiments. NCOR1 can interact with the TCF3 (E47), 
providing more support for this repressor as a novel TCF4-interacting protein 
(Murayama et al., 2004). Taken together my data suggests that NCOR1 and 
TBL1XR1 are promising TCF4-interacting proteins to investigate. The peptide data 
for these proteins is provided in Table 5.8. 
 
The cell cycle category overlaps with the chromatin organization category for certain 
terms such as the centromeric protein V (CENPV), as it forms a structural part of the 
kinetochore and aids chromosomal alignment during mitosis (Tadeu et al., 2008). 
Unique terms in the cell cycle category include two members of the minichromosome 
maintenance complex (MCM4 and MCM7) responsible for orchestrating the precise 
replication of DNA and two regulatory subunits of the 26S non-ATPase proteasome 
(PSMD11, PSMD14) that both play a key role in maintaining the high proteosomal 
activity required for stem cell pluripotency (Blow and Dutta, 2005; Buckley et al., 
2012; Vilchez et al., 2012). 
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Table 5.8 Mass spectrometry data for the TCF4-associated proteins NCOR1 
and TBL1XR1. The table shows the peptide sequences of NCoR complex members 
NCOR1 and TBL1XR1 derived from bands 1 and 4 in Figure 5.6. High confidence 
peptides are presented for each IAP together with the protein scores and % coverage 
values generated from the MS data. 
 
Protein  Peptide sequences  Parameters 
NCOR1 
 
2440 amino acids 
270kDa 
ALDPAAAAYLFQR 
SIVQIIYDENR 
SPGSISYLPSFFTK 
NFGLIASYLER 
TTITAANFIDVIITR 
GTAGAIQEGSITR 
YNTAADALAALVDAAASAPQmDVSK 
ADSVDVEVR 
GHSFADPASNLGLEDIIR 
QDSLLLLSQR 
ISVESIPSLR 
GMPPLEIVPENIK 
TCF4_01 IAP 
Protein score: 136.98 
Coverage: 9.06% 
Source: band 1B 
NFGLIASYLER 
GTAGAIQEGSITR 
TVLSGSIMQGTPR 
ALDPAAAAYLFQR 
SAAVSEQQQLEQK 
ESPVSAPLEGLIcR 
AQLSPGIYDDTSAR 
SIVQIIYDENR 
ADSVDVEVR 
QEQIDLECR 
EELIQSMDR 
TCF4_02 IAP 
Protein score: 139.56 
Coverage: 13.44% 
Source: band 1C 
TBL1XR1 
 
514 amino acids  
55.5 kDa 
IWNLSENSTSGSTQLVLR 
LAQQQAAAAAAAAAAASQQGSAK 
GTGGIFEVcWNAAGDK 
DKLAQQQAAAAAAAAAAASQQGSAK 
GNFILSAGVDK 
VGASASDGSVcVLDLR 
TCF4_01 IAP 
Protein score: 103.82 
Coverage: 27.63% 
Source: band 4B 
IWNLSENSTSGSTQLVLR 
GNFILSAGVDK 
VGASASDGSVcVLDLR 
LAQQQAAAAAAAAAAASQQGSAK 
GTGGIFEVcWNAAGDK 
SISSDEVNFLVYR 
WDPTGNLLAScSDDmTLK 
TCF4_02 IAP 
Protein score: 128.71 
Coverage: 32.68% 
Source: band 4C 
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5.3 Discussion 
 
Multiple alternatively spliced TCF4 transcripts have been described in humans 
however our understanding of the proteins they encode is very limited. In addition, 
the absence of specific TCF4 antibodies has constrained the study of TCF4 in human 
cells and tissues. To further characterise the TCF4 protein, polyclonal antibodies were 
generated to study TCF4 at the proteomic level. TCF4 antibodies were designed to 
target a shared epitope present in all known TCF4 isoforms that were subsequently 
characterised to validate their efficacy. The antibodies were used in IAP-MS 
experiments that identified distinct TCF4 isoforms in SH-SY5Y cells. The peptide 
data generated by IAP-MS was used to determine TCF4 phosphorylation sites and 
potentially novel TCF4-interacting proteins that are involved in chromatin 
modification, splicing and cell cycle regulation.  
 
5.3.1 TCF4 polyclonal antibodies detect short and long TCF4 isoforms in SH-
SY5Y cells and can be used in multiple applications 
TCF4 polyclonal antibodies were initially designed in order to immunoprecipitate 
endogenous TCF4 from SH-SY5Y cells. However, to ensure the quality of the 
antibodies, the antibodies were subjected to rigorous quality control experiments to 
assess their specificity and efficacy in different experiments. TCF4_01and TCF4_02 
were able to detect natively folded and denatured protein in various experimental 
contexts. The first set of experiments, using western blots, demonstrated the presence 
of two distinct TCF4 protein isoforms in SH-SY5Y cells that were highly reduced 
after TCF4 knockdown (Figure 5.2A). E-proteins (TCF4, TCF3 and TCF12) share a 
high degree of sequence similarity that contributes to the difficulty in studying each 
protein individually. Importantly, these antibodies did not cross-react with over-
expressed TCF3 on western blots illustrating the sequence-specificity of TCF4 
antibodies when detecting denatured TCF4 epitopes (Figure 5.2B). The utility of these 
antibodies for detecting native epitopes was also demonstrated in the 
immunocytochemistry experiments presented in Chapter 4 (Figure 4.2). Finally the 
antibodies proved to be efficacious in immunoprecipitation experiments. Both 
TCF4_01 and TCF4_02 antibodies were capable of depleting TCF4 from cellular 
extracts of SH-SY5Y, enabling TCF4 to be immunoaffinity purified for downstream 
MS (Figure 5.3) 
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5.3.2 Specific TCF4 isoforms are detected in SH-SY5Y cells 
To precisely identify the TCF4 isoforms in SH-SY5Y cells, the TCF4 protein was 
immunoaffinity purified and analyzed by MS. Peptides generated from this analysis 
revealed a strong enrichment of TCF4, identifying a total of 497 TCF4 peptides 
across the 7 bands that were sent for MS. The band with the highest enrichment of 
TCF4 was band 4 (Figure 5.4, 80kDa), with peptides covering approximately 70% 
full length TCF4-B amino acid sequence. The peptides in this data set were examined 
for the presence of isoform-specific amino acid sequences. The diversity of TCF4 
isoforms was investigated by exploring the peptide data for unique isoform-specific 
sequences.  
 
Unique peptides corresponding to TCF4-A (NCBI isoform j/k) were readily identified 
(Table 5.2). In addition, a single peptide for isoform l was identified among the 497 
TCF4 peptides generated by the IAP-MS experiment (Table 5.2). The peptide data 
suggested that although isoform l and TCF4-A are present in SH-SY5Y cells, TCF4-
A seemed to be the predominant short isoform. TCF4-A and TCF4 isoform l are both 
shorter TCF4 isoforms lacking the N-terminal sequences containing the AD1 domain 
and the NLS and have approximate molecular weight of 54kDa. Numerous peptides 
corresponding to TCF4-B (approximately 71kDa) were also identified (Figure 5.2). 
Form these experiments it can be concluded that SH-SY5Y cells synthesise both 
TCF4-A and TCF4-B isoforms.  
 
Additionally, TCF4 peptides were explored for the presence of the RSRS insertion 
sequence. This four amino acid insertion is located in the core region shared by all 
TCF4 isoforms, positioned N-terminal to bHLH domain. Although very little is 
known about the function of this insertion sequence, it has been proposed to affect the 
DNA binding properties of the bHLH domain, allowing TCF4 to bind imperfect E-
boxes (Liu et al., 1998). The peptide data contained evidence that certain isoforms 
contained the insertion whilst others did not. Both + and - isoforms were relatively 
abundant in SH-SY5Y cells as determined from the unique peptide counts relating to 
each isoform (Table 5.2). Analysis of TCF4 mRNA has previously shown that both of 
these isoforms are abundant in human tissues (Sepp et al., 2011). Interestingly, the - 
isoform was accompanied by a potential PKA/PKC phosphorylation site (T545) 
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located one amino acid proximally to the RSRS insertion site. This site was not 
apparently phosphorylated in the + isoform, indicating that it may be isoform-
specific. 
 
5.3.3 TCF4 phosphorylation 
MS data also provides potentially important information about post-translational 
modifications in proteins. Accordingly, the peptide data was searched for TCF4 
phosphopeptides (Table 5.3). My data suggest that many of the N-terminal serines in 
the vicinity of AD1 (S27, S66, S92, S140) and those surrounding AD2 (S351, S372) 
can be phosphorylated by large range of potential kinases including glycogen 
synthase kinase 3 (GSK3B), members of the mitogen-activated protein kinase 
signaling pathway (ERK1, ERK2, MAPKAPK2) and several of the cyclin-dependent 
kinases (CDK1, CDK2, CDK4, CDK5, CDK6). GSK3B is an important regulator of 
neural development and is required for coordinated neurogenesis, neuronal 
polarization and axon growth (Hur and Zhou, 2010). MAPK signaling can be 
activated by a variety of signals including growth factor stimulation and is essential 
for controlling proliferation, survival, and differentiation (Kim and Choi, 2010). 
Cyclin-dependent kinases work in concert with cyclins and cyclin-dependent kinase 
inhibitors (CDKIs) to harmonise progression through the cell cycle. Emerging 
evidence also suggests CDKs may have neuronal-specific functions such as neuronal 
migration, axon guidance, and synaptic transmission (Lim and Kaldis, 2013).  
 
In addition, some of the phosphorylated residues seem to be near more distinctive 
motifs with perhaps more specialised functions. S318 is a motif recognised and 
phosphorylated by the catalytic subunit of the DNA-dependent protein kinase 
(PRKDC) and ataxia telangiectasia mutated (ATM) that both have roles in double-
strand break repair, an essential process for DNA damage response and normal 
development (O'Driscoll and Jeggo, 2006). Interestingly, T545, specific to the - 
isoform, is potentially a target for cAMP-dependent protein kinase alpha (PKA) and 
the calcium-sensitive protein kinase C (PKC). Both of PKA and PKC have been 
shown to regulate signaling events during long-term potentiation (LTP) and long-term 
depression (LTD), two key mechanism underlying synaptic plasticity (Rebola et al., 
2010). Although empirical validation will be required to support these in silico 
Chapter 5: Proteomic Analysis of TCF4 Isoforms 
	  144 
predictions, this analysis may be useful to create hypotheses about upstream 
regulators of TCF4 function in neuronal cells. 
 
5.3.4 Co-immunopecipitation of bHLH proteins 
Three bHLH proteins were identified in the IAP-MS experiments providing support 
for the validity the data. The E-protein TCF3 (E47) has high degree of sequence 
similarity to TCF4 raising the possibility that it may be able to form heterodimers 
with TCF4. This interaction has also been proposed from a large-scale yeast two-
hybrid screen of transcription factors (Ravasi et al., 2010). HAND2 (dHAND) and 
TWIST2 (Dermo-1) are two related bHLH proteins that have both been shown to 
interact with E-proteins. HAND2 can specifically interact with TCF4 in mammalian 
two-hybrid assays and in GST pull down experiments whilst TCF3 interacts with 
TWIST2 in yeast two-hybrid screens (Li et al., 1995; Dai and Cserjesi, 2002; Jogi et 
al., 2002; Murakami et al., 2004). TWIST2 is regulator of epithelial-to-mesenchymal 
transition and causes Setleis syndrome, a rare inherited form of ectodermal dysplasia 
(Tukel et al., 2010; Fang et al., 2011). HAND2 is involved in terminal differential 
sympathetic neurons but its interaction with TWIST1 contributes to pathogenic 
mechanisms in Saethre–Chotzen syndrome, another developmental disorder 
associated with craniosynostosis, craniofacial and limb dysplasias (Howard et al., 
1997; Firulli et al., 2005). 
 
5.3.5 Co-immunoprecipitation suggests a role for TCF4 in chromatin 
organization, splicing and cell cycle regulation 
The repertoire of previously validated TCF4 interactions is essentially limited to a 
range of bHLH transcription factors that modulate TCF4 function (Sections 1.5 and 
1.7.2). In an attempt to identify new protein interactions and further characterise the 
function of TCF4 in neuronal cells, IAP-MS experiments were used to identify 
proteins that co-immunoprecipitated with TCF4 in SH-SY5Y cells (Figure 5.7). 
Despite the filtering process, the interactions identified remain putative until they 
have been validated using independent methods (Table 5.6). Nevertheless, several 
potential interactions that were discovered in these experiments merit further 
attention.  
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A subset of the co-immunoprecipitated proteins had a functional role in chromatin 
organization; a core cellular process required for dynamic control of transcription, cell 
division and development. This category included chromatin modifiers such as 
ARID1A and members of the NCoR complex. Chromatin modifiers are crucial during 
neural development as they can activate or repress gene expression by rearranging 
chromatin structure (Hirabayashi and Gotoh, 2010). The importance of this role has 
been highlighted in human sequencing studies that have associated several 
neurological and psychiatric diseases to chromatin regulators (Ronan et al., 2013).  
 
ARID1A is part of the SWI/SNF family of chromatin remodelers that causes Coffin-
Sirius syndrome (Tsurusaki et al., 2012). Interestingly, multiple members of the 
SWI/SNF remodeling complex were co-immunoprecipitated individually by the 
TCF4_01 (SMARCA4, SMARCB1, SMARCC1, SMARCD1, SMARCD2, 
SMARCD3) and TCF4_02 (SMARCC2) antibodies, although none of these subunits 
were found in both IAP experiments (data not shown). bHLH proteins may require 
interactions with members of the SWI/SNF remodeling complex to activate gene 
expression programs. The proneural bHLH proteins NEUROG1 and NEUROD1 are 
strong inducers of the neuronal fate however they fail to promote neuronal 
differentiation when the function of SWI/SNF remodeling complex protein 
SMARCA4 (Brg1) is abolished (Seo et al., 2005). Another bHLH protein Olig2, 
required of oligodendrocyte differentiation, has been shown to recruit SMARCA4 at 
distinct sets of myelin regulatory genes to drive fate specification in oligodendrocyte 
precursors. Accordingly, TCF4 may also function in combination with chromatin 
remodeling complexes to regulate its coordinated transcriptional program. 
 
NCOR1 is another chromatin modifier that co-immunoprecipitated with TCF4 in the 
IAP-MS experiments. NCOR1 participates in transcriptional repression, an important 
mechanism in diverse biological functions. The NCOR1 protein can be recruited by 
many classes of transcription factors including bHLH proteins and is often associated 
with large protein complexes (Jepsen and Rosenfeld, 2002). The majority of the 
transcriptional repression mediated by NCoR (nuclear co-repressor) complexes is 
conferred through histone deacetylase activity such as that of HDAC3, a co-
precipitated protein in this experiment (Wen et al., 2000). The NCoR complex can 
exist in several forms although some of the core interactions include NCOR1, TBL1, 
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TBL1XR1 and HDAC3 acting together to enforce transcriptional repression (Yoon et 
al., 2003). Strikingly, NCOR1, TBL1XR1 and HDAC3 were all co-
immunoprecipitated with TCF4 in these experiments (Table 5.6, Table 5.8). NCOR1 
provides a functional scaffold for recruitment of the complex and acts as a co-factor 
promoting histone deactylase activity (Guenther et al., 2001). NCOR1 and TBLXLR1 
were two of the more prominent proteins identified by the proteomic experiments as a 
high score was associated to each of the TCF4 IAP experiments (Table 5.6, Table 
5.8). In addition to TBL1, TBL1XR1 and HDAC3, some of the characterised NCoR 
complexes contain multiple components of the mammalian SWI/SNF complex 
(SMARCC1, SMARCC2, SMARCA4) (Underhill et al., 2000).  
 
NCOR1 is an interesting and plausible candidate TCF4-interacting protein because it 
is already implicated in bHLH transcription factor function. The NCOR1 protein can 
associate with the E-protein TCF3 as part of a vitamin D-dependent nuclear receptor 
co-repressor complex in kidney cells (Murayama et al., 2004). The presence of the 
vitamin D ligand causes the dissociation of the p300 co-activator from TCF3, and the 
association of a co-repressor complex including HDAC2 and NCOR1. Co-factor 
switching may be a crucial element controlling of E-protein activity in neuronal cells.  
 
TCF4-associated proteins in the IAP-MS experiments also suggest a role for TCF4 in 
the cell cycle. Here, a selection of proteins with multiple functions was identified that 
can each contribute to aspects cell cycle regulation (Table 5.7). Control of the cell 
cycle has a direct effect on the balance between proliferation and neurogenesis in the 
brain (Ohnuma and Harris, 2003). Interestingly, the NCOR1/TBL1/HDAC3 complex 
may also have a role independent of transcriptional regulation but directly related to 
the cell cycle (Ishii et al., 2008). Co-localization experiments have demonstrated that 
the NCoR complex localises to the mitotic spindle during mitosis. Follow up 
experiments illustrated the necessity of the complex for cytokinesis, as the mitotic 
spindle collapsed upon knockdown of either NCOR1 or HDAC3. The centromeric 
protein CENPV is also associated to the kinetochore during spindle formation and is 
co-immunoprecipitated in the proteomic experiments suggesting that TCF4 may also 
play a structural role during cell division (Tadeu et al., 2008). 
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Finally, RNA splicing is another core biological process that may involve TCF4 
through associations with different proteins. Recent evidence suggests that splicing 
occurs co-transcriptionally in the nucleus and therefore the splicing machinery is in 
close association with chromatin (Brown et al., 2012). It may therefore be possible 
that TCF4 interacts with certain splicing factors although this has never been 
demonstrated for E-proteins. The lack of evidence for bHLH factors being involved in 
splicing demands caution in the interpretation of these data. Nevertheless, the TCF4 
homologue TCF3 was also associated with splicing factor PRPF8 in IAP-MS 
experiment carried out in HEK293T cells (Teachenor et al., 2012).  
 
In summary, the proteomic analysis of TCF4 has provided valuable information to 
understand the context in which this transcription factor may operate. The expression 
of long and short isoforms in SH-SY5Y cells suggests that both proteins may be 
important mediators of TCF4 function in neurons. The identification of TCF4 
phosphorylation sites will be useful in predicting upstream modulators of TCF4 
function and their related signaling pathways. Furthermore, the interaction data 
generated by IAP-MS positions TCF4 in a potential biological framework intersecting 
with transcriptional regulation, RNA splicing and cell cycle regulation. However, the 
proteomic data is preliminary and further work will be required to confirm the validity 
and context of these interactions. 
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Chapter 6 
 
TCF4 Isoform-Specific Gene Expression Profiling 
 
 
6.1 Introduction 
TCF4-A and TCF4-B are the two main protein isoforms that are encoded by the TCF4 
gene.  Most of the current knowledge concerning the functions of these isoforms is 
based on transient transfection experiments in mammalian cells. Initial experiments 
were aimed at determining the transcriptional activity of these isoforms on specific 
promoters. TCF4-B and TCF4-A isoforms were initially reported to have different 
transcriptional activities on specific promoters in vitro (Skerjanc et al., 1996; 
Petropoulos and Skerjanc, 2000). In these studies, TCF4-B was described as a 
transcriptional inhibitor whilst the shorter isoforms TCF4-A was found to be a mild 
transcriptional activator. The difference in isoform-specific activities is likely to be 
mediated by differences in their domains architecture (Figure 6.1).  
 
However, it has also been demonstrated that TCF4-B can activate transcription in 
certain cell lines and on specific promoter constructs (Pscherer et al., 1996; Chen and 
Lim, 1997; de Pontual et al., 2009; Forrest et al., 2012). The function of TCF4-B is 
therefore highly context dependent as described in chapter 3. The reason for this 
dichotomy may reside in its interaction with transcriptional regulators through AD1 
and AD2 (Section 1.4). The spatio-temporal availability of co-factors during 
development may be crucial for determining TCF4’s transcription program. 
 
Interestingly, although TCF4-B and TCF4-A are reported to have different 
transcriptional activities, their physiological effects on myogenesis and EMT are 
reported to be similar (Petropoulos and Skerjanc, 2000; Sobrado et al., 2009). 
Transfection of MyoD with either TCF4-B or TCF4-A converts fibroblasts to 
myoblasts with the same apparent efficiency (Petropoulos and Skerjanc, 2000). 
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Similarly, TCF4-B and TCF4-A isoforms induce full EMT in epithelial MDCK cells 
stably over-expressing either isoform (Sobrado et al., 2009). 
 
To date, the isoform-specific effects on transcription in neuronal cells remain 
uncharacterised. Having established that SH-SY5Y cells express long and short TCF4 
isoforms, RNAi was used to knockdown the TCF4-B and TCF4-A isoforms 
individually in order to identify isoform-specific gene expression programs. Using the 
experimental design outlined in the Chapter 4, selected gene expression changes 
relating to each isoform were validated by qPCR and the effects of each isoform on 
the cellular transcriptome were determined using gene enrichment analysis. 
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6.2 Results 
 
6.2.1 Knockdown of TCF4 isoforms for microarray analysis 
To design isoform specific siRNAs, careful inspection of the unique nucleotide 
sequence between the long and short isoforms of TCF4 was required. TCF4-B has an 
additional 183 amino acids in its N-terminus compared to TCF4-A (Figure 6.1). The 
nucleotide sequence encoding this region was used to design two siRNAs that would 
specifically target TCF4-B (KDB1 and KDB2) (Figure 6.1). TCF4-A shares 488 of its 
511 amino acids with TCF4-B, however it contains a unique 5’ coding exon that is 
only found in this isoform (Figure 6.1). Consequently, this unique sequence was used 
to design two non-overlapping TCF4-A specific siRNAs (KDA1 and KDA2) (Figure 
6.1). Due to the limited length of the unique sequence in TCF4-A, the siRNA 
sequences tended to have lower predicted targeting efficacies compared to the TCF4-
B siRNA sequences (data not shown). Each of the four duplexes was transfected 
separately in SH-SY5Y cells over a period of 48h alongside the same anti-GAPDH 
siRNA used in Chapter 4 (KDGAP) and a mock transfection control (mock). Five 
technical replicates of each condition were prepared; four were used for RNA 
extraction while protein was prepared from the fifth.
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Figure 6.1 TCF4 isoforms and siRNA recognition sites. This illustration shows 
the transcript structure for the TCF4-B and TCF4-A isoforms. The approximate 
location of the recognition sequences for each of the four siRNA duplexes is indicated 
(red bars, KDB1; TCF4-B exon 1, KDB2; TCF4-B exon 2-3, KDA1; TCF4-A exon 1, 
KDA2; TCF4-A exon 1). Importantly, The KDA1 and KDA2 sequences do not 
overlap. The location of primers used for mRNA quantification of TCF4-B transcripts 
(exon 4), TCF4-A transcripts (unique exon 1a) and total TCF4 transcripts (shared 
exon 13) are indicated (black bars). The coding exons are numbered separately for 
each isoform (TCF4-B; 1-18, TCF4-A; 1-12). The 11 C-terminal coding exons are 
identical in the two isoforms (light grey, TCF4-B; 8-18, TCF4-A; 2-12). Note that 
TCF4-A contains a unique 5’ exon (exon 1a, blue). Illustration not to scale. 
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The efficacy of each knockdown was evaluated using qPCR and semi-quantitative 
western blotting (Figure 6.2). The western blot demonstrated the isoform-specific 
siRNAs successfully knocked down the long and short TCF4 isoforms, validating the 
siRNA design (Figure 6.2A). Importantly, mock and KDGAP treatments did not have 
any appreciable effect on TCF4 protein levels. The knockdown efficacy for both 
siRNAs directed against the TCF4-B (72kDa) was similar, reducing the TCF4 
isoform to approximately 30% of mock transfections (Figure 6.2B, left). However, the 
knockdown efficiency for each siRNA designed against TCF4-A was not the same; 
KDA1 reduced TCF4-A abundance to approximately 30% of mock whilst KDA2 
reduced abundance to only 50% (Figure 6.2B, middle). Total TCF4 protein levels 
were also measured and ranged from approximately 50% (KDB2) to approximately 
75% (KDA2) of mock (Figure 6.2B, right). KDA1 and KDB1 had an intermediate 
amount of total TCF4 protein, at approximately 65% of mock. The qPCR experiments 
closely reflected the knockdown efficiencies observed at the protein level (Figure 
6.2C). Interestingly, both the mRNA and protein quantification detected a small 
isoform-specific compensatory mechanism; knockdown of the short isoform seemed 
to slightly increase the abundance of the long isoform (Figure 6.2B and C). In 
contrast, knockdown of the long isoform appeared to moderately decrease short 
isoform abundance (Figure 6.2B and C). 
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Figure 6.2 siRNA-mediated knockdown of TCF4 isoforms in SH-SY5Y cells. 
SH-SY5Y cells were transfected with siRNA oligonucleotides targeting TCF4-B 
(KDB1 and KDB2), TCF4-A (KDA1 and KDA2) or GAPDH (KDGAP). After 48h, 
RNA and protein were extracted to assess the knockdown efficiency. (A) Western 
blots of protein lysates prepared from siRNA-treated SH-SY5Y cells demonstrated 
that TCF4 could be knocked down in an isoform-specific manner. α-tubulin was used 
as a loading control and for normalisation. (B) LI-COR quantitation of TCF4 protein 
levels in siRNA-treated cells. The levels of TCF4-B (71kDa), TCF4-A (54kDa) and 
total TCF4 (TCF4-A and TCF4-B) in each experiment were quantified and 
normalised to α-tubulin. (C) Primers complimentary to specific coding exons in 
TCF4-B (TCF4-B, exon 4), TCF4-A (TCF4-A, exon 1a) and a constitutive exon 
present in all TCF4 isoforms (exon 13) were used to measure transcript abundance by 
qPCR in four biological replicates of each group (primer binding sites are shown in 
Figure 6.1). 
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6.2.2 Microarray quality control and data processing 
To examine the genome wide expression changes in an isoform-specific manner, the 
RNA samples described above were also used for microarray analysis, as a 
reproducible knockdown had been measured for each isoform. RNA quality was 
assessed with an Agilent Bioanalyzer and was considered of high quality for all 
samples (RIN 8.5-10) except one sample that was of lower quality (KDB2 replicate 1, 
RIN 5.2). The RNA from each condition was converted to cDNA, fragmented, 
amplified and labeled by CBS for hybridisation to Affymetrix Human Gene 2.0 ST 
arrays (Section 2.9.10). During this procedure, one of the KDGAP replicates failed 
quality control and had to be removed from the downstream analysis, reducing the 
number of replicates for this group to 3. The rest of microarray data was received in 
the form of .CEL files that were imported into Partek genomics suite 6.6 and RMA 
normalised. Principal component analysis (PCA) was subsequently performed using 
Partek to assess the treatment effects (Figure 6.3.1). Mapping of the three principal 
components of the microarray experiment explained approximately 39% of the data 
and showed successful grouping of the replicates in each of the six treatment groups 
(Figure 6.3.1). The long isoform knockdown groups (KDB1, dark blue; KDB2, light 
blue) and one of the short isoform (KDA2, light green) treatment groups had the least 
amount of variability as determined by the close clustering of individual replicates 
(Figure 6.3.1). The remaining groups were more variable but most still clustered 
distinctly in the three-dimensional space of the PCA. The KDGAP group contained 
one sample that appeared to be an outlier as it was neighbouring two replicates of the 
KDB1 group and did not cluster closely to the other KDGAP replicates. However, 
performing the downstream analysis with and without the sample did not have a 
substantial effect on the results and consequently the sample was included in the 
reported data (data not shown). 
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Figure 6.3.1  Principle component analysis of the isoform-specific microarray. 
The genome-wide expression data from each sample is reduced to three principle 
components that capture 39.3% of the variation in the data. The principle components 
(PC) are plotted against 3 axes: PC1; X-axis, PC2; Y-axis, PC3; Z-axis. The 
percentage variance captured by each PC is displayed next to each axis label (PC1; 
18.9%, PC2; 12.4%, PC3; 8%).  For clarity, the treatment groups have been colour-
coded (see key to the left of the graph). 
 
According to the PCA, the second siRNA targeting the short TCF4-A isoform 
(KDA2) clustered very near the mock treated samples indicating that this knockdown 
may not have caused many gene expression changes. Accordingly, these samples also 
had the highest load TCF4 protein (75% remaining) and exhibited the weakest 
isoform-specific knockdown, with an approximately 50% reduction in the short 
isoform compared to mock (Figure 6.2). The KDA2 samples were subsequently 
excluded from the downstream analysis due to lack of significant gene expression 
changes and concordance with KDA1 (see below). This observation could be a 
testament to the importance of dosage in TCF4 function. The poor knockdown with 
KDA2 duplex is likely to reflect technical limitations in the design of RNAi duplexes 
targeting very short sequences. Finally, the KDB2 sample of lower quality identified 
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by the Agilent Bioanalyzer (RIN 5.2) clustered similarly to the other samples of the 
group and was therefore incorporated into the ensuing analysis.  
 
 
Figure 6.3.2. Comparison of differentially expressed transcripts in TCF4-
knockdown treatment groups. The microarray data was used to generate a list of 
differentially expressed transcripts from each TCF4 knockdown treatment group. 
Each list was generated by performing a one-way ANOVA between the TCF4 
knockdown group (KDB1, KDB2, KDA1 or KDA2) and the mock treated group. 
Individual lists were compared to determine the number of shared gene expression 
changes. The number of differentially expressed transcripts associated to each 
treatment and each overlap is indicated. Blue circles are used for long isoform 
knockdown experiments (KDB1, KDB2), green circles are used for short isoform 
knockdown experiments (KDA1, KDA2). The size of each circle is representative of 
the number of gene expression changes but is not to scale. 
 
After PCA analysis, the transcriptional profiles of different TCF4 knockdown groups 
were compared to assess the degree similarity between them (Figure 6.3.2). As 
described in Chapter 4 (section 4.2.2), a one-way ANOVA was performed between 
individual TCF4 knockdown treatment groups (KDB1, KDB2, KDA1 and KDA2) 
and the mock treated group, generating four lists differentially expressed transcripts 
(corrected with an FDR of 0.01). The overlap between the two TCF4-B-specific 
groups (KDB1 and KDB2) was 70%, indicating a strong concordance in the effect of 
each treatment on differentially expressed genes (Figure 6.3.2 A). In comparison, the 
overlap between KDB1 and each of the TCF4-A-specific groups (KDA1 and KDA2) 
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were 60% and 47% respectively (Figure 6.3.2 B and C). The considerable overlap in 
gene expression changes between TCF4-B and TCF4-A specific groups (e.g. KDB1 
and KDA1) suggests long and short isoforms may have shared effects on gene 
expression. However, some of the shared transcriptional changes may be non-specific 
in nature, caused by cells reacting to the presence of siRNA in the media and the 
activation of the gene silencing machinery. This analysis also underscored the lack of 
gene expression changes generated by the KDA2 treatment (403 differentially 
expressed transcripts) and the small overlap between the short isoform knockdown 
treatments (191 differentially expressed transcripts) (Figure 6.3.2 D). 
 
To identify isoform-associated gene expression changes in the microarray data, a one-
way ANOVA was implemented between the control and isoform-specific samples as 
described previous in Chapter 4. For example, to detect gene expression changes due 
to knockdown of TCF4-B transcripts, an ANOVA between the control group (4 mock 
samples and 3 KDGAP samples) and the long-isoform specific group (4 KDB1 
samples and 4 KDB2 samples) was performed. To generate a high confidence list of 
gene expression changes a FDR correction of 0.01 was applied. The hierarchical 
clustering of the genes generated from the pooled KDB1 and KDB2 ANOVA 
(FDR0.01) generated a significant amount of shared gene expression changes (457) 
that clustered according to their treatment groups (Figure 6.4) 
 
The TCF4-A associated ANOVA performed in this manner only generated limited 
amount of differentially expressed genes (14 genes, FDR 0.01) that were not 
sufficient for an informative enrichment analysis (Appendix V). Consequently, the 
less effective TCF4-A knockdown samples (KDA2) were removed from the 
downstream analysis and the following sections describes gene expression changes 
resulting from the KDA1 treatment (4 samples) alone. Hierarchical clustering of the 
top gene expression generated from the KDA1 ANOVA (1627, FDR0.01) showed 
appropriate clustering between control and treatment groups (Figure 6.4). 
Differentially expressed genes identified in this analysis were not represented in the 
KDA2 samples, as these appeared to be most similar to control groups (Appendix V). 
The hierarchical clustering of control and isoform-specific knockdown groups 
validated the use of the ANOVA for detecting gene expression changes associated to 
depletion of each isoform.
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Figure 6.4 Hierarchical clustering of the top differentially expressed genes. 
The top differentially expressed genes (FDR 0.01) from each isoform specific 
ANOVA were subjected to hierarchical clustering. Each sample is demonstrated to 
cluster by treatment group as evident from the dendrogram to left of the heatmap. In 
addition, the control treatments (mock and KDGAP) and specific isoform knock 
down treatment (KDB1 and KDB1 or KDA1) are shown to cluster into defined 
groups. The top section of the heat map displays differential expression relative to 
controls: up-regulated genes are shown in red while down-regulated genes are 
coloured blue. 
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6.2.3 TCF4 isoform-associated genes expression changes 
The gene expression changes obtained from the ANOVA described in the previous 
section established a list of high confidence transcriptional changes related to the 
TCF4-A and TCF4-B isoforms. The 40 top largest gene expression changes 
associated with each knockdown were apparently different and also diverged 
considerably from the top 40 gene expression changes identified from the global 
TCF4 knockdown described in Chapter 4 (Figure 4.6, Figure 6.5 and Figure 6.6). 
Nevertheless, downregulated genes such as dermatopontin (DPT), dachshund 
homolog 1 (DACH1), neurogenin 2 (NEUROG2), calsyntenin 2 (CLSTN2) and the 
upregulated gene, insulin-like growth factor binding protein 5 (IGFBP5) had amongst 
the highest fold changes in both global and isoform-specific TCF4 knockdown 
experiments (Figure 4.5, Figure 6.5 and Figure 6.6). This convergence may indicate 
that these genes are particularly important mediators of TCF4 function.  
 
To experimentally validate the gene expression changes detected on the microarray, 
genes across discrete functional categories and with the fold change above or below 
1.5 were selected for analysis by qPCR (Figure 6.7). SNAI1, NEUROG2, RCOR2, 
TLE1 and SKP2 were selected from the list of genes differentially expressed in the 
TCF4-B knockdown experiments (genes are denoted with a superscript B in Figure 
6.7). In the TCF4-A knockdown group, SNAI2, SEMA3A, RELN and DPT were 
chosen for qPCR validation (genes are denoted with a superscript A in Figure 6.7). 
The expression of each gene was measured across all the treatment groups used on the 
microarrays (except KDA2) in order to assess the isoform specific effects. For each 
gene detected in the TCF4-B associated ANOVA (KDB), the qPCR data validated the 
microarray analysis showing significant differential expression between the control 
group and the KDB samples (Figure 6.7, superscript B). In the TCF4-A related 
ANOVA (KDA1), all the selected genes were validated by qPCR except for 
SEMA3A. However, a trend of downregulation was visible for SEMA3A (Figure 6.7, 
superscript A). It is also apparent from the qPCR data that knockdown of each 
isoform can have shared (Figure 6.7, A) and differential (Figure 6.7, B and C) effects 
on gene expression. Within the genes that display isoform-specific effects, RCOR2, 
DPT, SEMA3A and RELN were significantly different between the TCF4-B and 
TCF4-A isoform knockdowns (Figure 6.7, B and C). 
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Figure 6.5  Gene expression changes in TCF4-B depleted cells. The top 40 
upregulated (upper panel) and downregulated (lower panel) genes in TCF4-B 
knockdown cells after FDR correction (0.01) ranked by fold change. The y-axis 
represents fold up-regulation (upper panel) and fold down-regulation (lower panel). 
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Figure 6.6 Gene expression changes in TCF4-A depleted cells. The top 40 
upregulated (upper panel) and downregulated (lower panel) genes in TCF4-A 
knockdown cells after FDR correction (0.01) ranked by fold change. The y-axis 
represents fold up-regulation (upper panel) and fold down-regulation (lower panel). 
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Figure 6.7 qPCR validation of differentially expressed genes. Nine 
differentially expressed genes belonging to various functional categories were chosen 
for qPCR validation. The genes identified as differentially expressed in the TCF4-B 
associated ANOVA are denoted with a superscript “B”. Similarly, genes identified as 
differentially expressed in the TCF4-A associated ANOVA are denoted with a 
superscript “A”. NEUROG2 was identified in both analyses and is denoted with “A” 
and “B”.  The expression of each gene was measured across all groups regardless of 
its significance in each ANOVA. (A) Genes similarly affected by TCF4-B and TCF4-
A knockdown, (B) Genes more susceptible to TCF4-B knockdown (C) Genes more 
susceptible to TCF4-A knockdown. A Student’s t-test was performed for each TCF4-
associated knockdown category (KDB or KDA1) in comparison to controls (KDGAP 
and mock). In addition, a Student’s t-test was also performed between the KDB and 
KDA1 knockdown groups to identify transcripts differentially expressed between 
each treatment group. Significant results are presented: *, P < 0.05; **, P < 0.01; ***, 
P < 0.001 
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6.2.4 TCF4 isoforms regulate distinct biological processes 
The list of differentially expressed genes in the TCF4-A and TCF4-B knockdowm 
grpups were subsequently converted to Entrez IDs and interrogated for process 
network enrichment in Metacore. The TCF4-A list was associated with 1319 unique 
Entrez IDs (FDR 0.01, 489 upregulated, 830 downregulated) whilst the TCF4-B list 
was associated with 386 unique Entrez IDs (FDR 0.01, 99 upregulated, 287 
downregulated). To avoid a bias in the enrichment, each analysis was performed 
against a background list that contained all Affymetrix probes with Entrez IDs 
(23,816 unique IDs). This analysis generated distinct results for TCF4-A and TCF4-
B, suggesting that each isoform may regulates different transcriptional programs in 
SH-SY5Y cells (Table 6.5 and Table 6.6, all differentially expressed genes). 
Specifically, knockdown of TCF4-B was associated with gene expression changes in 
processes associated to the cell cycle, DNA damage regulation and chromatin 
modification. By contrast, knockdown of TCF4-A resulted in differential expression 
of genes involved in cell adhesion, extracellular matrix interactions and cytoskeletal 
rearrangements. For each isoform the gene expression changes were significantly 
associated to several process network annotations that were distinct but functionally 
interconnected. The results of the enrichment analysis demonstrate a high degree of 
functional specificity for each isoform at the genome-wide level in SH-SY5Y cells. 
 
The genes in each list were also examined for network processes restricted to up- and 
downregulated genes. Each list was deconstructed into the upregulated and 
downregulated components and re-analysed using the same parameters as above. 
Remarkably, all of the enrichment categories associated  with each isoform-specific 
knockdown were only found in the downregulated genes. Accordingly no enrichment 
of any category was obtained from the upregulated genes (Table 6.5 and Table 6.6, 
downregulated genes and data not shown). In general, categories identified in the 
analysis of downregulated genes had more significant P-values, indicating a stronger 
enrichment of specific processes in downregulated genes compared to all the 
differentially expressed genes (Table 6.5 and Table 6.6 downregulated genes). This 
observation may suggest that TCF4 is predominantly a transcriptional activator in 
these cells, as gene expression changes are positively correlated to the abundance of 
TCF4. 
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Table 6.5  Enrichment analysis of differentially expressed genes after TCF4-
B knockdown. The Entrez gene IDs derived from all the differentially expressed 
genes (386 genes, upper table) or just the downregulated genes (287 genes, lower 
table) in TCF4-B knockdown cells were analysed for enrichment using MetaCore. 
Each term is presented with its functional category, process network and 
corresponding FDR-corrected P-value (FDR). Categories highlighted in yellow pass 
multiple test correction (FDR 0.05). 
 
All differentially expressed genes 
Category Process network FDR Genes 
Cell cycle S phase 5.89E-03 
RFC5, TOP3A, POLD3, HIST1H1T, CDC6, 
CCNB1, CCNB2, HIST1H4D, PTTG1, CHAF1A, 
PRIM1, E2F1, CDC45 
Cell cycle Core 2.32E-02 CDC25A, CDC18L (CDC6), CAP-G, Cyclin B1, BUB3, CCNB2, BIRC5, Securin, E2F1, CDC45L 
DNA damage Checkpoint 2.73E-02 RFC5, RAD17, CDC25A, Histone H2AX, Cyclin B2, MAP2K6, RAD1, Securin, c-Myc, E2F1 
Transcription Chromatin modification 3.96E-02 
H2AFZ, H2AFX, SMARCB1, HIST1H4D, 
RBBP4, TAF6L, HDAC5, Histone H3.3, SUDS3, 
HDAC2 
Development Hedgehog signaling 2.27E-01 
MMP-9, SNAIL1, Cyclin B1, SREBP1 precursor, 
SKP2, BMPR1B, DLX5, ID3, NAB2, DYRK2, 
ZIC1, c-Myc, ZNF143 
Development 
Regulation of 
angiogenesis 2.55E-01 
SREBP2 (nuclear), MMP-9, PAI1, SREBP1 
precursor, DBH, N-cadherin, SREBP1 (nuclear), 
SREBP2 precursor, Secretogranin II, c-Myc, 
Ephrin-B2 
Cell cycle G0-G1 3.59E-01 CDC25A, RBBP8 (CtIP), RBBP4 (RbAp48), E2F1, HDAC2 
Cell cycle G2-M 3.59E-01 
E2N(UBC13), Histone H1 testis, CDC25A, CAP-
G, Cyclin B1, BUB3, SKP2, Cyclin B2, Securin, c-
Myc 
Signal 
Transduction 
BMP/GDF signaling 4.14E-01 TLE1, BMPR1B, MEK6(MAP2K6), ActRIIB, c-Myc, ALK-1 
DNA damage Core 4.14E-01 RAD17, Histone H2AX, RAD1 	  
Downregulated genes 
Category Process network FDR Genes 
Cell cycle S phase 2.86E-04 
RFC5, TOP3A, POLD reg (p68), Histone H1 
testis, CDC18L (CDC6), Cyclin B1, Cyclin B2, 
Histone H4, Securin, ChAF1 subunit A, PRIM1, 
E2F1, CDC45L 
Cell cycle Core 2.21E-03 
CDC25A, CDC18L (CDC6), CAP-G, Cyclin B1, 
BUB3, Cyclin B2, Survivin, Securin, E2F1, 
CDC45L 
DNA damage Checkpoint 2.72E-03 
RFC5, RAD17, CDC25A, Histone H2AX, Cyclin 
B2, MEK6(MAP2K6), RAD1, Securin, c-Myc, 
E2F1 
Transcription Chromatin modification 4.15E-03 
H2AFZ, H2AFX, BAF47, Histone H4, RBBP4 
(RbAp48), PAF65A, HDAC5, Histone H3.3, 
SDS3, HDAC2 
Cell cycle G2-M 8.33E-02 
E2N(UBC13), Histone H1 testis, CDC25A, CAP-
G, Cyclin B1, BUB3, SKP2, Cyclin B2, Securin, 
c-Myc 
Cell cycle G0-G1 1.26E-01 CDC25A, RBBP8 (CtIP), RBBP4 (RbAp48), E2F1, HDAC2 
Development Hedgehog signaling 1.26E-01 
SNAIL1, Cyclin B1, SREBP1 precursor, SKP2, 
BMPR1B, DLX5, ID3, DYRK2, ZIC1, c-Myc, 
ZNF143 
DNA damage DBS repair 1.97E-01 E2N(UBC13), HMG2, Histone H2AX, Histone H4, RBBP4 (RbAp48), ChAF1 subunit A 
DNA damage Core 2.12E-01 RAD17, Histone H2AX, RAD1 
Transcription mRNA processing 2.12E-01 CPSF6, SFRS4, SAD1 (USP39), hnRNP A1, U2AF35, hnRNP K, snRNP-G, U1-70K 
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Table 6.6 Enrichment analysis of differentially expressed genes after TCF4-
A knockdown. The Entrez gene IDs derived from all the differentially expressed 
genes (1319 genes, this page) or just the downregulated genes (830 genes, next page) 
in TCF4-A knockdown cells were analysed for enrichment using MetaCore. Each 
term is presented with its functional category, process network and corresponding 
FDR-corrected P-value (FDR). Categories highlighted in yellow pass multiple test 
correction (FDR 0.05). Abbreviations: ECM, extracellular matrix. 	  
All differentially expressed genes 
Category Process FDR Genes 
Cell adhesion Cell-matrix interactions 3.95E-05 
Biglycan, Fibrillin 1, Vitronectin, Nidogen-2, ECM1, LAMG1, 
ADAM23, ITGA6, ADAM-TS3, Fibulin-1, ADAM-TS9, 
CD44 (ICD), Endostatin, TIMP3, ADAM9, ITGAV, Tenascin-
R, Aggrecanase-1, COL5A1, ITGA4, ADAM12, CD44, 
MAGP1, Tenascin-C, LAMA5, Nidogen, ITGB3, Layilin, 
MMP-24, EGFR, CD44 soluble, TIMP1, Connexin 43, CD44 
(EXT), Collagen III 
Cell adhesion 
Integrin-
mediated cell-
matrix adhesion 
4.05E-03 
TGM2, CD151, RhoA, Fibrillin 1, Vitronectin, Profilin II, 
Tensin 3, CRK, ITGA6, Filamin A, Actin cytoplasmic 2, 
ITGAV, CD9, ITGA4, Tubulin alpha 1A, RhoGDI gamma, 
Tenascin-C, RhoB, LAMA5, Migfilin, ITGB3, Filamin B 
(TABP), NAG-2, ILK, Paxillin, Filamin C, Tetraspanin-8, 
Collagen III 
Cytoskeleton 
Regulation of 
cytoskeleton 
rearrangement 
3.93E-02 
Ankyrin 1, Ankyrin-G, RhoA, Socius, G-protein alpha-i1, 
RhoGAP6, LyGDI, SVIL, Profilin II, CRK, PDZ-RhoGEF, 
Filamin A, SPA1, G-protein alpha-s, mDIA2(DIAPH3), 
Tubulin alpha 1A, CD44, Vimentin, Filamin B (TABP), PLK1, 
Destrin, Paxillin, Filamin C, ELMO1 
Cell adhesion 
Platelet-
endothelium-
leucocyte 
interactions 
3.93E-02 
HGF, DDR1, TGF-beta 2, Vitronectin, TGF-beta 1, Protein C 
inhibitor, Tetraspanin-2, CD9, Thrombospondin 4, ITGA4, 
CD44, TGF-beta 3, Protein S, LDLR, TGF-beta receptor type 
II, EGFR, Endoplasmin, ZO-1, PDGF-D, Semaphorin 4D, ILK, 
Thrombospondin 3, Collagen III, Thrombospondin 2 
Proteolysis 
Connective 
tissue 
degradation 
5.41E-02 
Prolylcarboxypeptidase, Cystatin C, MTCBP-1, Vitronectin, 
Protein C inhibitor, ADAM23, ADAM-TS3, ADAM-TS9, 
TIMP3, ADAM9, Aggrecanase-1, ADAM12, SERPINB6, 
Tenascin-C, Nidogen, MMP-24, ADAM19, TIMP1, Collagen 
III 
Proteolysis ECM remodeling 5.41E-02 
Cystatin C, MTCBP-1, Vitronectin, Protein C inhibitor, 
ADAM-TS3, Endostatin, TIMP3, Aggrecanase-1, SERPINB6, 
Tenascin-C, Nidogen, MMP-24, TIMP1, Clusterin, Collagen 
III 
Immune 
response 
Phagosome in 
antigen 
presentation 
6.840E-02 
Cathepsin L, RhoA, HLADPA1, Pyk2(FAK2), PSMD3, 
Vitronectin, Profilin II, PSMF1, CRK, PSMD14, GRP78, iC3b, 
Actin cytoplasmic 2, CD74, TRAM1, C3dg, JMJD6, 
ENDO180, CD63, C3, Endoplasmin, ERp72, PSMD13, PLC-
beta1, Paxillin, ELMO1 
Cytoskeleton Actin filaments 8.05E-02 
MYH9, Ankyrin 1, Ankyrin-G, Twinfilin, RhoA, SVIL, 
Profilin II, CRK, ABLIM1, Filamin A, mDIA2(DIAPH3), 
Piccolo, CD44, WASF3 (WAVE3), DAAM1, MYLK1, 
Migfilin, Filamin B (TABP), Destrin, Utrophin, Paxillin, 
Filamin C 
Cell adhesion Cadherins 1.37E-01 
CD151, RhoA, PTP-2, PTPRF (LAR), Cadherin 24, PTPR-mu, 
SSX2IP, IQGAP1, CLR3, Actin cytoplasmic 2, PEZ, FHL2, 
Protocadherin 15, RET, Cadherin 23, DKK2, EGFR, Reelin, 
ZO-1, ILK, WNT6 
Development 
Neurogenesis 
Axonal 
guidance 
1.76E-01 
Semaphorin 3C, MYH9, NEK1, RhoA, Semaphorin 5A, Plexin 
A1, AHNAK, ADAM23, Plexin D1, IQGAP1, ABLIM1, PDZ-
RhoGEF, DCAMKL1, Ephrin-A1, SPOCK2, G-protein alpha-
s, Tenascin-R, MICAL, cAMP-GEFII, Semaphorin 3A, 
Ryanodine receptor 2, Reelin, Semaphorin 4D, Neuropilin-1, 
Semaphorin 3D 	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Downregulated genes 
Category Process FDR Genes 
Cell adhesion Cell-matrix interactions 5.80E-09 
Biglycan, Fibrillin 1, Vitronectin, Nidogen-2, ECM1, 
LAMG1, ADAM23, ITGA6, ADAM-TS3, Fibulin-1, ADAM-
TS9, CD44 (ICD), Endostatin, TIMP3, ADAM9, ITGAV, 
Aggrecanase-1, COL5A1, ITGA4, ADAM12, CD44, MAGP1, 
Tenascin-C, LAMA5, Nidogen, ITGB3, Layilin, MMP-24, 
EGFR, CD44 soluble, TIMP1, Connexin 43, CD44 (EXT), 
Collagen III 
Cell adhesion 
Integrin-
mediated cell-
matrix adhesion 
1.75E-06 
TGM2, CD151, RhoA, Fibrillin 1, Vitronectin, Profilin II, 
Tensin 3, CRK, ITGA6, Filamin A, Actin cytoplasmic 2, 
ITGAV, CD9, ITGA4, Tubulin alpha 1A, RhoGDI gamma, 
Tenascin-C, RhoB, LAMA5, Migfilin, ITGB3, Filamin B 
(TABP), NAG-2, ILK, Paxillin, Filamin C, Tetraspanin-8, 
Collagen III 
Proteolysis 
Connective 
tissue 
degradation 
2.15E-03 
Prolylcarboxypeptidase, MTCBP-1, Vitronectin, Protein C 
inhibitor, ADAM23, ADAM-TS3, ADAM-TS9, TIMP3, 
ADAM9, Aggrecanase-1, ADAM12, SERPINB6, Tenascin-C, 
Nidogen, MMP-24, ADAM19, TIMP1, Collagen III 
Cell adhesion 
Platelet-
endothelium-
leucocyte 
interactions 
2.75E-03 
HGF, DDR1, TGF-beta 2, Vitronectin, TGF-beta 1, Protein C 
inhibitor, Tetraspanin-2, CD9, ITGA4, CD44, TGF-beta 3, 
Protein S, LDLR, TGF-beta receptor type II, EGFR, 
Endoplasmin, PDGF-D, ILK, Thrombospondin 3, Collagen 
III, Thrombospondin 2 
Proteolysis ECM remodeling 3.80E-03 
MTCBP-1, Vitronectin, Protein C inhibitor, ADAM-TS3, 
Endostatin, TIMP3, Aggrecanase-1, SERPINB6, Tenascin-C, 
Nidogen, MMP-24, TIMP1, Clusterin, Collagen III 
Cytoskeleton Actin filaments 2.82E-02 
MYH9, Ankyrin-G, Twinfilin, RhoA, Profilin II, CRK, 
ABLIM1, Filamin A, mDIA2(DIAPH3), CD44, WASF3 
(WAVE3), DAAM1, MYLK1, Migfilin, Filamin B (TABP), 
Destrin, Paxillin, Filamin C 
Cytoskeleton 
Regulation of 
cytoskeleton 
rearrangement 
2.82E-02 
Ankyrin-G, RhoA, G-protein alpha-i1, RhoGAP6, LyGDI, 
Profilin II, CRK, Filamin A, SPA1, mDIA2(DIAPH3), 
Tubulin alpha 1A, CD44, Vimentin, Filamin B (TABP), 
PLK1, Destrin, Paxillin, Filamin C 
Cell adhesion Cadherins 5.72E-02 
CD151, RhoA, PTP-2, PTPRF (LAR), Cadherin 24, PTPR-
mu, SSX2IP, IQGAP1, Actin cytoplasmic 2, PEZ, FHL2, 
RET, Cadherin 23, DKK2, EGFR, Reelin, ILK 
Development Regulation of EMT 5.81E-02 
HGF, RhoA, TGF-beta 2, TGF-beta 1, CRK, BMP7, Lysyl 
oxidase, NOX4, TGF-beta 3, Vimentin, ITGB3, ETS1, TGF-
beta receptor type II, SLUG, EGFR, PDGF-D, ILK, EDNRA, 
LOXL2, Collagen III 
Cell adhesion Integrin priming 9.59E-02 Vitronectin, Actin cytoplasmic 2, ITGAV, ITGB3, Calpain 2(m), CXCR4, PLC-beta1, Paxillin, Collagen III 	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6.3 Discussion 
 
The TCF4 gene is associated with two major protein isoforms: TCF4-B and TCF4-A. 
To advance our understanding of TCF4 function in the nervous system, experiments 
were designed to explore the system-wide effects of TCF4 isoforms on the neuronal 
transcriptome. RNAi experiments revealed that each isoform affects a unique set of 
cellular processes. TCF4-B affected genes involved in cell cycle regulation and 
chromatin structure whilst TCF4-A was associated to gene expression changes in 
processes such as cell adhesion and cytoskeletal dynamics. The experiments in this 
chapter uncover novel cellular processes associated to TCF4 function in neuronal 
cells. 
 
6.3.1 Knockdown of either TCF4-B or TCF4-A affects gene expression in SH-
SY5Y cells 
Having shown that two major isoforms are expressed in SH-SY5Y cells, siRNAs 
were used to knockdown TCF4-A or TCF4-B independently. The data derived from 
these experiments supports the MS identification of TCF4-A (54kDa) and TCF4-B 
(71kDa) as the two major TCF4 isoforms in SH-SY5Y cells (Table 5.2).  
Interestingly, knockdown of TCF4-A caused a compensatory increase in the 
expression of TCF4-B, indicating that homeostatic regulation may occur at the TCF4 
locus. This data suggests that a precise balance of each isoform may be required in 
cells. Despite compensatory mechanisms, a specific depletion of each isoform was 
possible using siRNA treatment. The gene expression profiles of TCF4-B and TCF4-
A knockdown cells were analysed by microarray and compared individually to 
control groups (KDGAP and mock) to identify gene expression changes related to 
each isoform. Hierarchical clustering demonstrated that each isoform was associated 
with gene expression changes distinct from control groups (Figure 6.4). Depletion of 
each isoform resulted in both positive and negative effects on gene expression, 
however each isoform had a predominance of downregulated genes in this study (75% 
for TCF4-B and 62% for TCF4-A), indicating that TCF4-B and TCF4-A have similar 
effects on transcriptional activity in these cells. qPCR was used to validate gene 
expression changes from the array and demonstrated that knockdown of each isoform 
could have both shared and differential effects on gene expression (Figure 6.7). 
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6.3.2 TCF4-B and TCF4-A isoforms have shared effects on specific genes 
Experimental validation of gene expression changes by qPCR demonstrated that in 
some cases TCF4-A and TCF4-B knockdown affected the expression of the same 
genes (Figure 6.7). This effect was particularly noticeable for SNAI1, SNAI2, 
NEUROG2, SKP2 and DPT. In addition SNAI2, DPT and NEUROG2 were identified 
in Chapter 4 as genes with high fold changes after global knockdown of TCF4 
(SNAI2; -2.5, DPT; -6, NEUROG2; -3, Figure 4.5). . 
 
SNAI2 is a zinc finger transcription factor that participates in developmental processes 
and EMT as described previously (Section 4.3.3). By contrast, NEUROG2 is 
proneural protein essential for early fate commitment of neural precursors and has a 
role in the early steps of neural delamination, a process that may be related to EMT 
(Famulski and Solecki, 2013). Both of these transcription factors bind E-box motifs, 
suggesting that TCF4, NEUROG2 and SNAI2 may operate in a regulatory E-box 
network. Dermatopontin is a widely expressed extracellular matrix (ECM) protein 
that interacts with a range of ECM components to promote cell adhesion and 
migration (Kato et al., 2011; Liu et al., 2013). DPT is consistently the most 
differentially expressed gene across all data sets (TCF4 KD; -6, KDB; -2.2, KDA; -9).  
These findings may imply that DPT is a direct downstream target of TCF4. 
 
DACH1, CLSTN2 and IGFBP5 were also genes with high fold changes (> 2) in the 
global TCF4 known and isoform-specific knockdown experiments (Figure 4.5, Figure 
6.5, Figure 6.6). IGFBP5 is an essential regulator of IGF signaling, that sequesters 
IGF ligands reducing their biological availability (Fernandez and Torres-Aleman, 
2012). The Drosophila paralogue of DACH1 (dac) is a master regulator of eye 
development and is also involved in developing mushroom bodies, a region of the 
Drosophila brain required for elementary cognitive functions (Chen et al., 1997; 
Kurusu et al., 2000). Abrogation of dac in flies results in disrupted and aberrant 
axonal projections in mushroom bodies (Kurusu et al., 2000). Calsyntenin 2 is a 
neuronally expressed transmembrane protein with N-terminal cadherin-like repeats 
and may therefore have a role in cell adhesion (Hintsch et al., 2002). However, very 
little is known about the functions of DACH1and CLSTN2 in mammalian neurons. 
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6.3.3 Knockdown of TCF4-B affects genes involved in cell cycle regulation and 
chromatin modification 
TCF4-B has been classified as both an activator and repressor of gene transcription 
depending on the cellular contexts and the promoter being studied (Skerjanc et al., 
1996; Forrest et al., 2012). Enrichment analysis of gene expression changes in TCF4-
B depleted cells identified a role for this isoform in cell cycle regulation and 
chromatin modification. The MetaCore database of process networks highlighted four 
terms that were statistically enriched for TCF4-B associated gene expression changes 
including, “Cell cycle_S phase”, “Cell cycle_Core”, “DNA damage_Checkpoint”, 
“Transcription_Chromatin modification” (Table 6.5). These terms all became more 
significant when only the downregulated genes were included in the analysis, whilst 
no significant categories were found in the dataset composed of upregulated genes 
(Table 6.5 and data not shown). This observation, allied with the fact that a greater 
proportion of genes in the analysis (75%) were downregulated after the knockdown 
treatment suggest that TCF4-B may function predominantly as a transcriptional 
activator in these cells. However, the small number of upregulated genes (99) may 
have prevented the identification of enriched processes in this analysis. 
 
Interestingly, the proteomic analysis of phosphorylation sites revealed that TCF4 
contains amino acid motifs potentially recognised by cyclin-dependent kinases 
(CDKs) as well as the PRKDC and ATM proteins (Table 5.4). CDKs are directly 
involved in cell cycle regulation whereas the PRKDC and ATM kinases that are 
activated in response to DNA strand breaks; these two mechanisms are represented in 
TCF4-B related gene expression changes (O'Driscoll and Jeggo, 2006; Lim and 
Kaldis, 2013). Thus several lines of evidence suggest that TCF4-B may have a 
function in cell cycle control and DNA repair. 
 
In the nervous system, neurogenesis is highly dependent on the different states of the 
cells cycle (Dehay and Kennedy, 2007). Controlling the timing and length of the cycle 
is decisive in regulating the balance of proliferative and differentiating neural 
precursors.  In this model, decreasing the rate of the cell cycle progression increases 
the neuron generation. Hence, determining the effect of TCF4 expression in 
proliferating neuronal cells could provide valuable information for its role in neuronal 
Chapter 6: TCF4 Isoform-Specific Gene Expression Profiling 
	  170 
development. There is already evidence that E-protein expression can influence the 
cell cycle and proliferation. In microarray experiments, cells overexpressing the TCF4 
paralogue TCF3 were also associated to gene expression changes related to the cell 
cycle, indicative of a conserved function in E-proteins (Schwartz et al., 2006). 
Furthermore, expression of TCF4 has been associated to reduced proliferation and 
cell cycle arrest in a number of non-neuronal cancer cell lines (Pagliuca et al., 2000; 
Herbst et al., 2009). In neuroblastoma, overexpression of TCF4 can also cause a 
reduction of proliferation although the mechanism is undetermined (Rothschild et al., 
2006). Similar evidence is available for TCF3 as it can induce cell cycle arrest in a 
number of different cell lines (Peverali et al., 1994; Engel and Murre, 2004). 
However, the precise role of E-proteins in cell cycle control is controversial as studies 
have also shown they can promote cell cycle progression (Zhao et al., 2001). Further 
cellular assays in neuronal models will be required to determine the exact function of 
TCF4-B on the cell cycle. 
 
6.3.4 Knockdown of TCF4-A affects genes involved in cell adhesion and 
cytoskeletal structure 
TCF4-A was identified as the second predominant isoform in SH-SY5Y cells. This 
isoform shares much of its sequence with TCF4-B although it is devoid of the N-
terminal activation domain (AD1) and the NLS (Figure 6.1). Although only one 
siRNA resulted in robust knockdown of TCF4-A, process enrichment analysis in 
MetaCore identified a selection of terms associated to cell adhesion and cytoskeletal 
remodeling. These data differed considerably from the gene expression changes in 
TCF4-B-depleted cells (Table 6.6 and Table 6.5). Performing the enrichment analysis 
with all the differentially expressed genes or with exclusively the downregulated 
genes did not change the functional categories identified (Table 6.6). However, 
additional terms associated to proteolysis and cytoskeletal rearrangement became 
significant when the upregulated were excluded form the analysis. These results 
suggest the upregulated genes did not have a substantial role in functional processes 
identified. 
 
The distinct enrichment categories identified in TCF4-A knockdown cells may 
suggest a form of cellular migration is being affected, as this process involves 
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restructuring of cell adhesion molecules and the cytoskeleton (Parsons et al., 2010). 
During cell migration, cells extending protrusions of the cell membrane that polarise 
the morphology of the cell. These protrusions are driven by the polymerisation of 
actin filaments that restructure the cytoskeleton. Cells can stabilise protrusions 
through cell adhesions molecules linking the actin cytoskeleton to ECM proteins. 
The depletion TCF4-A may therefore be associated to cellular migration or a related 
cellular process. Other terms that have been identified in the enrichment analysis 
could provide insight into the cellular processes that are being disrupted following 
TCF4-A knockdown (Table 6.6). In particular, the terms of 
“Development_Regulation of EMT” and “Neurogenesis_axon guidance” are 
intriguing, as EMT and axon guidance share some basic features of cellular migration. 
 
Experiments presented in Chapter 4 in addition to the published literature would 
support a role for TCF4-A in EMT. Although EMT is not a significant term in the 
present MetaCore analysis, the significant terms are highly reminiscent of cellular 
processes in EMT. Notably, EMT involves the loss of adhesion and a morphogenic 
transition to a migratory phenotype that requires cytoskeletal rearrangements (Lim 
and Thiery, 2012). The qPCR validation experiments also demonstrate that the EMT-
regulators SNAI1 and SNAI2 are differentially expressed in TCF4-A knockdown cells 
(Figure 6.7). This evidence may suggest that TCF4-A is the predominant isoform 
involved in regulating EMT. 
 
The TCF4-A knockdown may also affect mechanisms associated to axon guidance, as 
this process shares many general features associated to neuronal migration, including 
changes in adhesive properties and cellular cytoarchitecture (Araujo and Tear, 2003). 
In addition, genes relating to this mechanism have high fold changes after TCF4-A is 
knocked down in SH-SY5Y cells (Table 6.6). For example, RELN and SEMA3A are 
two proteins related to this process that were selected for qPCR validation 
experiments (Figure 6.7). The semaphorins act as axonal growth cone guidance 
molecules and are crucial for managing precise neuronal connections in the brain 
(Pasterkamp, 2012). In addition to SEMA3A, many other semaphorin family members 
are also differentially expressed in this experiment indicating they may be associated 
to TCF4-A function. Interestingly, SEMA3A is also reduced in the cerebellum of 
schizophrenia patients suggesting it may contribute to the pathology of 
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neurodevelopmental disorders (Eastwood et al., 2003). The differential expression of 
RELN is also notable in this experiment because mutations in this gene cause 
cerebellar malformations and several post-mortem studies have shown reduced RELN 
expression in the brain of schizophrenia patients (Impagnatiello et al., 1998; Fatemi et 
al., 2000; Guidotti et al., 2000; Hong et al., 2000). Through affecting the expression 
of important regulators of axon guidance genes, TCF4-A could therefore disrupt 
aspects of neurodevelopment that confer susceptibility to schizophrenia. 
 
In conclusion, experiments using RNAi have allowed for isoform-specific knockdown 
to be performed on TCF4 transcripts. In combination with the MS data presented in 
Chapter 5, this technique has established that TCF4-B and TCF4-A are the major 
TCF4 isoforms in SH-SY5Y cells. Knockdown experiments in these cells 
demonstrate that the TCF4-B and TCF4-A cause distinctly different gene expression 
changes. TCF4-B depletion is associated with gene expression changes associated to 
the cell cycle and chromatin modification whilst the TCF4-A depletion affects genes 
involved in cell adhesion, remodeling of the cytoskeleton and proteolysis of 
extracellular matrix. This study provides the first evidence that TCF4 isoforms can 
have unique effects in neuronal cells. The cellular processes identified have important 
implications for understanding the role of TCF4 in neurodevelopment and disease. 
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Chapter 7 
 
General Discussion 
 
 
7.1 The function of TCF4 missense mutations in PTHS  
PTHS is caused by mutations in TCF4 that result in haploinsufficiency of the encoded 
protein (Amiel et al., 2007). At the beginning of this study, a number of TCF4 
missense mutations had been identified in PTHS patients although their impact on the 
function of the protein had only been studied in the context of transactivation on 
synthetic promoters (de Pontual et al., 2009). Accordingly, one of the aims of this 
thesis was to further examine the effects of missense mutations on TCF4 function. 
Missense mutations are especially informative to study as they allow changes in 
single amino acids to be related to particular functional deficits. In this thesis I 
showed that most TCF4 missense mutations affected either the subcellular 
localization, dimerisation or transcriptional activity as assayed on one of two 
potentially physiological promoters: NRXN1β and CNTNAP2 (Forrest et al., 2012). 
Mutations in each of these loci have been shown to cause a PTHS-like disorder 
suggesting that TCF4, NXNR1β and CNTNAP2 may form a regulatory network 
(Zweier et al., 2009; Blake et al., 2010). 
 
One of the unexpected findings of this study was the idiosyncratic behavior of each 
mutant in the different functional tests (3.2.4 and 3.2.6). These observations were 
surprising because each of the missense mutations modeled cause PTHS, and no 
apparent correlation between genotype and phenotype has been reported (Marangi et 
al., 2011). However, the data in chapter 3 emphasises the importance of context in 
measuring functional deficits. In particular, distinct functional deficits were observed 
at the level of transcriptional activity when the same mutant was assayed on the 
NXNR1β and CNTNAP2 promoters (Figures 3.11 and 3.12). The same mutations also 
displayed context dependent deficits when different dimer configurations were used 
to measure protein:protein interactions (Figures 3.6 and 3.7).  These results suggest 
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that measuring the functional impact of a mutation in vivo requires an appreciation of 
the relevant physiological context in which TCF4 operates. 
 
One of the considerations in the functional analysis of TCF4 missense mutations is 
the choice of DNA sequence used to assay transcriptional activity. The NXNR1β and 
CNTNAP2 promoters were selected on the basis that TCF4 may regulate the 
expression of these genes, since common neurodevelopmental phenotypes can be 
caused by TCF4, NRXN1 and CNTNAP2 mutations (Zweier et al., 2009). Although I 
was able to show that these promoters are responsive to TCF4 expression and contain 
conserved E-boxes, it is still uncertain whether TCF4 directly regulates these genes 
physiologically (Figure 3.10). Consequently, it will be imperative to identify TCF4’s 
genomic binding sites, in order to select promoter or enhancer sequences that are 
relevant to its transcriptional activity. The use of chromatin immunoprecipitation 
combined and next generation sequencing (ChIP-seq) would directly facilitate the 
discovery of TCF4 binding sites in vivo (Furey, 2012). The gene expression changes 
from global TCF4 knockdown cells (Chapter 4) or the isoform-specific knockdown 
cells (Chapter 6) could be particularly useful to interpret such data. Nevertheless, the 
use of native promoter sequences, such as those used in Chapter 3, clearly 
demonstrate that the effects of TCF4 mutations can be more subtle than those 
observed on synthetic promoters containing multimerised E-boxes (Forrest et al., 
2012; Sepp et al., 2012b). Although useful, synthetic promoters do not model the 
inherent complexity of transcriptional regulation in vivo that results from the additive 
effects of multiple cis- and trans- acting factors (Coulon et al., 2013). Indeed E-box 
binding sites have been shown to cooperate with neighbouring sequences to mediate 
their functional effects (Castro et al., 2006; McDonald et al., 2013). In light of this 
information, it is crucial to identify physiologically regulated TCF4 targets to better 
our understanding of the molecular pathophysiology of PTHS, learning disability and 
schizophrenia. 
 
Differences in the transcriptional activities of the PTHS-associated TCF4 missense 
mutants could be mediated by impaired homo- and heterodimerisation (Figures 3.6 
and 3.7). Mutations in the bHLH domain (R578P, R580W and A610V) particularly 
affected protein association to partner bHLH proteins. Defective interactions with 
bHLH proteins may have important consequences for neurodevelopmental 
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phenotypes in PTHS, as proneural proteins are important for multiple aspects 
regulating neurogenesis and neuronal differentiation (Bertrand et al., 2002). The 
interaction of TCF4 with ATOH1 may represent such an example. In mice, Atoh1 is 
required for the migration and differentiation of hindbrain neurons critical for 
perinatal breathing (Rose et al., 2009). One of the salient features of PTHS is an 
abnormal breathing pattern characterised by intermittent hyperventilation and apnea 
(Peippo and Ignatius, 2012). In addition, studies on Tcf4 knockout mice have shown 
that a critical amount of the Tcf4/Atoh1 heterodimer is necessary to develop specific 
populations of cells in the hindbrain (Flora et al., 2007) (Section 1.9.2). These studies 
raise the intriguing possibility that mutations affecting the TCF4/ATOH1 interaction 
may subtly disrupt the development of hindbrain structures regulating autonomic 
function and cause the abnormal breathing patterns observed in PTHS.  
 
Although TCF4 missense mutations impaired dimerization with a selection of known 
TCF4-interacting proteins, each heterodimer was affected differently by individual 
mutations (Figure 3.7). Therefore, another consideration for the function analysis of 
PTHS missense mutations is the choice of binding partner used to assess the effects 
on protein:protein interactions. The proteomic analysis of proteins that co-purify with 
TCF4 (Chapter 5) generated an interesting resource of potential TCF4-interacting 
proteins. Interestingly, this analysis did not identify any of the known heterodimer 
partners used to characterise TCF4 missense mutants (ASCL1, ATOH1, NEUROD1 
or ID2). However, the bHLH proteins TCF3, HAND2 (dHAND) and TWIST2 co-
immunoprecipitated with TCF4 in SH-SY5Y cells (Table 5.6). HAND2 and TWIST2 
have been reported to interact with E-proteins (Howard et al., 1997; Firulli et al., 
2005). TWIST2 is also a mediator of EMT that was identified as an important TCF4-
associated cellular process (Section 4.2.5)(Fang et al., 2011). It would therefore be 
interesting to assess the effects of TCF4 missense mutations on interactions with each 
of these proteins. 
 
Whilst mutations in the bHLH domain impaired homo- and heterodimer formation, 
the more N-terminal TCF4 mutations G358V and D535G had a lesser effect on 
protein:protein interactions (Figures 3.6 and 3.7). By contrast, N-terminal mutations 
had context-dependent deficits in transcriptional activation measured on the NRXN1 
and CNTNAP2 promoters, indicating that their ability to regulate transcription was 
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affected (Figures 3.11 and 3.12). G358V is located in AD2 a region of TCF4 
proposed to interact with the transcriptional co-repressor ETO (Figure 3.1)(Zhang et 
al., 2004). D535G is located in the Rep domain that can functionally regulate the 
activity of AD1 and AD2 (Figure 3.1)(Markus et al., 2002b). Therefore, the mutations 
G358V and D535G might impair the recruitment of regulator proteins important for 
TCF4 function. In addition to ETO, interesting candidates to investigate in this 
context would be interactions with the NCoR complex (NCOR1, TBL1XR1 and 
HDAC3) that co-purified with TCF4 (Section 5.2.4). A recent study found that Mecp2 
missense mutations found in Rett syndrome patients abrogate the interaction between 
Mecp2 and NCoR in transgenic mice (Lyst et al., 2013). As mentioned previously, 
Rett syndrome has substantial phenotypic overlap with PTHS (Armani et al., 2012). 
Similar to PTHS, MECP2 missense mutations that cause Rett syndrome cluster in two 
distinct regions of the protein (Lyst et al., 2013). The majority of MECP2 mutations 
are located in the methyl-binding domain (MBD) of the protein however other 
mutations are located in the transcriptional repression domain (TRD). Whereas 
mutations in the MBD impair DNA binding to methylated DNA, the mutation R306C, 
located in the TRD, eliminates the protein interactions with NCOR1, TBL1XR1 and 
HDAC3 (Yusufzai and Wolffe, 2000; Lyst et al., 2013). Providing that the 
interactions described in Chapter 5 can be confirmed using different methodology, it 
would be interesting to determine whether the G358V and D535G mutations impair 
the interaction between TCF4 and NCoR.  
 
In addition to modeling mutations on TCF4-B, it may be useful to interpret the effects 
of PTHS-associated missense mutations on TCF4-A. TCF4-A appears to be equally 
abundant as TCF4-B in some human cell lines of neuronal origin (Chapter 5, Figure 
5.2A). TCF4-A does not contain AD1 therefore the effects of N-terminal mutations 
affecting regulatory domains may reveal stronger functional impairments in 
transcriptional assays. TCF4-A may also have differential effects on protein:protein 
interactions that could be investigated in the light of the findings described above. 
 
Finally, additional experiments could be designed to demonstrate the physiological 
effects of missense mutations in PTHS. One possibility would be to generate knock-in 
mice with alleles containing PTHS missense mutations, as has been done to 
understand the pathophysiology of certain autism spectrum disorders (Tabuchi et al., 
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2007; Lyst et al., 2013). Finally, induced pluripotent stem cells (iPS) could be created 
from PTHS fibroblasts allowing disease-specific cell models to be formed. Re-
programming iPS cells from PTHS patients into neurons could be an effective 
strategy to identify novel molecular and cellular mechanisms relevant to PTHS 
pathology (Brennand et al., 2011). 
 
7.2 TCF4-associated cellular processes and neurodevelopmental disease. 
As mentioned above, genetic studies have uncovered an important role for TCF4 in 
human neurodevelopmental disorders. However, the precise way in which TCF4 
contributes to disease in humans is unknown. Consequently, another aim of this thesis 
was to delineate the gene expression program that TCF4 may regulate in neuronal 
cells. I found that knockdown of all TCF4 transcripts in SH-SY5Y cells results in the 
differential expression of genes involved in cell signaling, cell survival, EMT and 
neuronal differentiation (Forrest et al., 2013).  
 
Although these microarray experiments uncovered potentially important cellular 
processes related to TCF4 function, this method did not allow for direct and indirect 
effects on gene expression to be distinguished. As previously mentioned in Section 
7.1, one of the aims of future experiments would be to examine the genome-wide 
binding sites for TCF4 in neuronal cells in order to identify direct genomic targets. 
Such experiments would provide additional understanding of TCF4 function and the 
genes it regulates. However, the RNAi-mediated knockdown approach was useful as 
it created a cellular model of TCF4 deficiency that may be relevant in PTHS and 
schizophrenia. Haploinsufficiency of TCF4 is widely assumed to be the cause of 
PTHS however the effects of common schizophrenia risk variants on TCF4 
expression are so far unknown. Preliminary evidence from mouse models and from 
the blood of psychosis patients may suggest that TCF4 up-regulation is associated 
with schizophrenia risk, however rigorous evidence of this is lacking (Brzozka et al., 
2010; Wirgenes et al., 2012). Nevertheless, the cellular processes revealed by 
knockdown of TCF4 are likely to be important in understanding the role of TCF4 in 
schizophrenia risk and PTHS (Figure 7.1).  
 
One the of the most intriguing findings in TCF4 knockdown cells was the differential 
expression of certain neurodevelopmental genes involved in dominantly inherited 
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forms of intellectual disability (Chapter 4, Table 4.6). In addition, several E-box 
binding transcription factors (ASCL1, NEUROG2, SNAI1, SNAI2, BHLHE40, ZEB2, 
TWIST1, MEF2C) were differentially expressed in TCF4-depleted cells. TCF4, 
SNAI1, SNAI2, ZEB1 and TWIST1 may operate in a transcriptional hierarchy in 
epithelial cells undergoing full EMT (Cano and Portillo, 2010). Interestingly, MEF2C 
is involved in the activity dependent transcription of TCF4 and synergises with 
neurogenic bHLH transcription factors at E-box sites (Black et al., 1996; Flavell et al., 
2008). Since heterozygous ZEB2 and MEF2C mutations cause severe forms mental 
retardation, these data may suggest a functional network of E-box regulators is also 
operating in neuronal cells to regulate crucial neurodevelopmental events important in 
human disorders. 
 
The knockdown experiments in neuroblastoma cells confirmed that TCF4 has a role 
in regulating EMT (Chapter 4). The process of EMT has been extensively studied in 
epithelial cells and cancer however, the role of an EMT-like process in the brain is 
less clear (Acloque et al., 2009). Nevertheless, there are considerable parallels 
between EMT and the events regulating neuronal development (Famulski and 
Solecki, 2013). During early steps of corticogenesis, neuroepithelial cells (neural stem 
cells) must delaminate from the basal surface of the ventricular zone to become 
multipolar cells (mesenchymal-like), in order to initiate migration into the cortical 
layers. Switching between polar (epithelial-like) and multipolar (mesenchymal-like) 
states is also required during migration through cortical layers and is an essential step 
of cortical development. The delamination of progenitor cells may be an important 
process to investigate in Tcf4 knockout mice, as Tcf4 expression is particularly high 
in the ventricular zones of the developing and adult brain (Soosaar et al., 1994). The 
change in the morphological and migratory properties of cells associated with EMT 
may also be of relevance to neurodevelopmental disorders because mutations in the 
EMT-regulator ZEB2, cause Mowat-Wilson syndrome (MWS) (Vandewalle et al., 
2005). MWS is associated with severe intellectual disability and is a differential 
diagnosis for PTHS suggesting that a common disease mechanisms may exist (Peippo 
and Ignatius, 2012) . However, ZEB2 also plays a crucial role in interneuron subtype 
specification indicating that TCF4 and ZEB2 may have pleiotropic functions in the 
nervous system (McKinsey et al., 2013). 
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The proteomic analysis of TCF4-interacting proteins suggests that TCF4 may have 
novel molecular functions in RNA splicing, cell cycle regulation and chromatin 
organisation (Table 5.6). Although these interactions require further validation, they 
potentially reveal a different aspect of TCF4 function that has not yet been addressed. 
The identification of members of the NCoR complex in IAP-MS experiment provides 
evidence that TCF4 may act as a repressor in particular contexts. This may explain the 
presence of up-regulated genes in the TCF4 knockdown experiment (Chapters 4 and 
6). In addition, the phosphorylation sites identified by MS may provide useful insight 
to predict upstream regulators of TCF4 function (Table 5.4). Understanding how 
TCF4 is regulated in neurons will be essential in determining its biological role in the 
integrated network of the cell. Proteomics also confirmed the present of the TCF4-B 
and TCF4-A isoforms in SH-SY5Y cells (Table 5.2). These data enabled a more 
refined analysis of TCF4 function to be performed using isoform-specific 
knockdowns (Chapter 6). These experiments revealed strikingly different functions 
for each isoform that were unexpected due to the apparent redundant effects of TCF4-
B and TCF4-A in epithelial (MDCK) cells (Sobrado et al., 2009). The results suggest 
that TCF4 isoforms may have unique functions in neuronal cells.  
 
Multiple terms in the enrichment analysis of TCF4-B knockdown cells suggested that 
this isoform has a role in cell cycle regulation (Table 6.5). In addition, cell cycle 
proteins co-purified with TCF4, indicating TCF4 may have an integrated role in the 
cell cycle. Tight regulation of cell cycle is essential during brain development as it has 
a direct impact on the balance between proliferation and differentiation of cells, and 
affects cortical architecture (Dehay and Kennedy, 2007). Further experiments 
assessing the effects of TCF4 on neuronal cell proliferation and differentiation would 
be very useful to understand the functional implications of these findings. Evidence 
from magnetic resonance imaging (MRI) studies of the brain in PTHS patients may 
provide support for TCF4 having a role in cell cycle control and proliferation. One of 
the most frequent brain abnormalities observed in PTHS patients are small 
hippocampi (34%) (Whalen et al., 2012b). In addition, dilated ventricles and frontal 
lobe hypoplasia have also been reported (Amiel et al., 2007; Zweier et al., 2008a). 
These structural defects could be the result of defective proliferation of developing 
neurons in the brain. Volumetric reduction of different brain regions is also a 
prominent finding in schizophrenia patients (Goldman et al., 2009; Balu and Coyle, 
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2011). However, the structural abnormalities in the brain can be caused by various 
mechanisms such as cell loss or cell packing, therefore further studies would be 
required to test these predictions (Balu and Coyle, 2011).  
 
Gene expression changes associated with TCF4-A knockdown suggested a role for 
this isoform in cell adhesion, cytoskeletal remodeling and proteolysis of the 
extracellular matrix (Table 6.6). These gene expression changes are reminiscent of 
processes related to EMT or forms of neuronal migration (Ayala et al., 2007). 
Functional characterization of these processes will be essential to determine whether 
TCF4-A knockdown and global knockdown of TCF4 can affect EMT and cell 
migration. Importantly, several schizophrenia candidate genes such as RELN (reelin) 
and DISC1 (disrupted in schizophrenia 1) are involved in neuronal migration 
suggesting this may be an important cellular process governing neuropsychiatric 
phenotypes (Anton et al., 2004; Franco et al., 2011; Tomita et al., 2011). Gene 
enrichment analyses of schizophrenia susceptibility genes also support a role for 
biological process such as cell adhesion and migration in disease pathophysiology 
(O'Dushlaine et al., 2011; Gilman et al., 2012). To further our understanding of TCF4 
in schizophrenia it will be important to determine whether TCF4 regulates validated 
schizophrenia susceptibility genes. Identification of new schizophrenia susceptibility 
loci by GWAS, CNV analysis and exome sequencing will be a useful resource to 
examine this possibility (Section 1.11.2). 
 
In summary, the data presented in this thesis describes novel molecular and cellular 
functions for TCF4 in SH-SY5Y cells that have important consequences for nervous 
system development. Global knockdown of TCF4 affects the expression of genes that are 
associated with intellectual disability and EMT. Furthermore, TCF4 isoforms are shown 
to have distinct effects in neuronal cells that together affect diverse cellular processes 
such as the cell cycle, cell adhesion and cytoskeletal dynamics. Accordingly, the 
transcriptional dysregulation of these processes may cause neurodevelopmental 
abnormalities that are associated to PTHS and schizophrenia (Figure 7.1). 
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Figure 7.1 Overview of key findings from this study and their relation to 
potential disease mechanisms. Genetic defects cause a change in the activity or 
expression levels of TCF4. These mechanisms disrupt TCF4-associated protein 
interactions and transcription, predisposing to developmental phenotypes in human 
disorders. Genes and proteins identified in this study are in black. Known TCF4-
interacting proteins previously found in other studies are in grey. 
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Appendix I 
Classification of the basic helix-loop-helix transcription factor family. 
The bHLH family is sub-divided into seven functional classes according to tissue 
expression, dimerisation capability and DNA binding specificity (Classes I-VII) 
(Massari and Murre, 2000). The official HUGO gene names of transcription factors in 
each class is provided with the basic characteristics of each group. Letters in brackets 
under the class number represent the categorisation of the bHLH family members by 
two other classification systems based on phylogenetic analysis (Ledent et al., 2002; 
Stevens et al., 2008). 
 
Class Family Human genes Defining features 
I 
(A, B) E-proteins 
TCF3 (E2A, E47/E12) 
TCF12 (HEB) 
TCF4 (E2-2, ITF2, SEF2) 
Homodimerisation; 
Heterodimerisation with class II, 
class V, and class VI 
transcription factors; each gene 
contains two main isoforms; 
widely expressed 
II 
(A, A) NEUROD 
NEUROD1, NEUROD2, 
NEUROD4, NEUROD6 
Heterodimerisation with E-
proteins; tissue specific 
expression; cell differentiation 
II 
(A, A) NEUROG 
NEUROG1, NEUROG2, 
NEUROG3 
II 
(A, A) ATOH ATOH1, ATOH7, ATOH8 
II 
(A, A) ASCL 
ASCL1, ASCL2, ASCL3, 
ASCL4, ASCL5 
II 
(A, E) OLIG OLIG1, OLIG2, OLIG3 
I 
(A, C) MYOD 
MYOD1, MYOG, MYF5, 
MYF6 
II 
(A, A) dHAND HAND1, HAND2 Homo and heterodimerisation 
II 
(A, A) TWIST TWIST1, TWIST2 
Homo and heterodimerisation; 
activates and represses 
transcription 
III 
(B1) TFEB  
bHLH/Z domain; Activates and 
represses transcription 
III 
(B1) TFE3  
III 
(B1) SREBF SREBF1, SREBF2 
III 
(B, E) MYC 
MYC, MYCN, MYCL1, 
MYCL2 
IV 
(B, C) 
MXD1 
(Mad) 
MXD1, MXD3, MXD4, 
MXI1 
IV 
(B, D) MAX MAX 
V 
(D, B) ID proteins ID1, ID2, ID3, ID4 
Inhibitors of differentiation; lack 
basic domain responsible for 
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DNA binding properties; 
heterodimerise with E-proteins 
to inhibit activity 
VI 
(E, B) HES 
HES1, HES2, HES3, 
HES4, HES5, HES6, 
HES7 
bHLH-O domain; Proline rich 
region; homodimers bind N-
boxes; Inhibit the activity of E-
proteins VI (E, B) HEY HEY1, HEY2, HEYL 
VII 
(C, E) AHR AHR, AHRR 
bHLH-PAS domain 
VII 
(C, E) SIM2 SIM1, SIM2 
VII 
(C, E) TRH NPAS3 
VII 
(C, E) CLOCK CLOCK, NPAS2 
VII 
(C, E) BMAL ARNTL, ARNTL2 
VII 
(C, E) ARNT ARNT, ARNT2 
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Appendix II 
List of primers and probes used in this thesis. All DNA sequences are written in 
the 5’ to 3’ direction. For the mutagenesis primers, only the forward sequence is 
provided. 
 
Name DNA sequence/probe name 
Plasmid primers (Section 2.3.2) 
HA/Myc-TCF4 F CTGCGAATTCGGATGCATCACCAACAGCGAATG 
HA/Myc-TCF4 R CTGGCGGCCGCATTACATCTGTCCCATGTGATTC 
TRX/GST-TCF4 F CTGGAATTCCTGTTTGGTCTAGAAATGGAG 
TRX/GST-TCF4 R CTGGTCGACATCGTCATTATTGCTAGTAATTG 
GFP-TCF4 F CTGTCGAATTCTATGCATCACCAACAGCGAATG 
GFP-TCF4 R CTGGTCGACTTACATCTGTCCCATGTGATTC 
HA-ATOH1 F GTCCGAATTCGGATGTCCCGCCTGCTGCATG 
HA-ATOH1 R CTGCGGTCGACCCTAACTTGCCTCATCCGAGTC 
myc-E47 F CTGCGAATTCGGATGAACCAGCCGCAGAGG  
myc-E47 R CTGCGGTCGACCTCACATGTGCCCGGCGG 
pLuc-CNTNAP2 F CTGAAGCTTCTGCTTGAGATACCCATGGAA 
pLuc-CNTNAP2 R CTGAAGCTTAAGAGCAGAGGCTGCAGAAG 
pLuc-NRXN1β F CTGAAGCTTAGAGTGCGCCCTTCTGAAG 
pLuc-NRXN1β R CTGAAGCTTAATGGGAAGAAGAATCCTTGT 
TCF4 600F CTATCCTTCCTCCAAACCAG 
TCF4 1200F CCGGAACCATGCAGTGGG 
TCF4 568R GGCAAACCTGGAGGAACTTT 
CNTNAP2 630F TAC ATA TCG AAA ACA TGT GCA TT 
E47 285F TTCATCCACATTCCTGGGAC 
E47 1385R TGGTTGTGCATGAGGCTGGT 
G358V CATCTCTCTCAGCAGTCACAGCTGTTTGGTC 
D535G GAGGACAAGAAATTAGGTGACGACAAGAAGAT 
R578P AACAATGCCCGAGAGCCTCTGCGGGTCCGTGAC 
R580W GCCCGAGAGCGTCTGTGGGTCCGTGACATCAAC 
A614V CTGATCCTCCACCAGGTGGTGGCCGTCATCCTC 
BHLHE40 F TACCTGATCCCACCTTCAGC 
BHLHE40 R TTGAGGCCTGGGTATAGCAC 
MEF2C F TCGAGATACCCACAACACAC 
MEF2C R TCGTACGAACTGCTACAGCT 
TCF3/E47 F AAGCCACTGCACACAGACAG 
TCF3/E47 R CGCATCACTTTCCACATGAC 
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SNAI1 F ACAGCTGCTTTGAGCTACAG 
SNAI1 R GCATAGTTAGTCACACCTCG 
SNAI2 F CAGTGCAAAAACTGCTCCAA 
SNAI2 R GCTTCGGAGTGAAGAAATGC 
ZEB1 F GTGCACAAGAAGAGCCACAA 
ZEB1 R TTGCGCAAGACAAGTTCAAG 
ZEB2 F TACGGATCCCGAAACGATAC 
ZEB2 R CCTCGTGGTCTGATTTGGTT 
TCF4 EX13 F ATGGCAAATAGAGGAAGCGG 
TCF4 EX13 R TGGAGAATAGATCGAAGCAAG 
TCF4A F  GAATCCGAGACCATGTACTG 
TCF4A R AGCATAGACCGCTTTCCCAT 
TCF4 EX4 F CTGGATTTCAGTGCGATGTT 
TCF4 EX4 R GTCTTCTACATTTGAGCCAG 
GAPDH F TGCACCACCAACTGCTTAGC 
GAPDH R GGCATGGACTGTGGTCATGAG 
18S F CCATCCAATCGGTAGTAGCG 
18S R GTAACCCGTTGAACCCCATT 
NDUFA4 F AGCTGAAGAAGGAACGTCCA 
NDUFA4 R GGCTTCTGGAAGACCTTCAT 
COX6A1 F AGAGAATCTGGACCACTACC 
COX6A1 R GTAATGGTCCAAACCAGTGC 
TaqMan probes (Section 2.9.5) 
IGF2 Hs01005964_g1 
CDKN1C Hs00908986_g1 
NEUROG2 Hs00935087_g1 
CDK6 Hs01026373_m1 
BMP7 Hs01002399_m1 
CASP1 Hs00354836_m1 
CASP8 Hs01018151_m1 
FAS Hs00236330_m1 
NTRK1 Hs01021006_g1 
NOTCH1 Hs01062014_m1 
18S Hs03003631_g1 
DPT Hs00355056_m1 
NEUROG2 Hs00935087_g1  
SNAI2 Hs00950344_m1 
SEMA3A Hs00173810_m1 
RELN Hs01022646_m1 
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TLE1 Hs00270768_m1  
RCOR2 Hs00293511_m1 
SNAI1 Hs00195591_m1 
SKP2 Hs01021864_m1 
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Appendix III 
List of genes differentially expressed in GAPDH knockdown cells. Differentially 
expressed genes were established from microarray data of mock and GAPDH KD 
treated cells. A one-way ANOVA was performed between the two groups that 
generated a list of 26 genes (FDR 0.01). 
 
Entrez ID Gene Symbol P-value Fold-Change 
3434 IFIT1 4.95E-06 186.82 
2195 FAT1 1.31E-07 2.52 
80314 EPC1 9.33E-06 1.79 
25953 PNKD 2.10E-06 1.64 
5445 PON2 7.69E-06 1.33 
100293266 - 3.86E-06 -1.22 
6256 RXRA 1.09E-05 -1.43 
199720 GGN 7.55E-06 -1.57 
497661 C18orf32 6.12E-06 -1.63 
122769 PPIL5 4.00E-06 -1.67 
146562 C16orf71 1.54E-06 -1.79 
100293485 - 8.85E-06 -1.93 
339345 NANOS2 7.08E-06 -2.13 
- RCN2 5.86E-06 -2.18 
8564 KMO 5.99E-08 -2.34 
144110 TMEM86A 4.26E-06 -2.85 
115653 KIR3DL3 6.65E-09 -3.55 
51540 SCLY 7.52E-06 -3.57 
91056 AP001266.4-2 2.43E-06 -5.50 
649137 ZSCAN5C 3.77E-10 -5.58 
4803 NGF 5.95E-08 -5.74 
- AL732579.5 5.04E-09 -5.74 
2597 GAPDH 1.88E-06 -6.91 
100134235 - 3.47E-07 -8.11 
- RP11-122A8.1 1.11E-10 -8.32 
- RP4-686J16.2 1.78E-06 -8.34 
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Appendix IV 
 
Amino acid sequence of the TCF4-B+ and TCF4-A+ isoforms. Selected functional 
domains are highlighted: basic helix-loop-helix domain, blue; activation domains, 
yellow; nuclear localisation signal, red; RSRS, bold type; isoform-specific sequences, 
grey. 
 
TCF4-B+ (E2-2B, ITF2-B, SEF2-1B) 
 
671 amino acids, +RSRS 
Ensembl: TCF4-201, ENSP00000455984 
NCBI: Transcription factor 4 isoform a, NP_001077431.1 
 
MHHQQRMAALGTDKELSDLLDFSAMFSPPVSSGKNGPTSLASGHFT
GSNVEDRSSSGSWGNGGHPSPSRNYGDGTPYDHMTSRDLGSHDNLS
PPFVNSRIQSKTERGSYSSYGRESNLQGCHQQSLLGGDMDMGNPGT
LSPTKPGSQYYQYSSNNPRRRPLHSSAMEVQTKKVRKVPPGLPSSVY
APSASTADYNRDSPGYPSSKPATSTFPSSFFMQDGHHSSDPWSSSSG
MNQPGYAGMLGNSSHIPQSSSYCSLHPHERLSYPSHSSADINSSLPPM
STFHRSGTNHYSTSSCTPPANGTDSIMANRGSGAAGSSQTGDALGK
ALASIYSPDHTNNSFSSNPSTPVGSPPSLSAGTAVWSRNGGQASSSPN
YEGPLHSLQSRIEDRLERLDDAIHVLRNHAVGPSTAMPGGHGDMHG
IIGPSHNGAMGGLGSGYGTGLLSANRHSLMVGTHREDGVALRGSHS
LLPNQVPVPQLPVQSATSPDLNPPQDPYRGMPPGLQGQSVSSGSSEI
KSDDEGDENLQDTKSSEDKKLDDDKKDIKSITRSRSSNNDDEDLTPE
QKAEREKERRMANNARERLRVRDINEAFKELGRMVQLHLKSDKPQ
TKLLILHQAVAVILSLEQQVRERNLNPKAACLKRREEEKVSSEPPPLS
LAGPHPGMGDASNHMGQM 
 
 
TCF4-A+ (E2-2A, ITF2-A, SEF2-1A) 
 
511 amino acids, +RSRS 
Ensembl: TCF4-015, ENSP00000409447 
NCBI: Transcription factor 4 isoform j, NP_001230163.1 
 
MYCAYTIPGMGGNSLMYYYNGKAVYAPSASTADYNRDSPGYPSSK
PATSTFPSSFFMQDGHHSSDPWSSSSGMNQPGYAGMLGNSSHIPQSS
SYCSLHPHERLSYPSHSSADINSSLPPMSTFHRSGTNHYSTSSCTPPAN
GTDSIMANRGSGAAGSSQTGDALGKALASIYSPDHTNNSFSSNPSTP
VGSPPSLSAGTAVWSRNGGQASSSPNYEGPLHSLQSRIEDRLERLDD
AIHVLRNHAVGPSTAMPGGHGDMHGIIGPSHNGAMGGLGSGYGTG
LLSANRHSLMVGTHREDGVALRGSHSLLPNQVPVPQLPVQSATSPD
LNPPQDPYRGMPPGLQGQSVSSGSSEIKSDDEGDENLQDTKSSEDKK
LDDDKKDIKSITRSRSSNNDDEDLTPEQKAEREKERRMANNARERL
RVRDINEAFKELGRMVQLHLKSDKPQTKLLILHQAVAVILSLEQQVR
ERNLNPKAACLKRREEEKVSSEPPPLSLAGPHPGMGDASNHMGQM 
 	   210 
Appendix V 
 
 
 
Hierarchical clustering of the top differentially expressed genes with both short 
isoform knockdown groups. The top differentially expressed genes (FDR 0.01) from 
pooled short isoform ANOVA were subjected to hierarchical clustering (top). The 
ANOVA compared the short isoform knockdown groups (KDA1 and KDA2) to 
controls (KDGAP and mock). This analysis generated 14 differentially expressed 
genes, indicating a lack of similarity in the gene expression changes between KDA1 
and KDA2. The bottom panel illustrates hierarchical clustering of the top 
differentially expressed genes (FDR 0.01) generated from the ANOVA comparing 
KDA1 samples to controls. This analysis is the same as Figure 6.4 except the KDA2 
samples have been included in the clusting analysis. In this figure KDA2 clusters with 
control groups (Mock and KDGAP) indicating that top gene expression changes for 
KDA1 are not comparable to KDA2. 
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Appendix VI 
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